﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2023v6.0">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2025-01-28T09:09:22-06:00</ReturnTs>
    <TaxPeriodEndDt>2024-03-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>873231666</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>PKF O'CONNOR DAVIES ADVISORY LLC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>245 PARK AVENUE 12TH FLOOR</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10167</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990PF</ReturnTypeCd>
    <TaxPeriodBeginDt>2023-04-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>137184401</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>THE LEONA M AND HARRY B HELMSLEY</BusinessNameLine1Txt>
        <BusinessNameLine2Txt>CHARITABLE TRUST</BusinessNameLine2Txt>
      </BusinessName>
      <BusinessNameControlTxt>LEON</BusinessNameControlTxt>
      <PhoneNum>2126793600</PhoneNum>
      <USAddress>
        <AddressLine1Txt>230 PARK AVENUE 659</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10169</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>NICHOLAS J SCHIAVO</PersonNm>
      <PersonTitleTxt>CFO</PersonTitleTxt>
      <PhoneNum>2126793600</PhoneNum>
      <SignatureDt>2025-01-21</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>0</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>THOMAS BLANEY</PreparerPersonNm>
      <PTIN>P00234022</PTIN>
      <PhoneNum>2122862600</PhoneNum>
      <PreparationDt>2025-01-21</PreparationDt>
    </PreparerPersonGrp>
    <TaxYr>2023</TaxYr>
    <BuildTS>2025-03-06 01:10:19Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="20">
    <IRS990PF documentId="RetDoc1235000001" referenceDocumentId="RetDoc2258700001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <FMVAssetsEOYAmt>7300077622</FMVAssetsEOYAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AnalysisOfRevenueAndExpenses>
        <ContriRcvdRevAndExpnssAmt>20000000</ContriRcvdRevAndExpnssAmt>
        <InterestOnSavRevAndExpnssAmt>4018817</InterestOnSavRevAndExpnssAmt>
        <InterestOnSavNetInvstIncmAmt>4018817</InterestOnSavNetInvstIncmAmt>
        <DividendsRevAndExpnssAmt>67095872</DividendsRevAndExpnssAmt>
        <DividendsNetInvstIncmAmt>132636674</DividendsNetInvstIncmAmt>
        <NetGainSaleAstRevAndExpnssAmt>234703900</NetGainSaleAstRevAndExpnssAmt>
        <GrossSalesPriceAmt>576339287</GrossSalesPriceAmt>
        <CapGainNetIncmNetInvstIncmAmt>132680049</CapGainNetIncmNetInvstIncmAmt>
        <OtherIncomeRevAndExpnssAmt referenceDocumentId="RetDoc2001500001">59409941</OtherIncomeRevAndExpnssAmt>
        <OtherIncomeNetInvstIncmAmt>31801322</OtherIncomeNetInvstIncmAmt>
        <TotalRevAndExpnssAmt>385228530</TotalRevAndExpnssAmt>
        <TotalNetInvstIncmAmt>301136862</TotalNetInvstIncmAmt>
        <CompOfcrDirTrstRevAndExpnssAmt>3982577</CompOfcrDirTrstRevAndExpnssAmt>
        <CompOfcrDirTrstNetInvstIncmAmt>1721636</CompOfcrDirTrstNetInvstIncmAmt>
        <CompOfcrDirTrstDsbrsChrtblAmt>2230741</CompOfcrDirTrstDsbrsChrtblAmt>
        <OthEmplSlrsWgsRevAndExpnssAmt>18660799</OthEmplSlrsWgsRevAndExpnssAmt>
        <OthEmplSlrsWgsNetInvstIncmAmt>3731814</OthEmplSlrsWgsNetInvstIncmAmt>
        <OthEmplSlrsWgsDsbrsChrtblAmt>14681014</OthEmplSlrsWgsDsbrsChrtblAmt>
        <PensionEmplBnftRevAndExpnssAmt>9268666</PensionEmplBnftRevAndExpnssAmt>
        <PensionEmplBnftNetInvstIncmAmt>1603592</PensionEmplBnftNetInvstIncmAmt>
        <PensionEmplBnftDsbrsChrtblAmt>7214783</PensionEmplBnftDsbrsChrtblAmt>
        <LegalFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002100001">423260</LegalFeesRevAndExpnssAmt>
        <LegalFeesNetInvstIncmAmt>113927</LegalFeesNetInvstIncmAmt>
        <LegalFeesDsbrsChrtblAmt>327915</LegalFeesDsbrsChrtblAmt>
        <AccountingFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002200001">427089</AccountingFeesRevAndExpnssAmt>
        <AccountingFeesNetInvstIncmAmt>116230</AccountingFeesNetInvstIncmAmt>
        <AccountingFeesChrtblPrpsAmt>345725</AccountingFeesChrtblPrpsAmt>
        <OtherProfFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002300001">7146568</OtherProfFeesRevAndExpnssAmt>
        <OtherProfFeesNetInvstIncmAmt>4363289</OtherProfFeesNetInvstIncmAmt>
        <OtherProfFeesDsbrsChrtblAmt>2631560</OtherProfFeesDsbrsChrtblAmt>
        <InterestNetInvstIncmAmt>4793771</InterestNetInvstIncmAmt>
        <TaxesRevAndExpnssAmt referenceDocumentId="RetDoc2002500001">9587210</TaxesRevAndExpnssAmt>
        <TaxesNetInvstIncmAmt>2384774</TaxesNetInvstIncmAmt>
        <TaxesDsbrsChrtblAmt>0</TaxesDsbrsChrtblAmt>
        <DeprecAndDpltnRevAndExpnssAmt>816356</DeprecAndDpltnRevAndExpnssAmt>
        <DeprecAndDpltnNetInvstIncmAmt>47140</DeprecAndDpltnNetInvstIncmAmt>
        <OccupancyRevAndExpnssAmt>1761672</OccupancyRevAndExpnssAmt>
        <OccupancyNetInvstIncmAmt>25625</OccupancyNetInvstIncmAmt>
        <OccupancyDsbrsChrtblAmt>1535307</OccupancyDsbrsChrtblAmt>
        <TravConfMeetingRevAndExpnssAmt>2174294</TravConfMeetingRevAndExpnssAmt>
        <TravConfMeetingNetInvstIncmAmt>265868</TravConfMeetingNetInvstIncmAmt>
        <TravConfMeetingDsbrsChrtblAmt>1991530</TravConfMeetingDsbrsChrtblAmt>
        <OtherExpensesRevAndExpnssAmt referenceDocumentId="RetDoc2003200001">18716551</OtherExpensesRevAndExpnssAmt>
        <OtherExpensesNetInvstIncmAmt>57271241</OtherExpensesNetInvstIncmAmt>
        <OtherExpensesDsbrsChrtblAmt>2427378</OtherExpensesDsbrsChrtblAmt>
        <TotOprExpensesRevAndExpnssAmt>72965042</TotOprExpensesRevAndExpnssAmt>
        <TotOprExpensesNetInvstIncmAmt>76438907</TotOprExpensesNetInvstIncmAmt>
        <TotOprExpensesDsbrsChrtblAmt>33385953</TotOprExpensesDsbrsChrtblAmt>
        <ContriPaidRevAndExpnssAmt>527121300</ContriPaidRevAndExpnssAmt>
        <ContriPaidDsbrsChrtblAmt>445672622</ContriPaidDsbrsChrtblAmt>
        <TotalExpensesRevAndExpnssAmt>600086342</TotalExpensesRevAndExpnssAmt>
        <TotalExpensesNetInvstIncmAmt>76438907</TotalExpensesNetInvstIncmAmt>
        <TotalExpensesDsbrsChrtblAmt>479058575</TotalExpensesDsbrsChrtblAmt>
        <ExcessRevenueOverExpensesAmt>-214857812</ExcessRevenueOverExpensesAmt>
        <NetInvestmentIncomeAmt>224697955</NetInvestmentIncomeAmt>
      </AnalysisOfRevenueAndExpenses>
      <Form990PFBalanceSheetsGrp>
        <CashBOYAmt>85800732</CashBOYAmt>
        <CashEOYAmt>89496038</CashEOYAmt>
        <CashEOYFMVAmt>89496038</CashEOYFMVAmt>
        <SavAndTempCashInvstBOYAmt>143734047</SavAndTempCashInvstBOYAmt>
        <SavAndTempCashInvstEOYAmt>55980540</SavAndTempCashInvstEOYAmt>
        <SavAndTempCashInvstEOYFMVAmt>55980540</SavAndTempCashInvstEOYFMVAmt>
        <AcctRcvblAmt>604736</AcctRcvblAmt>
        <AcctRcvblBOYAmt>680960</AcctRcvblBOYAmt>
        <AcctRcvblEOYAmt>604736</AcctRcvblEOYAmt>
        <AcctRcvblEOYFMVAmt>604736</AcctRcvblEOYFMVAmt>
        <PrepaidExpensesBOYAmt>1129528</PrepaidExpensesBOYAmt>
        <PrepaidExpensesEOYAmt>1033231</PrepaidExpensesEOYAmt>
        <PrepaidExpensesEOYFMVAmt>1033231</PrepaidExpensesEOYFMVAmt>
        <CorporateStockBOYAmt>512806017</CorporateStockBOYAmt>
        <CorporateStockEOYAmt referenceDocumentId="RetDoc2018900001">643618129</CorporateStockEOYAmt>
        <CorporateStockEOYFMVAmt>643618129</CorporateStockEOYFMVAmt>
        <OtherInvestmentsBOYAmt>6449780993</OtherInvestmentsBOYAmt>
        <OtherInvestmentsEOYAmt referenceDocumentId="RetDoc2018100001">6446813297</OtherInvestmentsEOYAmt>
        <OtherInvestmentsEOYFMVAmt>6446813297</OtherInvestmentsEOYFMVAmt>
        <LandBldgEquipCostOrOtherBssAmt>10532026</LandBldgEquipCostOrOtherBssAmt>
        <LandBldgEquipAccumDeprecAmt>3861764</LandBldgEquipAccumDeprecAmt>
        <LandBOYAmt>6890319</LandBOYAmt>
        <LandEOYAmt referenceDocumentId="RetDoc2059000001">6670262</LandEOYAmt>
        <LandEOYFMVAmt>6670262</LandEOYFMVAmt>
        <OtherAssetsBOYAmt referenceDocumentId="RetDoc2046600001">56013040</OtherAssetsBOYAmt>
        <OtherAssetsEOYAmt referenceDocumentId="RetDoc2046600001">55861389</OtherAssetsEOYAmt>
        <OtherAssetsEOYFMVAmt referenceDocumentId="RetDoc2046600001">55861389</OtherAssetsEOYFMVAmt>
        <TotalAssetsBOYAmt>7256835636</TotalAssetsBOYAmt>
        <TotalAssetsEOYAmt>7300077622</TotalAssetsEOYAmt>
        <TotalAssetsEOYFMVAmt>7300077622</TotalAssetsEOYFMVAmt>
        <AccountsPayableBOYAmt>11336884</AccountsPayableBOYAmt>
        <AccountsPayableEOYAmt>11499434</AccountsPayableEOYAmt>
        <GrantsPayableBOYAmt>482673051</GrantsPayableBOYAmt>
        <GrantsPayableEOYAmt>564121729</GrantsPayableEOYAmt>
        <OtherLiabilitiesBOYAmt referenceDocumentId="RetDoc2065700001">41684887</OtherLiabilitiesBOYAmt>
        <OtherLiabilitiesEOYAmt referenceDocumentId="RetDoc2065700001">45857428</OtherLiabilitiesEOYAmt>
        <TotalLiabilitiesBOYAmt>535694822</TotalLiabilitiesBOYAmt>
        <TotalLiabilitiesEOYAmt>621478591</TotalLiabilitiesEOYAmt>
        <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
        <NoDonorRstrNetAssestsBOYAmt>6721140814</NoDonorRstrNetAssestsBOYAmt>
        <NoDonorRstrNetAssestsEOYAmt>6678599031</NoDonorRstrNetAssestsEOYAmt>
        <TotNetAstOrFundBalancesBOYAmt>6721140814</TotNetAstOrFundBalancesBOYAmt>
        <TotNetAstOrFundBalancesEOYAmt>6678599031</TotNetAstOrFundBalancesEOYAmt>
        <TotalLiabilitiesNetAstBOYAmt>7256835636</TotalLiabilitiesNetAstBOYAmt>
        <TotalLiabilitiesNetAstEOYAmt>7300077622</TotalLiabilitiesNetAstEOYAmt>
      </Form990PFBalanceSheetsGrp>
      <ChgInNetAssetsFundBalancesGrp>
        <TotNetAstOrFundBalancesBOYAmt>6721140814</TotNetAstOrFundBalancesBOYAmt>
        <ExcessRevenueOverExpensesAmt>-214857812</ExcessRevenueOverExpensesAmt>
        <OtherIncreasesAmt referenceDocumentId="RetDoc2049700001">186800511</OtherIncreasesAmt>
        <SubtotalAmt>6693083513</SubtotalAmt>
        <OtherDecreasesAmt referenceDocumentId="RetDoc2049800001">14484482</OtherDecreasesAmt>
        <TotNetAstOrFundBalancesEOYAmt>6678599031</TotNetAstOrFundBalancesEOYAmt>
      </ChgInNetAssetsFundBalancesGrp>
      <CapGainsLossTxInvstIncmDetail>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SALE OF PUBLICLY TRADED SECURITIES</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>41971866</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>14475270</CostOrOtherBasisAmt>
          <GainOrLossAmt>27496596</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>27496596</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-17</SoldDt>
          <GrossSalesPriceAmt>61991</GrossSalesPriceAmt>
          <GainOrLossAmt>61991</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>61991</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-01</SoldDt>
          <GrossSalesPriceAmt>93958</GrossSalesPriceAmt>
          <GainOrLossAmt>93958</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>93958</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-14</SoldDt>
          <GrossSalesPriceAmt>141696</GrossSalesPriceAmt>
          <GainOrLossAmt>141696</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>141696</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-02</SoldDt>
          <GrossSalesPriceAmt>241066</GrossSalesPriceAmt>
          <GainOrLossAmt>241066</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>241066</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-16</SoldDt>
          <GrossSalesPriceAmt>707008</GrossSalesPriceAmt>
          <GainOrLossAmt>707008</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>707008</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-09</SoldDt>
          <GrossSalesPriceAmt>1686366</GrossSalesPriceAmt>
          <GainOrLossAmt>1686366</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1686366</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-02</SoldDt>
          <GrossSalesPriceAmt>641959</GrossSalesPriceAmt>
          <GainOrLossAmt>641959</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>641959</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-01</SoldDt>
          <GrossSalesPriceAmt>341451</GrossSalesPriceAmt>
          <GainOrLossAmt>341451</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>341451</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-05</SoldDt>
          <GrossSalesPriceAmt>338656</GrossSalesPriceAmt>
          <GainOrLossAmt>338656</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>338656</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-31</SoldDt>
          <GrossSalesPriceAmt>309496</GrossSalesPriceAmt>
          <GainOrLossAmt>309496</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>309496</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-15</SoldDt>
          <GrossSalesPriceAmt>272315</GrossSalesPriceAmt>
          <GainOrLossAmt>272315</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>272315</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-14</SoldDt>
          <GrossSalesPriceAmt>247578</GrossSalesPriceAmt>
          <GainOrLossAmt>247578</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>247578</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-11</SoldDt>
          <GrossSalesPriceAmt>223412</GrossSalesPriceAmt>
          <GainOrLossAmt>223412</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>223412</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-31</SoldDt>
          <GrossSalesPriceAmt>514861</GrossSalesPriceAmt>
          <GainOrLossAmt>514861</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>514861</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-14</SoldDt>
          <GrossSalesPriceAmt>368531</GrossSalesPriceAmt>
          <GainOrLossAmt>368531</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>368531</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-02</SoldDt>
          <GrossSalesPriceAmt>185061</GrossSalesPriceAmt>
          <GainOrLossAmt>185061</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>185061</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-21</SoldDt>
          <GrossSalesPriceAmt>180041</GrossSalesPriceAmt>
          <GainOrLossAmt>180041</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>180041</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-01</SoldDt>
          <GrossSalesPriceAmt>174007</GrossSalesPriceAmt>
          <GainOrLossAmt>174007</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>174007</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-22</SoldDt>
          <GrossSalesPriceAmt>159662</GrossSalesPriceAmt>
          <GainOrLossAmt>159662</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>159662</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-07</SoldDt>
          <GrossSalesPriceAmt>159340</GrossSalesPriceAmt>
          <GainOrLossAmt>159340</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>159340</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-31</SoldDt>
          <GrossSalesPriceAmt>133478</GrossSalesPriceAmt>
          <GainOrLossAmt>133478</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>133478</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL GROWTH FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-04</SoldDt>
          <GrossSalesPriceAmt>1176640</GrossSalesPriceAmt>
          <GainOrLossAmt>1176640</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1176640</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-21</SoldDt>
          <GrossSalesPriceAmt>566375</GrossSalesPriceAmt>
          <GainOrLossAmt>566375</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>566375</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-29</SoldDt>
          <GrossSalesPriceAmt>488445</GrossSalesPriceAmt>
          <GainOrLossAmt>488445</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>488445</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-08</SoldDt>
          <GrossSalesPriceAmt>186078</GrossSalesPriceAmt>
          <GainOrLossAmt>186078</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>186078</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-11</SoldDt>
          <GrossSalesPriceAmt>186078</GrossSalesPriceAmt>
          <GainOrLossAmt>186078</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>186078</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-04</SoldDt>
          <GrossSalesPriceAmt>515517</GrossSalesPriceAmt>
          <GainOrLossAmt>515517</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>515517</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACCEL LEADERS FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-11</SoldDt>
          <CostOrOtherBasisAmt>186078</CostOrOtherBasisAmt>
          <GainOrLossAmt>-186078</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-186078</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-29</SoldDt>
          <GrossSalesPriceAmt>16437071</GrossSalesPriceAmt>
          <GainOrLossAmt>16437071</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16437071</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-14</SoldDt>
          <GrossSalesPriceAmt>143082</GrossSalesPriceAmt>
          <GainOrLossAmt>143082</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>143082</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-29</SoldDt>
          <GrossSalesPriceAmt>216948</GrossSalesPriceAmt>
          <GainOrLossAmt>216948</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>216948</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-29</SoldDt>
          <GrossSalesPriceAmt>1941818</GrossSalesPriceAmt>
          <GainOrLossAmt>1941818</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1941818</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-14</SoldDt>
          <GrossSalesPriceAmt>563540</GrossSalesPriceAmt>
          <GainOrLossAmt>563540</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>563540</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-14</SoldDt>
          <GrossSalesPriceAmt>306422</GrossSalesPriceAmt>
          <GainOrLossAmt>306422</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>306422</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-25</SoldDt>
          <GrossSalesPriceAmt>3070384</GrossSalesPriceAmt>
          <GainOrLossAmt>3070384</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3070384</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-25</SoldDt>
          <GrossSalesPriceAmt>3057987</GrossSalesPriceAmt>
          <GainOrLossAmt>3057987</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3057987</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-25</SoldDt>
          <CostOrOtherBasisAmt>12397</CostOrOtherBasisAmt>
          <GainOrLossAmt>-12397</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-12397</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ LSV FD I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-25</SoldDt>
          <CostOrOtherBasisAmt>3057987</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3057987</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3057987</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FUND V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-15</SoldDt>
          <GrossSalesPriceAmt>559245</GrossSalesPriceAmt>
          <GainOrLossAmt>559245</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>559245</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANDREESSEN HOROWITZ FUND V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-15</SoldDt>
          <GrossSalesPriceAmt>39048</GrossSalesPriceAmt>
          <GainOrLossAmt>39048</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>39048</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-15</SoldDt>
          <GrossSalesPriceAmt>307809</GrossSalesPriceAmt>
          <GainOrLossAmt>307809</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>307809</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-15</SoldDt>
          <GrossSalesPriceAmt>233</GrossSalesPriceAmt>
          <GainOrLossAmt>233</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>233</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>AH PARALLEL FUND V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-15</SoldDt>
          <CostOrOtherBasisAmt>465</CostOrOtherBasisAmt>
          <GainOrLossAmt>-465</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-465</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ANGELENO INVESTORS III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-21</SoldDt>
          <GrossSalesPriceAmt>2192741</GrossSalesPriceAmt>
          <GainOrLossAmt>2192741</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2192741</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ARBORETUM VENTURES IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-19</SoldDt>
          <GrossSalesPriceAmt>294556</GrossSalesPriceAmt>
          <GainOrLossAmt>294556</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>294556</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-06</SoldDt>
          <GrossSalesPriceAmt>16811</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>15711</CostOrOtherBasisAmt>
          <GainOrLossAmt>1100</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1100</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-24</SoldDt>
          <GrossSalesPriceAmt>19874</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>22596</CostOrOtherBasisAmt>
          <GainOrLossAmt>-2722</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-2722</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-09</SoldDt>
          <GrossSalesPriceAmt>20186</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>22964</CostOrOtherBasisAmt>
          <GainOrLossAmt>-2778</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-2778</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-30</SoldDt>
          <GrossSalesPriceAmt>20087</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>23849</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3762</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3762</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-18</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>9336356</CostOrOtherBasisAmt>
          <GainOrLossAmt>663644</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>663644</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-11</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>9517648</CostOrOtherBasisAmt>
          <GainOrLossAmt>482352</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>482352</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-04</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>9552881</CostOrOtherBasisAmt>
          <GainOrLossAmt>447119</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>447119</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-27</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>10338558</CostOrOtherBasisAmt>
          <GainOrLossAmt>-338558</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-338558</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-20</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>11283926</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1283926</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1283926</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-13</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>11452818</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1452818</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1452818</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-06</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>11477585</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1477585</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1477585</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>BLACKROCK US DEBT INDEX FUND B</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-01</SoldDt>
          <GrossSalesPriceAmt>10000000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>11676991</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1676991</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1676991</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM ASSET PARTNERS HIGH YIELD FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-30</SoldDt>
          <GrossSalesPriceAmt>2064</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>1048</CostOrOtherBasisAmt>
          <GainOrLossAmt>1016</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1016</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-03-31</SoldDt>
          <GrossSalesPriceAmt>72486</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>229186</CostOrOtherBasisAmt>
          <GainOrLossAmt>-156700</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-156700</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CHATHAM CO INVEST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-03-31</SoldDt>
          <GrossSalesPriceAmt>245370</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>72486</CostOrOtherBasisAmt>
          <GainOrLossAmt>172884</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>172884</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-22</SoldDt>
          <GrossSalesPriceAmt>161048</GrossSalesPriceAmt>
          <GainOrLossAmt>161048</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>161048</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-15</SoldDt>
          <GrossSalesPriceAmt>256134</GrossSalesPriceAmt>
          <GainOrLossAmt>256134</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>256134</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-27</SoldDt>
          <GrossSalesPriceAmt>278766</GrossSalesPriceAmt>
          <GainOrLossAmt>278766</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>278766</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-26</SoldDt>
          <GrossSalesPriceAmt>315000</GrossSalesPriceAmt>
          <GainOrLossAmt>315000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>315000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTERNATIONAL PARTNERS VI</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-10</SoldDt>
          <GrossSalesPriceAmt>628652</GrossSalesPriceAmt>
          <GainOrLossAmt>628652</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>628652</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTL PARTNERS VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-22</SoldDt>
          <GrossSalesPriceAmt>274598</GrossSalesPriceAmt>
          <GainOrLossAmt>274598</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>274598</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTL PARTNERS VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-18</SoldDt>
          <GrossSalesPriceAmt>935000</GrossSalesPriceAmt>
          <GainOrLossAmt>935000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>935000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTL PARTNERS VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-31</SoldDt>
          <GrossSalesPriceAmt>1540000</GrossSalesPriceAmt>
          <GainOrLossAmt>1540000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1540000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>COLLER INTL PARTNERS VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-28</SoldDt>
          <GrossSalesPriceAmt>1974500</GrossSalesPriceAmt>
          <GainOrLossAmt>1974500</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1974500</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CRESTVIEW PARTNERS III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-12</SoldDt>
          <GrossSalesPriceAmt>2492866</GrossSalesPriceAmt>
          <GainOrLossAmt>2492866</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2492866</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CRESTVIEW PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-27</SoldDt>
          <GrossSalesPriceAmt>6168962</GrossSalesPriceAmt>
          <GainOrLossAmt>6168962</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>6168962</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FUND XVI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-06</SoldDt>
          <GrossSalesPriceAmt>45902</GrossSalesPriceAmt>
          <GainOrLossAmt>45902</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>45902</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FUND XVI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-02</SoldDt>
          <GrossSalesPriceAmt>119599</GrossSalesPriceAmt>
          <GainOrLossAmt>119599</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>119599</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FUND XVI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-10</SoldDt>
          <GrossSalesPriceAmt>911617</GrossSalesPriceAmt>
          <GainOrLossAmt>911617</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>911617</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ENERGY FUND XV-A LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-10</SoldDt>
          <GrossSalesPriceAmt>84929</GrossSalesPriceAmt>
          <GainOrLossAmt>84929</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>84929</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FD XVII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-28</SoldDt>
          <GrossSalesPriceAmt>74382</GrossSalesPriceAmt>
          <GainOrLossAmt>74382</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>74382</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FD XVII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-26</SoldDt>
          <GrossSalesPriceAmt>172069</GrossSalesPriceAmt>
          <GainOrLossAmt>172069</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>172069</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FD XVII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-15</SoldDt>
          <GrossSalesPriceAmt>172171</GrossSalesPriceAmt>
          <GainOrLossAmt>172171</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>172171</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EIG ENERGY FD XVII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-27</SoldDt>
          <GrossSalesPriceAmt>185641</GrossSalesPriceAmt>
          <GainOrLossAmt>185641</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>185641</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EMERGENCE CAPITAL PARTNERS III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-15</SoldDt>
          <GrossSalesPriceAmt>2029399</GrossSalesPriceAmt>
          <GainOrLossAmt>2029399</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2029399</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PROJECT ELECTRON LP-TBU</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-06</SoldDt>
          <GrossSalesPriceAmt>43582</GrossSalesPriceAmt>
          <GainOrLossAmt>43582</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>43582</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND II B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-04</SoldDt>
          <GrossSalesPriceAmt>5816</GrossSalesPriceAmt>
          <GainOrLossAmt>5816</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5816</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND II B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-07</SoldDt>
          <GrossSalesPriceAmt>9600</GrossSalesPriceAmt>
          <GainOrLossAmt>9600</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>9600</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND II B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-04</SoldDt>
          <GrossSalesPriceAmt>13026</GrossSalesPriceAmt>
          <GainOrLossAmt>13026</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13026</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND II B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-06</SoldDt>
          <GrossSalesPriceAmt>15550</GrossSalesPriceAmt>
          <GainOrLossAmt>15550</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15550</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND II B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-06</SoldDt>
          <GrossSalesPriceAmt>20426</GrossSalesPriceAmt>
          <GainOrLossAmt>20426</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20426</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND II B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-22</SoldDt>
          <GrossSalesPriceAmt>31955</GrossSalesPriceAmt>
          <GainOrLossAmt>31955</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>31955</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-07</SoldDt>
          <CostOrOtherBasisAmt>3301</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3301</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3301</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-18</SoldDt>
          <GrossSalesPriceAmt>19455</GrossSalesPriceAmt>
          <GainOrLossAmt>19455</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>19455</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>EPIRIS FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-12</SoldDt>
          <GrossSalesPriceAmt>43691</GrossSalesPriceAmt>
          <GainOrLossAmt>43691</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>43691</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FDAF DISLOCATED I LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-01-05</SoldDt>
          <CostOrOtherBasisAmt>10929899</CostOrOtherBasisAmt>
          <GainOrLossAmt>-10929899</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-10929899</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FORTISSIMO CAPITAL FUND IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-28</SoldDt>
          <GrossSalesPriceAmt>2670500</GrossSalesPriceAmt>
          <GainOrLossAmt>2670500</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2670500</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-24</SoldDt>
          <GrossSalesPriceAmt>348083</GrossSalesPriceAmt>
          <GainOrLossAmt>348083</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>348083</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-22</SoldDt>
          <GrossSalesPriceAmt>562691</GrossSalesPriceAmt>
          <GainOrLossAmt>562691</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>562691</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCI PUBLIC OVERAGE LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-21</SoldDt>
          <GrossSalesPriceAmt>116033</GrossSalesPriceAmt>
          <GainOrLossAmt>116033</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>116033</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCI PUBLIC OVERAGE LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-06</SoldDt>
          <GrossSalesPriceAmt>401071</GrossSalesPriceAmt>
          <GainOrLossAmt>401071</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>401071</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCI PUBLIC OVERAGE LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-25</SoldDt>
          <GrossSalesPriceAmt>859141</GrossSalesPriceAmt>
          <GainOrLossAmt>859141</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>859141</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCI PUBLIC FD LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-06</SoldDt>
          <GrossSalesPriceAmt>205532</GrossSalesPriceAmt>
          <GainOrLossAmt>205532</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>205532</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCI PUBLIC FD LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-15</SoldDt>
          <GrossSalesPriceAmt>324214</GrossSalesPriceAmt>
          <GainOrLossAmt>324214</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>324214</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCI PUBLIC FD LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-25</SoldDt>
          <GrossSalesPriceAmt>834039</GrossSalesPriceAmt>
          <GainOrLossAmt>834039</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>834039</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCI PUBLIC FD LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-16</SoldDt>
          <GrossSalesPriceAmt>1099199</GrossSalesPriceAmt>
          <GainOrLossAmt>1099199</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1099199</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES X LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-29</SoldDt>
          <GrossSalesPriceAmt>99208</GrossSalesPriceAmt>
          <GainOrLossAmt>99208</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>99208</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES X LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-08</SoldDt>
          <GrossSalesPriceAmt>355152</GrossSalesPriceAmt>
          <GainOrLossAmt>355152</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>355152</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES X LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-15</SoldDt>
          <GrossSalesPriceAmt>571281</GrossSalesPriceAmt>
          <GainOrLossAmt>571281</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>571281</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES XI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-15</SoldDt>
          <GrossSalesPriceAmt>221313</GrossSalesPriceAmt>
          <GainOrLossAmt>221313</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>221313</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>FRAZIER LIFE SCIENCES XI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-29</SoldDt>
          <GrossSalesPriceAmt>240824</GrossSalesPriceAmt>
          <GainOrLossAmt>240824</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>240824</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GAVEA INVEST FD V PLUS B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-06</SoldDt>
          <GrossSalesPriceAmt>294147</GrossSalesPriceAmt>
          <GainOrLossAmt>294147</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>294147</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-12</SoldDt>
          <CostOrOtherBasisAmt>560323</CostOrOtherBasisAmt>
          <GainOrLossAmt>-560323</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-560323</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-01</SoldDt>
          <CostOrOtherBasisAmt>116591</CostOrOtherBasisAmt>
          <GainOrLossAmt>-116591</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-116591</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-14</SoldDt>
          <GrossSalesPriceAmt>5090</GrossSalesPriceAmt>
          <GainOrLossAmt>5090</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>5090</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-07</SoldDt>
          <GrossSalesPriceAmt>35517</GrossSalesPriceAmt>
          <GainOrLossAmt>35517</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>35517</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-26</SoldDt>
          <GrossSalesPriceAmt>89476</GrossSalesPriceAmt>
          <GainOrLossAmt>89476</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>89476</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-20</SoldDt>
          <GrossSalesPriceAmt>675902</GrossSalesPriceAmt>
          <GainOrLossAmt>675902</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>675902</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-06</SoldDt>
          <GrossSalesPriceAmt>780032</GrossSalesPriceAmt>
          <GainOrLossAmt>780032</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>780032</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-03</SoldDt>
          <GrossSalesPriceAmt>12238639</GrossSalesPriceAmt>
          <GainOrLossAmt>12238639</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12238639</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <CostOrOtherBasisAmt>285850</CostOrOtherBasisAmt>
          <GainOrLossAmt>-285850</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-285850</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-26</SoldDt>
          <CostOrOtherBasisAmt>16702</CostOrOtherBasisAmt>
          <GainOrLossAmt>-16702</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-16702</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-17</SoldDt>
          <CostOrOtherBasisAmt>15953</CostOrOtherBasisAmt>
          <GainOrLossAmt>-15953</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-15953</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-20</SoldDt>
          <CostOrOtherBasisAmt>11027</CostOrOtherBasisAmt>
          <GainOrLossAmt>-11027</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-11027</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-14</SoldDt>
          <GrossSalesPriceAmt>2400</GrossSalesPriceAmt>
          <GainOrLossAmt>2400</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2400</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-07</SoldDt>
          <GrossSalesPriceAmt>2691</GrossSalesPriceAmt>
          <GainOrLossAmt>2691</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2691</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-01</SoldDt>
          <GrossSalesPriceAmt>100250</GrossSalesPriceAmt>
          <GainOrLossAmt>100250</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100250</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-28</SoldDt>
          <GrossSalesPriceAmt>109987</GrossSalesPriceAmt>
          <GainOrLossAmt>109987</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>109987</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-22</SoldDt>
          <GrossSalesPriceAmt>230515</GrossSalesPriceAmt>
          <GainOrLossAmt>230515</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>230515</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-26</SoldDt>
          <GrossSalesPriceAmt>280928</GrossSalesPriceAmt>
          <GainOrLossAmt>280928</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>280928</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-08</SoldDt>
          <GrossSalesPriceAmt>352328</GrossSalesPriceAmt>
          <GainOrLossAmt>352328</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>352328</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-01</SoldDt>
          <GrossSalesPriceAmt>2602251</GrossSalesPriceAmt>
          <GainOrLossAmt>2602251</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2602251</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-15</SoldDt>
          <GrossSalesPriceAmt>2628414</GrossSalesPriceAmt>
          <GainOrLossAmt>2628414</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2628414</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GA MANAGED ACCOUNT PROGRAM</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-03</SoldDt>
          <GrossSalesPriceAmt>12298199</GrossSalesPriceAmt>
          <GainOrLossAmt>12298199</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12298199</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-24</SoldDt>
          <GrossSalesPriceAmt>40637</GrossSalesPriceAmt>
          <GainOrLossAmt>40637</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>40637</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-17</SoldDt>
          <GrossSalesPriceAmt>2206780</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3039263</CostOrOtherBasisAmt>
          <GainOrLossAmt>-832483</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-832483</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTIONS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-17</SoldDt>
          <GrossSalesPriceAmt>2206780</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>3039263</CostOrOtherBasisAmt>
          <GainOrLossAmt>-832483</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-832483</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO CAPITAL SOLUTION</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-25</SoldDt>
          <CostOrOtherBasisAmt>12952701</CostOrOtherBasisAmt>
          <GainOrLossAmt>-12952701</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-12952701</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BIOVENTURES II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-29</SoldDt>
          <GrossSalesPriceAmt>2599898</GrossSalesPriceAmt>
          <GainOrLossAmt>2599898</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2599898</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-28</SoldDt>
          <GrossSalesPriceAmt>370738</GrossSalesPriceAmt>
          <GainOrLossAmt>370738</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>370738</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER B LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-19</SoldDt>
          <GrossSalesPriceAmt>1105465</GrossSalesPriceAmt>
          <GainOrLossAmt>1105465</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1105465</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER C LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-28</SoldDt>
          <GrossSalesPriceAmt>370738</GrossSalesPriceAmt>
          <GainOrLossAmt>370738</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>370738</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG BRAZIL &amp; LATIN AME PTNRS MASTER C LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-19</SoldDt>
          <GrossSalesPriceAmt>1105465</GrossSalesPriceAmt>
          <GainOrLossAmt>1105465</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1105465</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG CAPITAL PARTNERS V L P</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-28</SoldDt>
          <GrossSalesPriceAmt>769340</GrossSalesPriceAmt>
          <GainOrLossAmt>769340</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>769340</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG CAPITAL PARTNERS V L P</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-16</SoldDt>
          <GrossSalesPriceAmt>2174116</GrossSalesPriceAmt>
          <GainOrLossAmt>2174116</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2174116</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG CAPITAL PARTNERS V L P</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-26</SoldDt>
          <GrossSalesPriceAmt>2445695</GrossSalesPriceAmt>
          <GainOrLossAmt>2445695</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2445695</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>H.I.G. GROWTH BUYOUTS &amp; EQUITY FUND II L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-01</SoldDt>
          <GrossSalesPriceAmt>174007</GrossSalesPriceAmt>
          <GainOrLossAmt>174007</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>174007</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>H.I.G. GROWTH BUYOUTS &amp; EQUITY FUND II L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-29</SoldDt>
          <GrossSalesPriceAmt>337752</GrossSalesPriceAmt>
          <GainOrLossAmt>337752</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>337752</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>H.I.G. GROWTH BUYOUTS &amp; EQUITY FUND II L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-28</SoldDt>
          <GrossSalesPriceAmt>670766</GrossSalesPriceAmt>
          <GainOrLossAmt>670766</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>670766</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>H.I.G. GROWTH BUYOUTS &amp; EQUITY FUND II L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-01</SoldDt>
          <CostOrOtherBasisAmt>174007</CostOrOtherBasisAmt>
          <GainOrLossAmt>-174007</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-174007</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG GROWTH B&amp;EQ FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-26</SoldDt>
          <GrossSalesPriceAmt>428164</GrossSalesPriceAmt>
          <GainOrLossAmt>428164</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>428164</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-26</SoldDt>
          <GrossSalesPriceAmt>167041</GrossSalesPriceAmt>
          <GainOrLossAmt>167041</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>167041</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-21</SoldDt>
          <GrossSalesPriceAmt>690013</GrossSalesPriceAmt>
          <GainOrLossAmt>690013</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>690013</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-31</SoldDt>
          <GrossSalesPriceAmt>87119</GrossSalesPriceAmt>
          <GainOrLossAmt>87119</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>87119</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>94205</GrossSalesPriceAmt>
          <GainOrLossAmt>94205</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>94205</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-30</SoldDt>
          <GrossSalesPriceAmt>95900</GrossSalesPriceAmt>
          <GainOrLossAmt>95900</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>95900</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-31</SoldDt>
          <GrossSalesPriceAmt>96735</GrossSalesPriceAmt>
          <GainOrLossAmt>96735</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>96735</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-30</SoldDt>
          <GrossSalesPriceAmt>98466</GrossSalesPriceAmt>
          <GainOrLossAmt>98466</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>98466</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-29</SoldDt>
          <GrossSalesPriceAmt>98589</GrossSalesPriceAmt>
          <GainOrLossAmt>98589</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>98589</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-31</SoldDt>
          <GrossSalesPriceAmt>99042</GrossSalesPriceAmt>
          <GainOrLossAmt>99042</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>99042</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-31</SoldDt>
          <GrossSalesPriceAmt>99346</GrossSalesPriceAmt>
          <GainOrLossAmt>99346</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>99346</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-30</SoldDt>
          <GrossSalesPriceAmt>99834</GrossSalesPriceAmt>
          <GainOrLossAmt>99834</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>99834</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-31</SoldDt>
          <GrossSalesPriceAmt>100113</GrossSalesPriceAmt>
          <GainOrLossAmt>100113</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100113</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-31</SoldDt>
          <GrossSalesPriceAmt>101098</GrossSalesPriceAmt>
          <GainOrLossAmt>101098</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>101098</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMALL CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <GrossSalesPriceAmt>101460</GrossSalesPriceAmt>
          <GainOrLossAmt>101460</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>101460</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-31</SoldDt>
          <GrossSalesPriceAmt>42927</GrossSalesPriceAmt>
          <GainOrLossAmt>42927</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>42927</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-30</SoldDt>
          <GrossSalesPriceAmt>44717</GrossSalesPriceAmt>
          <GainOrLossAmt>44717</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>44717</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-31</SoldDt>
          <GrossSalesPriceAmt>45669</GrossSalesPriceAmt>
          <GainOrLossAmt>45669</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>45669</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>46271</GrossSalesPriceAmt>
          <GainOrLossAmt>46271</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>46271</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-30</SoldDt>
          <GrossSalesPriceAmt>46408</GrossSalesPriceAmt>
          <GainOrLossAmt>46408</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>46408</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-31</SoldDt>
          <GrossSalesPriceAmt>46503</GrossSalesPriceAmt>
          <GainOrLossAmt>46503</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>46503</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-29</SoldDt>
          <GrossSalesPriceAmt>46670</GrossSalesPriceAmt>
          <GainOrLossAmt>46670</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>46670</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-31</SoldDt>
          <GrossSalesPriceAmt>47218</GrossSalesPriceAmt>
          <GainOrLossAmt>47218</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>47218</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-30</SoldDt>
          <GrossSalesPriceAmt>47332</GrossSalesPriceAmt>
          <GainOrLossAmt>47332</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>47332</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-31</SoldDt>
          <GrossSalesPriceAmt>47737</GrossSalesPriceAmt>
          <GainOrLossAmt>47737</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>47737</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <GrossSalesPriceAmt>48180</GrossSalesPriceAmt>
          <GainOrLossAmt>48180</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>48180</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIGHCLERE INTL SMID CAP FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-31</SoldDt>
          <GrossSalesPriceAmt>48401</GrossSalesPriceAmt>
          <GainOrLossAmt>48401</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>48401</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP GR FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-01</SoldDt>
          <GrossSalesPriceAmt>545347</GrossSalesPriceAmt>
          <GainOrLossAmt>545347</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>545347</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP GR FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-14</SoldDt>
          <GrossSalesPriceAmt>567039</GrossSalesPriceAmt>
          <GainOrLossAmt>567039</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>567039</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP GR FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-14</SoldDt>
          <GrossSalesPriceAmt>2679640</GrossSalesPriceAmt>
          <GainOrLossAmt>2679640</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2679640</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP GR FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-11</SoldDt>
          <GrossSalesPriceAmt>1763479</GrossSalesPriceAmt>
          <GainOrLossAmt>1763479</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1763479</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP GR FD V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-11</SoldDt>
          <GrossSalesPriceAmt>144901</GrossSalesPriceAmt>
          <GainOrLossAmt>144901</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>144901</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP GR FD V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-13</SoldDt>
          <GrossSalesPriceAmt>184690</GrossSalesPriceAmt>
          <GainOrLossAmt>184690</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>184690</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP GR FD V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>265310</GrossSalesPriceAmt>
          <GainOrLossAmt>265310</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>265310</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP VENT FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-20</SoldDt>
          <GrossSalesPriceAmt>460581</GrossSalesPriceAmt>
          <GainOrLossAmt>460581</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>460581</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP VENT FD V LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-16</SoldDt>
          <GrossSalesPriceAmt>256791</GrossSalesPriceAmt>
          <GainOrLossAmt>256791</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>256791</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP VENT FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-28</SoldDt>
          <GrossSalesPriceAmt>140494</GrossSalesPriceAmt>
          <GainOrLossAmt>140494</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>140494</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HONGSHAN CAP VENT FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-24</SoldDt>
          <GrossSalesPriceAmt>392473</GrossSalesPriceAmt>
          <GainOrLossAmt>392473</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>392473</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA CAPITAL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-05</SoldDt>
          <GrossSalesPriceAmt>112939</GrossSalesPriceAmt>
          <GainOrLossAmt>112939</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>112939</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA CAPITAL FUND III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-26</SoldDt>
          <GrossSalesPriceAmt>162581</GrossSalesPriceAmt>
          <GainOrLossAmt>162581</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>162581</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA VENTURE CAP FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-27</SoldDt>
          <GrossSalesPriceAmt>1164005</GrossSalesPriceAmt>
          <GainOrLossAmt>1164005</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1164005</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA VENTURE CAP FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-27</SoldDt>
          <GrossSalesPriceAmt>3280128</GrossSalesPriceAmt>
          <GainOrLossAmt>3280128</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3280128</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG CHINA VENTURE CAP FD IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-26</SoldDt>
          <GrossSalesPriceAmt>8618234</GrossSalesPriceAmt>
          <GainOrLossAmt>8618234</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8618234</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA GROWTH FUND III L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-28</SoldDt>
          <GrossSalesPriceAmt>753350</GrossSalesPriceAmt>
          <GainOrLossAmt>753350</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>753350</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IDG-ACCEL CHINA GROWTH FUND III L.P.</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-21</SoldDt>
          <GrossSalesPriceAmt>903149</GrossSalesPriceAmt>
          <GainOrLossAmt>903149</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>903149</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT RE PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-31</SoldDt>
          <GrossSalesPriceAmt>54545</GrossSalesPriceAmt>
          <GainOrLossAmt>54545</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>54545</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT RE PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-31</SoldDt>
          <GrossSalesPriceAmt>311033</GrossSalesPriceAmt>
          <GainOrLossAmt>311033</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>311033</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT RE PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-28</SoldDt>
          <GrossSalesPriceAmt>929694</GrossSalesPriceAmt>
          <GainOrLossAmt>929694</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>929694</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT RE PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-29</SoldDt>
          <GrossSalesPriceAmt>1037775</GrossSalesPriceAmt>
          <GainOrLossAmt>1037775</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1037775</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>IRON POINT RE PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <GrossSalesPriceAmt>1616034</GrossSalesPriceAmt>
          <GainOrLossAmt>1616034</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1616034</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>JERICHO CAPITAL INTERNATIONAL LTD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-31</SoldDt>
          <GrossSalesPriceAmt>9222102</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>4985910</CostOrOtherBasisAmt>
          <GainOrLossAmt>4236192</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4236192</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>JERICHO CAPITAL INTERNATIONAL LTD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-31</SoldDt>
          <GrossSalesPriceAmt>175219935</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>94732298</CostOrOtherBasisAmt>
          <GainOrLossAmt>80487637</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>80487637</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-13</SoldDt>
          <GrossSalesPriceAmt>291623</GrossSalesPriceAmt>
          <GainOrLossAmt>291623</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>291623</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEG SECONDARY PE INVESTORS III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-26</SoldDt>
          <GrossSalesPriceAmt>468454</GrossSalesPriceAmt>
          <GainOrLossAmt>468454</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>468454</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-31</SoldDt>
          <GrossSalesPriceAmt>13133</GrossSalesPriceAmt>
          <GainOrLossAmt>13133</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13133</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-31</SoldDt>
          <GrossSalesPriceAmt>13309</GrossSalesPriceAmt>
          <GainOrLossAmt>13309</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13309</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-30</SoldDt>
          <GrossSalesPriceAmt>13441</GrossSalesPriceAmt>
          <GainOrLossAmt>13441</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13441</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-30</SoldDt>
          <GrossSalesPriceAmt>13625</GrossSalesPriceAmt>
          <GainOrLossAmt>13625</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13625</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-30</SoldDt>
          <GrossSalesPriceAmt>13794</GrossSalesPriceAmt>
          <GainOrLossAmt>13794</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13794</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-31</SoldDt>
          <GrossSalesPriceAmt>13982</GrossSalesPriceAmt>
          <GainOrLossAmt>13982</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13982</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>14189</GrossSalesPriceAmt>
          <GainOrLossAmt>14189</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14189</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <GrossSalesPriceAmt>14231</GrossSalesPriceAmt>
          <GainOrLossAmt>14231</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14231</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-31</SoldDt>
          <GrossSalesPriceAmt>14721</GrossSalesPriceAmt>
          <GainOrLossAmt>14721</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14721</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-31</SoldDt>
          <GrossSalesPriceAmt>15051</GrossSalesPriceAmt>
          <GainOrLossAmt>15051</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15051</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-29</SoldDt>
          <GrossSalesPriceAmt>15537</GrossSalesPriceAmt>
          <GainOrLossAmt>15537</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15537</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LA CAPITAL GLOBAL EQUITY FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-31</SoldDt>
          <GrossSalesPriceAmt>16041</GrossSalesPriceAmt>
          <GainOrLossAmt>16041</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16041</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-31</SoldDt>
          <GrossSalesPriceAmt>12889</GrossSalesPriceAmt>
          <GainOrLossAmt>12889</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12889</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-31</SoldDt>
          <GrossSalesPriceAmt>12928</GrossSalesPriceAmt>
          <GainOrLossAmt>12928</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>12928</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-28</SoldDt>
          <GrossSalesPriceAmt>13394</GrossSalesPriceAmt>
          <GainOrLossAmt>13394</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13394</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-29</SoldDt>
          <GrossSalesPriceAmt>13511</GrossSalesPriceAmt>
          <GainOrLossAmt>13511</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13511</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-30</SoldDt>
          <GrossSalesPriceAmt>13854</GrossSalesPriceAmt>
          <GainOrLossAmt>13854</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13854</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>14025</GrossSalesPriceAmt>
          <GainOrLossAmt>14025</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14025</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-31</SoldDt>
          <GrossSalesPriceAmt>14061</GrossSalesPriceAmt>
          <GainOrLossAmt>14061</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14061</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <GrossSalesPriceAmt>14442</GrossSalesPriceAmt>
          <GainOrLossAmt>14442</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14442</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-31</SoldDt>
          <GrossSalesPriceAmt>15243</GrossSalesPriceAmt>
          <GainOrLossAmt>15243</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15243</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-29</SoldDt>
          <GrossSalesPriceAmt>15310</GrossSalesPriceAmt>
          <GainOrLossAmt>15310</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15310</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-29</SoldDt>
          <GrossSalesPriceAmt>15837</GrossSalesPriceAmt>
          <GainOrLossAmt>15837</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15837</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>LACM WORLD SMALL CAP EQUITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-28</SoldDt>
          <GrossSalesPriceAmt>16458</GrossSalesPriceAmt>
          <GainOrLossAmt>16458</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16458</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-29</SoldDt>
          <GrossSalesPriceAmt>77811</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>51011</CostOrOtherBasisAmt>
          <GainOrLossAmt>26800</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>26800</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-31</SoldDt>
          <GrossSalesPriceAmt>75832</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>51681</CostOrOtherBasisAmt>
          <GainOrLossAmt>24151</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>24151</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-29</SoldDt>
          <GrossSalesPriceAmt>75212</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>51924</CostOrOtherBasisAmt>
          <GainOrLossAmt>23288</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>23288</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <GrossSalesPriceAmt>74306</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>52408</CostOrOtherBasisAmt>
          <GainOrLossAmt>21898</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>21898</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>73095</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>52717</CostOrOtherBasisAmt>
          <GainOrLossAmt>20378</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20378</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-31</SoldDt>
          <GrossSalesPriceAmt>73301</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>52742</CostOrOtherBasisAmt>
          <GainOrLossAmt>20559</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20559</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-30</SoldDt>
          <GrossSalesPriceAmt>72354</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>53169</CostOrOtherBasisAmt>
          <GainOrLossAmt>19185</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>19185</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-29</SoldDt>
          <GrossSalesPriceAmt>70779</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>53699</CostOrOtherBasisAmt>
          <GainOrLossAmt>17080</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>17080</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-31</SoldDt>
          <GrossSalesPriceAmt>69874</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>54220</CostOrOtherBasisAmt>
          <GainOrLossAmt>15654</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15654</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-28</SoldDt>
          <GrossSalesPriceAmt>69683</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>54337</CostOrOtherBasisAmt>
          <GainOrLossAmt>15346</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15346</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-31</SoldDt>
          <GrossSalesPriceAmt>68728</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>54553</CostOrOtherBasisAmt>
          <GainOrLossAmt>14175</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>14175</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-28</SoldDt>
          <GrossSalesPriceAmt>79980</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>80044</CostOrOtherBasisAmt>
          <GainOrLossAmt>-64</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-64</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR LONGEVITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-03-21</SoldDt>
          <GrossSalesPriceAmt>3381794</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2896439</CostOrOtherBasisAmt>
          <GainOrLossAmt>485355</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>485355</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR LONGEVITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-01</SoldDt>
          <GrossSalesPriceAmt>4999720</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>4274989</CostOrOtherBasisAmt>
          <GainOrLossAmt>724731</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>724731</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR LONGEVITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-26</SoldDt>
          <GrossSalesPriceAmt>5999703</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>4953794</CostOrOtherBasisAmt>
          <GainOrLossAmt>1045909</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1045909</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR LONGEVITY FUND LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-15</SoldDt>
          <GrossSalesPriceAmt>7280573</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>6044903</CostOrOtherBasisAmt>
          <GainOrLossAmt>1235670</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1235670</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INSTITUTIONAL PTNRS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-25</SoldDt>
          <GrossSalesPriceAmt>59327</GrossSalesPriceAmt>
          <GainOrLossAmt>59327</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>59327</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>MHR INSTITUTIONAL PTNRS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-22</SoldDt>
          <GrossSalesPriceAmt>846247</GrossSalesPriceAmt>
          <GainOrLossAmt>846247</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>846247</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ASIA PARTNERS III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-07</SoldDt>
          <GrossSalesPriceAmt>4004245</GrossSalesPriceAmt>
          <GainOrLossAmt>4004245</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4004245</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED ISRAEL PTNRS II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-21</SoldDt>
          <GrossSalesPriceAmt>1171332</GrossSalesPriceAmt>
          <GainOrLossAmt>1171332</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1171332</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-14</SoldDt>
          <GainOrLossAmt>0</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>0</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-10</SoldDt>
          <GainOrLossAmt>0</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>0</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-10</SoldDt>
          <GrossSalesPriceAmt>105137</GrossSalesPriceAmt>
          <GainOrLossAmt>105137</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>105137</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-22</SoldDt>
          <GrossSalesPriceAmt>118065</GrossSalesPriceAmt>
          <GainOrLossAmt>118065</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>118065</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-08</SoldDt>
          <GrossSalesPriceAmt>127931</GrossSalesPriceAmt>
          <GainOrLossAmt>127931</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>127931</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-27</SoldDt>
          <GrossSalesPriceAmt>262761</GrossSalesPriceAmt>
          <GainOrLossAmt>262761</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>262761</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-14</SoldDt>
          <GrossSalesPriceAmt>313400</GrossSalesPriceAmt>
          <GainOrLossAmt>313400</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>313400</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-15</SoldDt>
          <GrossSalesPriceAmt>361361</GrossSalesPriceAmt>
          <GainOrLossAmt>361361</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>361361</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-26</SoldDt>
          <GrossSalesPriceAmt>1303634</GrossSalesPriceAmt>
          <GainOrLossAmt>1303634</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1303634</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VIII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-15</SoldDt>
          <GrossSalesPriceAmt>1496878</GrossSalesPriceAmt>
          <GainOrLossAmt>1496878</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1496878</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ORBIMED PRIVATE INVEST VIII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-12</SoldDt>
          <GrossSalesPriceAmt>2663109</GrossSalesPriceAmt>
          <GainOrLossAmt>2663109</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2663109</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV PARTNERS V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-20</SoldDt>
          <GrossSalesPriceAmt>156151</GrossSalesPriceAmt>
          <GainOrLossAmt>156151</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>156151</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PEAK XV PARTNERS V</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-22</SoldDt>
          <GrossSalesPriceAmt>178485</GrossSalesPriceAmt>
          <GainOrLossAmt>178485</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>178485</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>RIDGEWOOD ENERGY OIL &amp; GAS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-26</SoldDt>
          <GrossSalesPriceAmt>171472</GrossSalesPriceAmt>
          <GainOrLossAmt>171472</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>171472</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>RIDGEWOOD ENERGY OIL &amp; GAS FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-22</SoldDt>
          <GrossSalesPriceAmt>375446</GrossSalesPriceAmt>
          <GainOrLossAmt>375446</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>375446</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>S CAPITAL LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-19</SoldDt>
          <GrossSalesPriceAmt>257700</GrossSalesPriceAmt>
          <GainOrLossAmt>257700</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>257700</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-10-21</SoldDt>
          <GrossSalesPriceAmt>628894</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>524759</CostOrOtherBasisAmt>
          <GainOrLossAmt>104135</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>104135</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-11-04</SoldDt>
          <GrossSalesPriceAmt>626904</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>524759</CostOrOtherBasisAmt>
          <GainOrLossAmt>102145</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>102145</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-09-20</SoldDt>
          <GrossSalesPriceAmt>409493</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>333938</CostOrOtherBasisAmt>
          <GainOrLossAmt>75555</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>75555</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-11-30</SoldDt>
          <GrossSalesPriceAmt>212708</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>178050</CostOrOtherBasisAmt>
          <GainOrLossAmt>34658</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>34658</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-07-31</SoldDt>
          <GrossSalesPriceAmt>194997</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>159018</CostOrOtherBasisAmt>
          <GainOrLossAmt>35979</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>35979</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-11-30</SoldDt>
          <GrossSalesPriceAmt>94986</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>79509</CostOrOtherBasisAmt>
          <GainOrLossAmt>15477</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15477</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-08-26</SoldDt>
          <GrossSalesPriceAmt>58499</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>47705</CostOrOtherBasisAmt>
          <GainOrLossAmt>10794</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>10794</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-08-26</SoldDt>
          <GrossSalesPriceAmt>25798</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>21038</CostOrOtherBasisAmt>
          <GainOrLossAmt>4760</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4760</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-10-21</SoldDt>
          <GrossSalesPriceAmt>25213</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>21038</CostOrOtherBasisAmt>
          <GainOrLossAmt>4175</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4175</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-11-30</SoldDt>
          <GrossSalesPriceAmt>25133</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>21038</CostOrOtherBasisAmt>
          <GainOrLossAmt>4095</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>4095</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-01-31</SoldDt>
          <GrossSalesPriceAmt>24796</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>21038</CostOrOtherBasisAmt>
          <GainOrLossAmt>3758</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3758</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-12-31</SoldDt>
          <GrossSalesPriceAmt>24796</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>21038</CostOrOtherBasisAmt>
          <GainOrLossAmt>3758</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>3758</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-03-31</SoldDt>
          <GrossSalesPriceAmt>24035</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>21038</CostOrOtherBasisAmt>
          <GainOrLossAmt>2997</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2997</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-30</SoldDt>
          <GrossSalesPriceAmt>7122</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>7114</CostOrOtherBasisAmt>
          <GainOrLossAmt>8</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-03-31</SoldDt>
          <GrossSalesPriceAmt>21038</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>20947</CostOrOtherBasisAmt>
          <GainOrLossAmt>91</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>91</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-08-26</SoldDt>
          <GrossSalesPriceAmt>21038</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>20951</CostOrOtherBasisAmt>
          <GainOrLossAmt>87</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>87</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-10-21</SoldDt>
          <GrossSalesPriceAmt>21038</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>20951</CostOrOtherBasisAmt>
          <GainOrLossAmt>87</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>87</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-11-30</SoldDt>
          <GrossSalesPriceAmt>21038</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>20951</CostOrOtherBasisAmt>
          <GainOrLossAmt>87</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>87</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-12-31</SoldDt>
          <GrossSalesPriceAmt>21038</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>20951</CostOrOtherBasisAmt>
          <GainOrLossAmt>87</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>87</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-01-31</SoldDt>
          <GrossSalesPriceAmt>21038</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>20951</CostOrOtherBasisAmt>
          <GainOrLossAmt>87</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>87</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-15</SoldDt>
          <GrossSalesPriceAmt>20909</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>22926</CostOrOtherBasisAmt>
          <GainOrLossAmt>-2017</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-2017</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-31</SoldDt>
          <GrossSalesPriceAmt>35610</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>35881</CostOrOtherBasisAmt>
          <GainOrLossAmt>-271</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-271</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-31</SoldDt>
          <GrossSalesPriceAmt>42053</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>42007</CostOrOtherBasisAmt>
          <GainOrLossAmt>46</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>46</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-08-26</SoldDt>
          <GrossSalesPriceAmt>47705</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>47508</CostOrOtherBasisAmt>
          <GainOrLossAmt>197</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>197</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <GrossSalesPriceAmt>43950</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>47547</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3597</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3597</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-28</SoldDt>
          <GrossSalesPriceAmt>43950</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>48414</CostOrOtherBasisAmt>
          <GainOrLossAmt>-4464</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-4464</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-21</SoldDt>
          <GrossSalesPriceAmt>53400</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>53837</CostOrOtherBasisAmt>
          <GainOrLossAmt>-437</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-437</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-31</SoldDt>
          <GrossSalesPriceAmt>63079</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>63559</CostOrOtherBasisAmt>
          <GainOrLossAmt>-480</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-480</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>63079</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>63631</CostOrOtherBasisAmt>
          <GainOrLossAmt>-552</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-552</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-31</SoldDt>
          <GrossSalesPriceAmt>63079</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>67155</CostOrOtherBasisAmt>
          <GainOrLossAmt>-4076</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-4076</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-16</SoldDt>
          <GrossSalesPriceAmt>63079</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>68241</CostOrOtherBasisAmt>
          <GainOrLossAmt>-5162</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-5162</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-06</SoldDt>
          <GrossSalesPriceAmt>71220</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>71762</CostOrOtherBasisAmt>
          <GainOrLossAmt>-542</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-542</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-30</SoldDt>
          <GrossSalesPriceAmt>71220</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>77049</CostOrOtherBasisAmt>
          <GainOrLossAmt>-5829</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-5829</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-11-30</SoldDt>
          <GrossSalesPriceAmt>79509</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>79181</CostOrOtherBasisAmt>
          <GainOrLossAmt>328</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>328</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-31</SoldDt>
          <GrossSalesPriceAmt>79509</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>80114</CostOrOtherBasisAmt>
          <GainOrLossAmt>-605</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-605</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-19</SoldDt>
          <GrossSalesPriceAmt>87900</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>87805</CostOrOtherBasisAmt>
          <GainOrLossAmt>95</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>95</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-29</SoldDt>
          <GrossSalesPriceAmt>89000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>89728</CostOrOtherBasisAmt>
          <GainOrLossAmt>-728</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-728</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-15</SoldDt>
          <GrossSalesPriceAmt>87900</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>96380</CostOrOtherBasisAmt>
          <GainOrLossAmt>-8480</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-8480</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-01</SoldDt>
          <GrossSalesPriceAmt>106800</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>107612</CostOrOtherBasisAmt>
          <GainOrLossAmt>-812</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-812</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-29</SoldDt>
          <GrossSalesPriceAmt>142440</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>143605</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1165</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1165</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-30</SoldDt>
          <GrossSalesPriceAmt>142440</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>156161</CostOrOtherBasisAmt>
          <GainOrLossAmt>-13721</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-13721</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-07-31</SoldDt>
          <GrossSalesPriceAmt>159018</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>158361</CostOrOtherBasisAmt>
          <GainOrLossAmt>657</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>657</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-19</SoldDt>
          <GrossSalesPriceAmt>174920</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>174730</CostOrOtherBasisAmt>
          <GainOrLossAmt>190</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>190</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-11-30</SoldDt>
          <GrossSalesPriceAmt>178050</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>177315</CostOrOtherBasisAmt>
          <GainOrLossAmt>735</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>735</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-31</SoldDt>
          <GrossSalesPriceAmt>178000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>179455</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1455</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1455</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-21</SoldDt>
          <GrossSalesPriceAmt>213660</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>215407</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1747</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1747</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-21</SoldDt>
          <GrossSalesPriceAmt>318036</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>320636</CostOrOtherBasisAmt>
          <GainOrLossAmt>-2600</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-2600</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-09-20</SoldDt>
          <GrossSalesPriceAmt>333938</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>332559</CostOrOtherBasisAmt>
          <GainOrLossAmt>1379</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1379</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-01</SoldDt>
          <GrossSalesPriceAmt>356100</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>359011</CostOrOtherBasisAmt>
          <GainOrLossAmt>-2911</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-2911</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-31</SoldDt>
          <GrossSalesPriceAmt>391710</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>394913</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3203</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3203</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-17</SoldDt>
          <GrossSalesPriceAmt>397545</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>400568</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3023</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3023</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-06</SoldDt>
          <GrossSalesPriceAmt>508858</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>512728</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3870</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3870</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <GrossSalesPriceAmt>477054</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>516097</CostOrOtherBasisAmt>
          <GainOrLossAmt>-39043</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-39043</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-10-21</SoldDt>
          <GrossSalesPriceAmt>524759</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>522592</CostOrOtherBasisAmt>
          <GainOrLossAmt>2167</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2167</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-11-04</SoldDt>
          <GrossSalesPriceAmt>524759</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>522592</CostOrOtherBasisAmt>
          <GainOrLossAmt>2167</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2167</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL FUND</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-22</SoldDt>
          <GrossSalesPriceAmt>1160831</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>1170322</CostOrOtherBasisAmt>
          <GainOrLossAmt>-9491</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-9491</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-14</SoldDt>
          <GrossSalesPriceAmt>1578466</GrossSalesPriceAmt>
          <GainOrLossAmt>1578466</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1578466</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-08</SoldDt>
          <GrossSalesPriceAmt>1491943</GrossSalesPriceAmt>
          <GainOrLossAmt>1491943</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1491943</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-04</SoldDt>
          <GrossSalesPriceAmt>1471819</GrossSalesPriceAmt>
          <GainOrLossAmt>1471819</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1471819</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>1466554</GrossSalesPriceAmt>
          <GainOrLossAmt>1466554</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1466554</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-28</SoldDt>
          <GrossSalesPriceAmt>1434034</GrossSalesPriceAmt>
          <GainOrLossAmt>1434034</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1434034</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-27</SoldDt>
          <GrossSalesPriceAmt>1376040</GrossSalesPriceAmt>
          <GainOrLossAmt>1376040</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1376040</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-08</SoldDt>
          <GrossSalesPriceAmt>1353030</GrossSalesPriceAmt>
          <GainOrLossAmt>1353030</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1353030</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-01</SoldDt>
          <GrossSalesPriceAmt>615323</GrossSalesPriceAmt>
          <GainOrLossAmt>615323</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>615323</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-11</SoldDt>
          <GrossSalesPriceAmt>425044</GrossSalesPriceAmt>
          <GainOrLossAmt>425044</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>425044</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-27</SoldDt>
          <GrossSalesPriceAmt>170131</GrossSalesPriceAmt>
          <GainOrLossAmt>170131</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>170131</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-05</SoldDt>
          <GrossSalesPriceAmt>294498</GrossSalesPriceAmt>
          <GainOrLossAmt>294498</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>294498</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL GLOBAL GROWTH FD III - ENDURANCE PARTNERS LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-07</SoldDt>
          <GrossSalesPriceAmt>400047</GrossSalesPriceAmt>
          <GainOrLossAmt>400047</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>400047</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GR FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-01</SoldDt>
          <GrossSalesPriceAmt>763899</GrossSalesPriceAmt>
          <GainOrLossAmt>763899</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>763899</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GR FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-05</SoldDt>
          <GrossSalesPriceAmt>260781</GrossSalesPriceAmt>
          <GainOrLossAmt>260781</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>260781</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GR FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-27</SoldDt>
          <GrossSalesPriceAmt>306458</GrossSalesPriceAmt>
          <GainOrLossAmt>306458</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>306458</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GR FD</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-23</SoldDt>
          <GrossSalesPriceAmt>484514</GrossSalesPriceAmt>
          <GainOrLossAmt>484514</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>484514</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-11</SoldDt>
          <GrossSalesPriceAmt>1238639</GrossSalesPriceAmt>
          <GainOrLossAmt>1238639</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1238639</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-20</SoldDt>
          <GrossSalesPriceAmt>790194</GrossSalesPriceAmt>
          <GainOrLossAmt>790194</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>790194</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-13</SoldDt>
          <GrossSalesPriceAmt>766541</GrossSalesPriceAmt>
          <GainOrLossAmt>766541</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>766541</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-07</SoldDt>
          <GrossSalesPriceAmt>758718</GrossSalesPriceAmt>
          <GainOrLossAmt>758718</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>758718</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-08</SoldDt>
          <GrossSalesPriceAmt>719783</GrossSalesPriceAmt>
          <GainOrLossAmt>719783</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>719783</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-05</SoldDt>
          <GrossSalesPriceAmt>711141</GrossSalesPriceAmt>
          <GainOrLossAmt>711141</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>711141</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-29</SoldDt>
          <GrossSalesPriceAmt>695494</GrossSalesPriceAmt>
          <GainOrLossAmt>695494</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>695494</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-27</SoldDt>
          <GrossSalesPriceAmt>164365</GrossSalesPriceAmt>
          <GainOrLossAmt>164365</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>164365</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP GBL GROWTH FD II</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-05</SoldDt>
          <GrossSalesPriceAmt>484298</GrossSalesPriceAmt>
          <GainOrLossAmt>484298</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>484298</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA US E EXPANSION FUND I</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2022-12-31</SoldDt>
          <CostOrOtherBasisAmt>287317</CostOrOtherBasisAmt>
          <GainOrLossAmt>-287317</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-287317</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GR FD VIII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-08</SoldDt>
          <GrossSalesPriceAmt>248987</GrossSalesPriceAmt>
          <GainOrLossAmt>248987</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>248987</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GR FD VIII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-30</SoldDt>
          <GrossSalesPriceAmt>35306</GrossSalesPriceAmt>
          <GainOrLossAmt>35306</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>35306</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GR FD VIII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-14</SoldDt>
          <GrossSalesPriceAmt>388842</GrossSalesPriceAmt>
          <GainOrLossAmt>388842</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>388842</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-14</SoldDt>
          <GrossSalesPriceAmt>490651</GrossSalesPriceAmt>
          <GainOrLossAmt>490651</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>490651</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-08</SoldDt>
          <GrossSalesPriceAmt>489349</GrossSalesPriceAmt>
          <GainOrLossAmt>489349</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>489349</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-04</SoldDt>
          <GrossSalesPriceAmt>483019</GrossSalesPriceAmt>
          <GainOrLossAmt>483019</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>483019</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>481363</GrossSalesPriceAmt>
          <GainOrLossAmt>481363</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>481363</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-28</SoldDt>
          <GrossSalesPriceAmt>471133</GrossSalesPriceAmt>
          <GainOrLossAmt>471133</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>471133</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-27</SoldDt>
          <GrossSalesPriceAmt>452890</GrossSalesPriceAmt>
          <GainOrLossAmt>452890</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>452890</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-08</SoldDt>
          <GrossSalesPriceAmt>445652</GrossSalesPriceAmt>
          <GainOrLossAmt>445652</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>445652</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-08</SoldDt>
          <GrossSalesPriceAmt>361878</GrossSalesPriceAmt>
          <GainOrLossAmt>361878</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>361878</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-20</SoldDt>
          <GrossSalesPriceAmt>277360</GrossSalesPriceAmt>
          <GainOrLossAmt>277360</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>277360</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-13</SoldDt>
          <GrossSalesPriceAmt>266861</GrossSalesPriceAmt>
          <GainOrLossAmt>266861</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>266861</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-07</SoldDt>
          <GrossSalesPriceAmt>264138</GrossSalesPriceAmt>
          <GainOrLossAmt>264138</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>264138</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-08</SoldDt>
          <GrossSalesPriceAmt>250583</GrossSalesPriceAmt>
          <GainOrLossAmt>250583</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>250583</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-05</SoldDt>
          <GrossSalesPriceAmt>247574</GrossSalesPriceAmt>
          <GainOrLossAmt>247574</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>247574</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-29</SoldDt>
          <GrossSalesPriceAmt>242127</GrossSalesPriceAmt>
          <GainOrLossAmt>242127</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>242127</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-07</SoldDt>
          <GrossSalesPriceAmt>208725</GrossSalesPriceAmt>
          <GainOrLossAmt>208725</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>208725</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-22</SoldDt>
          <GrossSalesPriceAmt>169544</GrossSalesPriceAmt>
          <GainOrLossAmt>169544</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>169544</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-17</SoldDt>
          <GrossSalesPriceAmt>158500</GrossSalesPriceAmt>
          <GainOrLossAmt>158500</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>158500</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VII LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-07</SoldDt>
          <CostOrOtherBasisAmt>1308</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1308</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1308</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GR FUND IX LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-05</SoldDt>
          <GrossSalesPriceAmt>109870</GrossSalesPriceAmt>
          <GainOrLossAmt>109870</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>109870</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-25</SoldDt>
          <GrossSalesPriceAmt>704494</GrossSalesPriceAmt>
          <GainOrLossAmt>704494</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>704494</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-30</SoldDt>
          <GrossSalesPriceAmt>684604</GrossSalesPriceAmt>
          <GainOrLossAmt>684604</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>684604</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-16</SoldDt>
          <GrossSalesPriceAmt>507592</GrossSalesPriceAmt>
          <GainOrLossAmt>507592</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>507592</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-22</SoldDt>
          <GrossSalesPriceAmt>486637</GrossSalesPriceAmt>
          <GainOrLossAmt>486637</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>486637</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-21</SoldDt>
          <GrossSalesPriceAmt>486637</GrossSalesPriceAmt>
          <GainOrLossAmt>486637</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>486637</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-05</SoldDt>
          <GrossSalesPriceAmt>405664</GrossSalesPriceAmt>
          <GainOrLossAmt>405664</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>405664</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-20</SoldDt>
          <GrossSalesPriceAmt>259879</GrossSalesPriceAmt>
          <GainOrLossAmt>259879</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>259879</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-13</SoldDt>
          <GrossSalesPriceAmt>242794</GrossSalesPriceAmt>
          <GainOrLossAmt>242794</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>242794</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-07</SoldDt>
          <GrossSalesPriceAmt>240337</GrossSalesPriceAmt>
          <GainOrLossAmt>240337</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>240337</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-08</SoldDt>
          <GrossSalesPriceAmt>228109</GrossSalesPriceAmt>
          <GainOrLossAmt>228109</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>228109</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-05</SoldDt>
          <GrossSalesPriceAmt>225395</GrossSalesPriceAmt>
          <GainOrLossAmt>225395</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>225395</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-29</SoldDt>
          <GrossSalesPriceAmt>220481</GrossSalesPriceAmt>
          <GainOrLossAmt>220481</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>220481</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-01</SoldDt>
          <GrossSalesPriceAmt>195805</GrossSalesPriceAmt>
          <GainOrLossAmt>195805</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>195805</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAP US GROWTH FD VI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-05</SoldDt>
          <CostOrOtherBasisAmt>405664</CostOrOtherBasisAmt>
          <GainOrLossAmt>-405664</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-405664</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-16</SoldDt>
          <GrossSalesPriceAmt>1542538</GrossSalesPriceAmt>
          <GainOrLossAmt>1542538</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1542538</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-22</SoldDt>
          <GrossSalesPriceAmt>1483792</GrossSalesPriceAmt>
          <GainOrLossAmt>1483792</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1483792</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-21</SoldDt>
          <GrossSalesPriceAmt>1483792</GrossSalesPriceAmt>
          <GainOrLossAmt>1483792</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1483792</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-25</SoldDt>
          <GrossSalesPriceAmt>1435175</GrossSalesPriceAmt>
          <GainOrLossAmt>1435175</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1435175</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-30</SoldDt>
          <GrossSalesPriceAmt>1413082</GrossSalesPriceAmt>
          <GainOrLossAmt>1413082</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1413082</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-05</SoldDt>
          <GrossSalesPriceAmt>1245562</GrossSalesPriceAmt>
          <GainOrLossAmt>1245562</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1245562</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-20</SoldDt>
          <GrossSalesPriceAmt>713589</GrossSalesPriceAmt>
          <GainOrLossAmt>713589</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>713589</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-13</SoldDt>
          <GrossSalesPriceAmt>671663</GrossSalesPriceAmt>
          <GainOrLossAmt>671663</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>671663</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-07</SoldDt>
          <GrossSalesPriceAmt>665176</GrossSalesPriceAmt>
          <GainOrLossAmt>665176</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>665176</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-08</SoldDt>
          <GrossSalesPriceAmt>632892</GrossSalesPriceAmt>
          <GainOrLossAmt>632892</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>632892</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-05</SoldDt>
          <GrossSalesPriceAmt>625726</GrossSalesPriceAmt>
          <GainOrLossAmt>625726</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>625726</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-29</SoldDt>
          <GrossSalesPriceAmt>612752</GrossSalesPriceAmt>
          <GainOrLossAmt>612752</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>612752</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SEQUOIA CAPITAL U.S. VENTURE FUND XIV L.P..</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-05</SoldDt>
          <CostOrOtherBasisAmt>1245562</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1245562</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1245562</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-03-28</SoldDt>
          <GrossSalesPriceAmt>77882</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>56580</CostOrOtherBasisAmt>
          <GainOrLossAmt>21302</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>21302</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-29</SoldDt>
          <GrossSalesPriceAmt>76640</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>59264</CostOrOtherBasisAmt>
          <GainOrLossAmt>17376</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>17376</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-02-29</SoldDt>
          <GrossSalesPriceAmt>75760</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>59365</CostOrOtherBasisAmt>
          <GainOrLossAmt>16395</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16395</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2024-01-31</SoldDt>
          <GrossSalesPriceAmt>75792</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>59390</CostOrOtherBasisAmt>
          <GainOrLossAmt>16402</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>16402</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-07-31</SoldDt>
          <GrossSalesPriceAmt>74806</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>59763</CostOrOtherBasisAmt>
          <GainOrLossAmt>15043</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>15043</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-11-30</SoldDt>
          <GrossSalesPriceAmt>73114</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>59975</CostOrOtherBasisAmt>
          <GainOrLossAmt>13139</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13139</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-08-31</SoldDt>
          <GrossSalesPriceAmt>73207</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>60050</CostOrOtherBasisAmt>
          <GainOrLossAmt>13157</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>13157</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-09-30</SoldDt>
          <GrossSalesPriceAmt>72128</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>60243</CostOrOtherBasisAmt>
          <GainOrLossAmt>11885</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>11885</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-30</SoldDt>
          <GrossSalesPriceAmt>71467</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>60479</CostOrOtherBasisAmt>
          <GainOrLossAmt>10988</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>10988</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-04-28</SoldDt>
          <GrossSalesPriceAmt>71068</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>60630</CostOrOtherBasisAmt>
          <GainOrLossAmt>10438</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>10438</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-10-31</SoldDt>
          <GrossSalesPriceAmt>69126</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>60882</CostOrOtherBasisAmt>
          <GainOrLossAmt>8244</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>8244</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>THE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-05-31</SoldDt>
          <GrossSalesPriceAmt>68852</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>61106</CostOrOtherBasisAmt>
          <GainOrLossAmt>7746</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>7746</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>SPDR S&amp;P 500 ETF TRUST</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-04</SoldDt>
          <GrossSalesPriceAmt>25091453</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>25566371</CostOrOtherBasisAmt>
          <GainOrLossAmt>-474918</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-474918</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>STARWOOD GLOBAL OPP FD XI LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-12-15</SoldDt>
          <GrossSalesPriceAmt>386971</GrossSalesPriceAmt>
          <GainOrLossAmt>386971</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>386971</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>VENTURE LENDING &amp; LEASING VII LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-06</SoldDt>
          <GrossSalesPriceAmt>541673</GrossSalesPriceAmt>
          <GainOrLossAmt>541673</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>541673</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>VENTURE LENDING &amp; LEASING VIII LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <SoldDt>2023-06-06</SoldDt>
          <GrossSalesPriceAmt>599367</GrossSalesPriceAmt>
          <GainOrLossAmt>599367</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>599367</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>3149477</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3149477</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3149477</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>187389</CostOrOtherBasisAmt>
          <GainOrLossAmt>-187389</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-187389</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>10180</CostOrOtherBasisAmt>
          <GainOrLossAmt>-10180</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-10180</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>139443</CostOrOtherBasisAmt>
          <GainOrLossAmt>-139443</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-139443</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>490824</CostOrOtherBasisAmt>
          <GainOrLossAmt>-490824</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-490824</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>45353</CostOrOtherBasisAmt>
          <GainOrLossAmt>-45353</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-45353</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>502258</CostOrOtherBasisAmt>
          <GainOrLossAmt>-502258</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-502258</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>45698</CostOrOtherBasisAmt>
          <GainOrLossAmt>-45698</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-45698</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>598000</CostOrOtherBasisAmt>
          <GainOrLossAmt>-598000</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-598000</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>46322</CostOrOtherBasisAmt>
          <GainOrLossAmt>-46322</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-46322</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>3056144</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3056144</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3056144</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>46183</CostOrOtherBasisAmt>
          <GainOrLossAmt>-46183</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-46183</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>77786</CostOrOtherBasisAmt>
          <GainOrLossAmt>-77786</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-77786</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>46472</CostOrOtherBasisAmt>
          <GainOrLossAmt>-46472</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-46472</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>120255</CostOrOtherBasisAmt>
          <GainOrLossAmt>-120255</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-120255</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>74636</CostOrOtherBasisAmt>
          <GainOrLossAmt>-74636</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-74636</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>92393</CostOrOtherBasisAmt>
          <GainOrLossAmt>-92393</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-92393</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>1705</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1705</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1705</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>26772</CostOrOtherBasisAmt>
          <GainOrLossAmt>-26772</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-26772</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>3852</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3852</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3852</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>46005</CostOrOtherBasisAmt>
          <GainOrLossAmt>-46005</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-46005</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>142267</CostOrOtherBasisAmt>
          <GainOrLossAmt>-142267</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-142267</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>135500</CostOrOtherBasisAmt>
          <GainOrLossAmt>-135500</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-135500</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>4140</CostOrOtherBasisAmt>
          <GainOrLossAmt>-4140</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-4140</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>54177</CostOrOtherBasisAmt>
          <GainOrLossAmt>-54177</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-54177</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>3297</CostOrOtherBasisAmt>
          <GainOrLossAmt>-3297</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-3297</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>730</CostOrOtherBasisAmt>
          <GainOrLossAmt>-730</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-730</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>631</CostOrOtherBasisAmt>
          <GainOrLossAmt>-631</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-631</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>136</CostOrOtherBasisAmt>
          <GainOrLossAmt>-136</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-136</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>1927</CostOrOtherBasisAmt>
          <GainOrLossAmt>-1927</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-1927</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>60704</GrossSalesPriceAmt>
          <GainOrLossAmt>60704</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>60704</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>20977</GrossSalesPriceAmt>
          <GainOrLossAmt>20977</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>20977</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>26896</GrossSalesPriceAmt>
          <GainOrLossAmt>26896</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>26896</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>521242</GrossSalesPriceAmt>
          <GainOrLossAmt>521242</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>521242</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>1260</GrossSalesPriceAmt>
          <GainOrLossAmt>1260</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1260</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>62366</GrossSalesPriceAmt>
          <GainOrLossAmt>62366</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>62366</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>1118</GrossSalesPriceAmt>
          <GainOrLossAmt>1118</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1118</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>43755</GrossSalesPriceAmt>
          <GainOrLossAmt>43755</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>43755</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>1</GrossSalesPriceAmt>
          <GainOrLossAmt>1</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>1870</GrossSalesPriceAmt>
          <GainOrLossAmt>1870</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>1870</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>2205</CostOrOtherBasisAmt>
          <GainOrLossAmt>-2205</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-2205</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>31869</GrossSalesPriceAmt>
          <GainOrLossAmt>31869</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>31869</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>286390</GrossSalesPriceAmt>
          <GainOrLossAmt>286390</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>286390</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CRESTVIEW PARTNERS III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>27043</GrossSalesPriceAmt>
          <GainOrLossAmt>27043</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>27043</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>2245125</GrossSalesPriceAmt>
          <GainOrLossAmt>2245125</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>2245125</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD II LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>552608</GrossSalesPriceAmt>
          <GainOrLossAmt>552608</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>552608</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GENERAL ATLANTIC SERVICE COMPANY LLC</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>56092</GrossSalesPriceAmt>
          <GainOrLossAmt>56092</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>56092</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CRESTVIEW PARTNERS IV LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>22328</GrossSalesPriceAmt>
          <GainOrLossAmt>22328</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>22328</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>HIG MIDDLE MKT LBO FD III LP</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>100602</GrossSalesPriceAmt>
          <GainOrLossAmt>100602</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>100602</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>24965982</CostOrOtherBasisAmt>
          <GainOrLossAmt>-24965982</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-24965982</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO III</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>234621</GrossSalesPriceAmt>
          <GainOrLossAmt>234621</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>234621</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO III AIV-1</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>515966</CostOrOtherBasisAmt>
          <GainOrLossAmt>-515966</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-515966</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO III AIV-2</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>484356</CostOrOtherBasisAmt>
          <GainOrLossAmt>-484356</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-484356</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO III AIV-3</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>463790</CostOrOtherBasisAmt>
          <GainOrLossAmt>-463790</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-463790</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO III AIV-5</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>711774</CostOrOtherBasisAmt>
          <GainOrLossAmt>-711774</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-711774</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>GSO III AIV-6</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>39883</CostOrOtherBasisAmt>
          <GainOrLossAmt>-39883</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-39883</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>ACADIAN FRONTIER MARKETS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <CostOrOtherBasisAmt>227186</CostOrOtherBasisAmt>
          <GainOrLossAmt>-227186</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-227186</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>K-1 ADJUSTMENTS, NET OF UBI AND RELATED AMOUNTS ABOVE</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GainOrLossAmt>-116807506</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-116807506</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapitalGainNetIncomeAmt>132680049</CapitalGainNetIncomeAmt>
      </CapGainsLossTxInvstIncmDetail>
      <ExciseTaxBasedOnInvstIncmGrp>
        <InvestmentIncomeExciseTaxAmt>3123302</InvestmentIncomeExciseTaxAmt>
        <TaxUnderSection511Amt>0</TaxUnderSection511Amt>
        <SubtotalAmt>3123302</SubtotalAmt>
        <SubtitleATaxAmt>0</SubtitleATaxAmt>
        <TaxBasedOnInvestmentIncomeAmt>3123302</TaxBasedOnInvestmentIncomeAmt>
        <EstimatedPlusOvpmtIncmTxAmt>9523536</EstimatedPlusOvpmtIncmTxAmt>
        <ExemptFrgnOrgTaxWthldAtSrceAmt>0</ExemptFrgnOrgTaxWthldAtSrceAmt>
        <ExtsnRequestIncomeTaxPaidAmt>0</ExtsnRequestIncomeTaxPaidAmt>
        <BackupWithholdingWithheldAmt>0</BackupWithholdingWithheldAmt>
        <TotalPaymentsAndCreditsAmt>9523536</TotalPaymentsAndCreditsAmt>
        <Form2220AttachedInd referenceDocumentId="RetDoc1192000001">X</Form2220AttachedInd>
        <EsPenaltyAmt>0</EsPenaltyAmt>
        <OverpaymentAmt>6400234</OverpaymentAmt>
        <AppliedToESTaxAmt>6400234</AppliedToESTaxAmt>
        <RefundAmt>0</RefundAmt>
      </ExciseTaxBasedOnInvstIncmGrp>
      <StatementsRegardingActyGrp>
        <LegislativePoliticalActyInd>0</LegislativePoliticalActyInd>
        <MoreThan100SpentInd>0</MoreThan100SpentInd>
        <Form1120POLFiledInd>0</Form1120POLFiledInd>
        <Section4955OrganizationTaxAmt>0</Section4955OrganizationTaxAmt>
        <Section4955ManagersTaxAmt>0</Section4955ManagersTaxAmt>
        <TaxReimbursedAmt>0</TaxReimbursedAmt>
        <ActivitiesNotPreviouslyRptInd>0</ActivitiesNotPreviouslyRptInd>
        <ChangesToArticlesOrBylawsInd>0</ChangesToArticlesOrBylawsInd>
        <UnrelatedBusIncmOverLimitInd>1</UnrelatedBusIncmOverLimitInd>
        <Form990TFiledInd>1</Form990TFiledInd>
        <OrganizationDissolvedEtcInd>0</OrganizationDissolvedEtcInd>
        <Section508eRqrSatisfiedInd>1</Section508eRqrSatisfiedInd>
        <AtLeast5000InAssetsInd>1</AtLeast5000InAssetsInd>
        <OrgReportOrRegisterStateCd>NY</OrgReportOrRegisterStateCd>
        <Form990PFFiledWithAttyGenInd>1</Form990PFFiledWithAttyGenInd>
        <PrivateOperatingFoundationInd>0</PrivateOperatingFoundationInd>
        <NewSubstantialContributorsInd>0</NewSubstantialContributorsInd>
        <OwnControlledEntityInd referenceDocumentId="RetDoc2204900001 RetDoc2205000001">1</OwnControlledEntityInd>
        <DonorAdvisedFundInd>0</DonorAdvisedFundInd>
        <ComplyWithPublicInspRqrInd>1</ComplyWithPublicInspRqrInd>
        <WebsiteAddressTxt>HELMSLEYTRUST.ORG</WebsiteAddressTxt>
        <PersonsWithBooksName>
          <BusinessNameLine1Txt>NICHOLAS J SCHIAVO CFO</BusinessNameLine1Txt>
        </PersonsWithBooksName>
        <PhoneNum>2126793600</PhoneNum>
        <LocationOfBooksUSAddress>
          <AddressLine1Txt>230 PARK AVENUE SUITE 659</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10169</ZIPCd>
        </LocationOfBooksUSAddress>
        <ForeignAccountsQuestionInd>1</ForeignAccountsQuestionInd>
        <ForeignCountryCd>AS</ForeignCountryCd>
        <ForeignCountryCd>AU</ForeignCountryCd>
        <ForeignCountryCd>BE</ForeignCountryCd>
        <ForeignCountryCd>CA</ForeignCountryCd>
        <ForeignCountryCd>DA</ForeignCountryCd>
        <ForeignCountryCd>FI</ForeignCountryCd>
        <ForeignCountryCd>FR</ForeignCountryCd>
        <ForeignCountryCd>GM</ForeignCountryCd>
        <ForeignCountryCd>HK</ForeignCountryCd>
        <ForeignCountryCd>ID</ForeignCountryCd>
        <ForeignCountryCd>IT</ForeignCountryCd>
        <ForeignCountryCd>JA</ForeignCountryCd>
        <ForeignCountryCd>NL</ForeignCountryCd>
        <ForeignCountryCd>NZ</ForeignCountryCd>
        <ForeignCountryCd>NO</ForeignCountryCd>
        <ForeignCountryCd>PO</ForeignCountryCd>
        <ForeignCountryCd>SN</ForeignCountryCd>
        <ForeignCountryCd>SF</ForeignCountryCd>
        <ForeignCountryCd>KS</ForeignCountryCd>
        <ForeignCountryCd>SP</ForeignCountryCd>
        <ForeignCountryCd>SW</ForeignCountryCd>
        <ForeignCountryCd>SZ</ForeignCountryCd>
        <ForeignCountryCd>TW</ForeignCountryCd>
        <ForeignCountryCd>UK</ForeignCountryCd>
      </StatementsRegardingActyGrp>
      <StatementsRegardingActy4720Grp>
        <SaleOrExchDisqualifiedPrsnInd>1</SaleOrExchDisqualifiedPrsnInd>
        <BrrwOrLendDisqualifiedPrsnInd>0</BrrwOrLendDisqualifiedPrsnInd>
        <FurnGoodsDisqualifiedPrsnInd>1</FurnGoodsDisqualifiedPrsnInd>
        <PayCompDisqualifiedPrsnInd>1</PayCompDisqualifiedPrsnInd>
        <TransferAstDisqualifiedPrsnInd>0</TransferAstDisqualifiedPrsnInd>
        <PaymentToGovernmentOfficialInd>0</PaymentToGovernmentOfficialInd>
        <ActsFailToQlfyAsExceptionsInd>0</ActsFailToQlfyAsExceptionsInd>
        <UncorrectedPriorActsInd>0</UncorrectedPriorActsInd>
        <UndistributedIncomePYInd>0</UndistributedIncomePYInd>
        <BusinessHoldingsInd>1</BusinessHoldingsInd>
        <ExcessBusinessHoldingsInd>0</ExcessBusinessHoldingsInd>
        <JeopardyInvestmentsInd>0</JeopardyInvestmentsInd>
        <UncorrectedPYJeopardyInvstInd>0</UncorrectedPYJeopardyInvstInd>
        <InfluenceLegislationInd>0</InfluenceLegislationInd>
        <InfluenceElectionInd>0</InfluenceElectionInd>
        <GrantsToIndividualsInd>0</GrantsToIndividualsInd>
        <GrantsToOrganizationsInd>1</GrantsToOrganizationsInd>
        <NoncharitablePurposeInd>0</NoncharitablePurposeInd>
        <TransactionsFailToQlfyAsExcInd>0</TransactionsFailToQlfyAsExcInd>
        <MaintainedExpenditureRspnsInd referenceDocumentId="RetDoc2118100001">1</MaintainedExpenditureRspnsInd>
        <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
        <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
        <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
        <SubjToTaxRmnrtnExPrchtPymtInd>1</SubjToTaxRmnrtnExPrchtPymtInd>
      </StatementsRegardingActy4720Grp>
      <OfficerDirTrstKeyEmplInfoGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>SANDOR FRANKEL</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>25.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>150000</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>DAVID PANZIRER</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>35.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>150000</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>WALTER PANZIRER</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>32.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>150000</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>SARAH E PAUL</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF EXECUTIVE OFFICER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>918521</CompensationAmt>
          <EmployeeBenefitProgramAmt>213448</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>JACQUELINE F BAUSCH</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>GENERAL COUNSEL</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>592495</CompensationAmt>
          <EmployeeBenefitProgramAmt>94658</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>ROSALIND M HEWSENIAN</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF INVESTMENT OFFICER THRU 12/31/23</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>1148308</CompensationAmt>
          <EmployeeBenefitProgramAmt>175873</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>JOSHUA W FENTON</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF INVESTMENT OFFICER FROM 1/1/24</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>794891</CompensationAmt>
          <EmployeeBenefitProgramAmt>190587</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>NICHOLAS J SCHIAVO</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>CHIEF FINANCIAL OFFICER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>472114</CompensationAmt>
          <EmployeeBenefitProgramAmt>121468</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>AL Y KIM</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIRECTOR OF INVESTME</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>735817</CompensationAmt>
          <EmployeeBenefitsAmt>187033</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>MEENAKSHI C LAKSHMAN</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIR. OF STRATEGY &amp; R</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>728700</CompensationAmt>
          <EmployeeBenefitsAmt>185916</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>CHRISTOPHER J RAPCEWICZ</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIR. OF RISK MNGMT.</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>735462</CompensationAmt>
          <EmployeeBenefitsAmt>167904</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>MAUREEN E RAYHILL</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIRECTOR OF HUMAN RE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>458150</CompensationAmt>
          <EmployeeBenefitsAmt>96071</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <CompensationHighestPaidEmplGrp>
          <PersonNm>BRIAN B CHUN</PersonNm>
          <USAddress>
            <AddressLine1Txt>C/O TRUST 230 PARK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10169</ZIPCd>
          </USAddress>
          <TitleTxt>DIRECTOR OF INVESTME</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>40.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>454231</CompensationAmt>
          <EmployeeBenefitsAmt>80661</EmployeeBenefitsAmt>
          <ExpenseAccountAmt>0</ExpenseAccountAmt>
        </CompensationHighestPaidEmplGrp>
        <OtherEmployeePaidOver50kCnt>104</OtherEmployeePaidOver50kCnt>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>CRESTVIEW III</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>590 MADISON AVENUE 36TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>3690235</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>HIGHCLERE INTERNATIONAL INVESTORS</BusinessNameLine1Txt>
          </BusinessName>
          <ForeignAddress>
            <AddressLine1Txt>2 MANCHESTER SQUARE</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
            <ForeignPostalCd>W1U 3PA</ForeignPostalCd>
          </ForeignAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>1729940</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>IFP GLOBAL FRANCHISE</BusinessNameLine1Txt>
          </BusinessName>
          <ForeignAddress>
            <AddressLine1Txt>LEVEL 1 10 PORTMAN SQUARE</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
            <ForeignPostalCd>W1H 6AZ</ForeignPostalCd>
          </ForeignAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>1241609</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>MARATHON GLOBAL</BusinessNameLine1Txt>
          </BusinessName>
          <ForeignAddress>
            <AddressLine1Txt>ORION HOUSE 5 UPPER ST MARTINS LANE</AddressLine1Txt>
            <CountryCd>UK</CountryCd>
            <ForeignPostalCd>WC2H 9EA</ForeignPostalCd>
          </ForeignAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>880955</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>SILCHESTER INTL</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>780 3RD AVE 4201</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>INVESTMENT MANAGEMENT</ServiceTypeTxt>
          <CompensationAmt>879842</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <ContractorPaidOver50kCnt>53</ContractorPaidOver50kCnt>
      </OfficerDirTrstKeyEmplInfoGrp>
      <SummaryOfDirectChrtblActyGrp>
        <Description1Txt>FOR THE PRODUCTION OF WEBSITE, VIDEO AND OTHER DESIGN SUPPORT TO COMMUNICATE IMPACT IN FURTHERANCE OF THE FOUNDATION'S MISSION.</Description1Txt>
        <Expenses1Amt>1217774</Expenses1Amt>
        <Description2Txt>FOR TECHNICAL SUPPORT TO GRANTEES TO MEET THEIR STRATEGIC AND COMMUNICATIONS NEEDS TO DRIVE FURTHER IMPACT OF THEIR CHARITABLE WORK.</Description2Txt>
        <Expenses2Amt>170066</Expenses2Amt>
        <Description3Txt>FOR CONVENING EXPERTS TO EXPLORE PROGRAM PRIORITIES, SHARE RESEARCH AND IDEAS, AND BRAINSTORM NEW AREAS OF IMPACT IN SUPPORT OF THE FOUNDATION'S MISSION.</Description3Txt>
        <Expenses3Amt>249368</Expenses3Amt>
      </SummaryOfDirectChrtblActyGrp>
      <SumOfProgramRelatedInvstGrp>
        <Description1Txt>STARTUP HEALTH T1D PRI LP - CATALYZING SEED AND EARLY STAGE COMPANIES DEVELOPING INNOVATIVE T1D CARE SOLUTIONS</Description1Txt>
        <Expenses1Amt>2500000</Expenses1Amt>
        <Description2Txt>THETIS PHARMACEUTICALS, LLC - DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHN'S DISEASE</Description2Txt>
        <Expenses2Amt>880756</Expenses2Amt>
        <AllOtherProgramRltdInvstTotAmt referenceDocumentId="RetDoc2063500001">1187500</AllOtherProgramRltdInvstTotAmt>
        <TotalAmt>4568256</TotalAmt>
      </SumOfProgramRelatedInvstGrp>
      <MinimumInvestmentReturnGrp>
        <AverageMonthlyFMVOfSecAmt>6913612076</AverageMonthlyFMVOfSecAmt>
        <AverageMonthlyCashBalancesAmt>199653289</AverageMonthlyCashBalancesAmt>
        <FMVAllOtherNoncharitableAstAmt>429267</FMVAllOtherNoncharitableAstAmt>
        <TotalFMVOfUnusedAssetsAmt>7113694632</TotalFMVOfUnusedAssetsAmt>
        <ReductionClaimedAmt>0</ReductionClaimedAmt>
        <AcquisitionIndebtednessAmt>0</AcquisitionIndebtednessAmt>
        <AdjustedTotalFMVOfUnusedAstAmt>7113694632</AdjustedTotalFMVOfUnusedAstAmt>
        <CashDeemedCharitableAmt>106705419</CashDeemedCharitableAmt>
        <NetVlNoncharitableAssetsAmt>7006989213</NetVlNoncharitableAssetsAmt>
        <MinimumInvestmentReturnAmt>350349461</MinimumInvestmentReturnAmt>
      </MinimumInvestmentReturnGrp>
      <DistributableAmountGrp>
        <MinimumInvestmentReturnAmt>350349461</MinimumInvestmentReturnAmt>
        <TaxBasedOnInvestmentIncomeAmt>3123302</TaxBasedOnInvestmentIncomeAmt>
        <IncomeTaxAmt>189633</IncomeTaxAmt>
        <TotalTaxAmt>3312935</TotalTaxAmt>
        <DistributableBeforeAdjAmt>347036526</DistributableBeforeAdjAmt>
        <RecoveriesQualfiedDistriAmt>7742969</RecoveriesQualfiedDistriAmt>
        <DistributableBeforeDedAmt>354779495</DistributableBeforeDedAmt>
        <DeductionFromDistributableAmt>0</DeductionFromDistributableAmt>
        <DistributableAsAdjustedAmt>354779495</DistributableAsAdjustedAmt>
      </DistributableAmountGrp>
      <PFQualifyingDistributionsGrp>
        <ExpensesAndContributionsAmt>479058575</ExpensesAndContributionsAmt>
        <ProgramRelatedInvstTotalAmt>4568256</ProgramRelatedInvstTotalAmt>
        <CharitableAssetsAcquisPaidAmt>570169</CharitableAssetsAcquisPaidAmt>
        <QualifyingDistributionsAmt>484197000</QualifyingDistributionsAmt>
      </PFQualifyingDistributionsGrp>
      <UndistributedIncomeGrp>
        <DistributableAsAdjustedAmt>354779495</DistributableAsAdjustedAmt>
        <UndistributedIncomePYAmt>168607</UndistributedIncomePYAmt>
        <TotalForPriorYearsAmt>0</TotalForPriorYearsAmt>
        <TotalExcessDistributionCyovAmt>0</TotalExcessDistributionCyovAmt>
        <QualifyingDistributionsAmt>484197000</QualifyingDistributionsAmt>
        <AppliedToYear1Amt>168607</AppliedToYear1Amt>
        <AppliedToPriorYearsAmt>0</AppliedToPriorYearsAmt>
        <TreatedAsDistriFromCorpusAmt>0</TreatedAsDistriFromCorpusAmt>
        <AppliedToCurrentYearAmt>354779495</AppliedToCurrentYearAmt>
        <RemainingDistriFromCorpusAmt>129248898</RemainingDistriFromCorpusAmt>
        <ExcessDistriCyovAppCYCorpusAmt>0</ExcessDistriCyovAppCYCorpusAmt>
        <ExcessDistributionCyovAppCYAmt>0</ExcessDistributionCyovAppCYAmt>
        <TotalCorpusAmt>129248898</TotalCorpusAmt>
        <PriorYearUndistributedIncmAmt>0</PriorYearUndistributedIncmAmt>
        <PriorYearDeficiencyOrTaxAmt>0</PriorYearDeficiencyOrTaxAmt>
        <Taxable1Amt>0</Taxable1Amt>
        <Taxable2Amt>0</Taxable2Amt>
        <UndistributedIncomeCYAmt>0</UndistributedIncomeCYAmt>
        <CorpusDistri170b1EOr4942g3Amt>0</CorpusDistri170b1EOr4942g3Amt>
        <ExcessDistriCyovFromYr5Amt>0</ExcessDistriCyovFromYr5Amt>
        <ExcessDistriCyovToNextYrAmt>129248898</ExcessDistriCyovToNextYrAmt>
        <ExcessFromCurrentYearAmt>129248898</ExcessFromCurrentYearAmt>
      </UndistributedIncomeGrp>
      <SupplementaryInformationGrp>
        <OnlyContriToPreselectedInd>X</OnlyContriToPreselectedInd>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3103 BEE CAVES ROAD</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>78746</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PF</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY</GrantOrContributionPurposeTxt>
          <Amt>2053426</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACADEMISCH ZIEKENHUIS LEIDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 ALBINUSDREEF</AddressLine1Txt>
            <CityNm>LEIDEN</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)</GrantOrContributionPurposeTxt>
          <Amt>230038</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACTION4DIABETES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>9 PARKFIELD ROAD</AddressLine1Txt>
            <CityNm>TAUNTON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHILIPPINES T1D TASK FORCE</GrantOrContributionPurposeTxt>
          <Amt>156500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACUMEN AMERICA LLC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 WORTH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL SUPPORT TO ADDRESS SOCIAL DETERMINANTS OF HEALTH FOR PEOPLE WITH INSULIN REQUIRING DIABETES</GrantOrContributionPurposeTxt>
          <Amt>502312</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ADI NEGEV-NAHALAT ERAN RA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MERHAVIM REGIONAL COUNCIL</AddressLine1Txt>
            <CityNm>OFAKIM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REHABILITATION WARD EQUIPMENT PROJECT</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVENUE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL ACTIVITIES TO ADVANCE D-PEPTIDES AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>494612</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVENUE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL ACTIVITIES TO ADVANCE D-PEPTIDES AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>556499</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVENUE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROMOTE DIABETES TECHNOLOGY USE IN YOUNG ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D PILOT STUDY</GrantOrContributionPurposeTxt>
          <Amt>168556</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALEH - HELP FOR THE SPECIAL CHILD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>111 ABARBANEL ST</AddressLine1Txt>
            <CityNm>BNEI BRAK</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NEXT GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>267835</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1825 EYE STREET NW 401</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING (CGM)</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALVIN AILEY DANCE FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE JOAN WEILL CENTER FOR DANCE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10019</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>84 SHMARYAHU LEVIN ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATION OF EMERGENCY MEDICAL AIR-RAID SHELTER</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALYN HOSPITAL - REHABILITATION CENTER FOR CHILDREN AND YOUTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>84 SHMARYAHU LEVIN ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALYN CENTER FOR INNOVATION IN PEDIATRIC REHABILITATION RESEARCH</GrantOrContributionPurposeTxt>
          <Amt>694034</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>50570</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE: OMICROHN</GrantOrContributionPurposeTxt>
          <Amt>1607013</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT AND VALIDATION OF AN EPIGENETIC BIOMARKER THAT PREDICTS TREATMENT SUCCESS AND ALLOWS PERSONALIZED MANAGEMENT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>197373</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN CAMPING ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5000 STATE ROAD 67 NORTH</AddressLine1Txt>
            <CityNm>MARTINSVILLE</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46151</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACA PROFESSIONAL DEVELOPMENT 2022-2024</GrantOrContributionPurposeTxt>
          <Amt>51040</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN COLLEGE OF DIABETOLOGY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 87633</AddressLine1Txt>
            <CityNm>FAYETTEVILLE</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>28304</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS</GrantOrContributionPurposeTxt>
          <Amt>981349</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING AND MENTORSHIP PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>805382</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2022-2024 TYPE 1 DIABETES CAMP INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>399368</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MENTAL HEALTH EDUCATION PROGRAM PHASE 2 (2022 2024)</GrantOrContributionPurposeTxt>
          <Amt>278350</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MENTAL HEALTH EDUCATION PROGRAM PHASE 2 (2022 2024)</GrantOrContributionPurposeTxt>
          <Amt>337310</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN FRIENDS OF MAGEN DAVID ADOM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>20 WEST 36TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY SUPPORT FOR MAGEN DAVID ADOM</GrantOrContributionPurposeTxt>
          <Amt>152000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4930 DEL RAY AVE</AddressLine1Txt>
            <CityNm>BETHESDA</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20814</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMPLIFYING LEARNING FROM THE CEDARS-SINAI ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION</GrantOrContributionPurposeTxt>
          <Amt>74768</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION: LIFELINE STROKE IOWA</GrantOrContributionPurposeTxt>
          <Amt>2105298</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH</GrantOrContributionPurposeTxt>
          <Amt>4194494</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>286146</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION: LIFELINE STROKE MONTANA AND POST-ACUTE STROKE CARE QUALITY STANDARDS FIELD TESTING</GrantOrContributionPurposeTxt>
          <Amt>1024257</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POST-ACUTE STROKE CARE: IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA</GrantOrContributionPurposeTxt>
          <Amt>723366</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN SAMOA MEDICAL CENTER AUTHORITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX LBJ</AddressLine1Txt>
            <CityNm>PAGO PAGO</CityNm>
            <StateAbbreviationCd>AS</StateAbbreviationCd>
            <ZIPCd>96799</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MRI AT LBJ TROPICAL MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>1878805</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICANS FOR BEN-GURION UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 AVENUE OF THE AMERICAS 19TH</AddressLine1Txt>
            <AddressLine2Txt>FLOOR</AddressLine2Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICANS FOR BEN-GURION UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 AVENUE OF THE AMERICAS 19TH</AddressLine1Txt>
            <AddressLine2Txt>FLOOR</AddressLine2Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>20000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICARES FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>88 HAMILTON AVE</AddressLine1Txt>
            <CityNm>STAMFORD</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL, NEWBORN, AND CHILD HEALTH INTERVENTIONS</GrantOrContributionPurposeTxt>
          <Amt>749599</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>APHP ST ANTOINE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>184 RUE DU FAUBOURG SAINT-ANTOINE</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)</GrantOrContributionPurposeTxt>
          <Amt>367129</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ARAD MUNICIPALITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 HAPALMACH STREET</AddressLine1Txt>
            <CityNm>ARAD</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ARAD OCCUPATIONAL REHABILITATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>183236</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ARAD MUNICIPALITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 HAPALMACH STREET</AddressLine1Txt>
            <CityNm>ARAD</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY FUNDING FOR SAFETY AND SECURITY EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>166407</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASIAN HEALTH CARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6-3-661 SOMAJIGUDA</AddressLine1Txt>
            <CityNm>HYDERABAD</CityNm>
            <CountryCd>IN</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING ACCESS TO DIAGNOSTICS FOR CROHN'S DISEASE PATIENTS LIVING BELOW THE POVERTY LINE IN SOUTHERN INDIA</GrantOrContributionPurposeTxt>
          <Amt>83381</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF THE DANATECH PLATFORM</GrantOrContributionPurposeTxt>
          <Amt>831327</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION SANTE DIABETE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>5 RUE FEDERICO GARCIA LORCA</AddressLine1Txt>
            <CityNm>GRENOBLE</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVE THE MANAGEMENT OF DIABETES (ESPECIALLY T1D) AND THE SUPPORT TO PEOPLE AFFECTED BY THE DISEASE IN BURKINA FASO, MALI, AND THE UNION OF COMOROS</GrantOrContributionPurposeTxt>
          <Amt>475984</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 2</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY.</GrantOrContributionPurposeTxt>
          <Amt>410936</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1325 S CLIFF AVENUE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA BEHAVIORAL HEALTH CENTER EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AVERA MCKENNAN HOSPITAL AND UNIVERSITY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1325 S CLIFF AVENUE</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA BEHAVIORAL HEALTH CENTER EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BALLAD RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3525 JOHN HOPKINS COURT</AddressLine1Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD127-HIGH T-CELL POPULATIONS AS BIOMARKERS</GrantOrContributionPurposeTxt>
          <Amt>325801</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BANNER HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2901 N CENTRAL AVENUE</AddressLine1Txt>
            <CityNm>PHOENIX</CityNm>
            <StateAbbreviationCd>AZ</StateAbbreviationCd>
            <ZIPCd>85012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BANNER HEALTH WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1869864</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAR ILAN UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MAX VE-ANNA WEBB ST</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE LEONA M. AND HARRY B. HELMSLEY ENERGY PROTOTYPE LAB AT BAR-ILAN UNIVERSITY</GrantOrContributionPurposeTxt>
          <Amt>3216875</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BARZILAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HAHISTADROUT ST 2</AddressLine1Txt>
            <CityNm>ASHKELON</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY FUNDING FOR EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>776930</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE</GrantOrContributionPurposeTxt>
          <Amt>566062</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOT STUDY TO ADDRESS DIABETES HEALTH-RELATED QUALITY OF LIFE</GrantOrContributionPurposeTxt>
          <Amt>520313</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS: SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>532841</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRUCULTURE SAMPLE ANALYSIS FOR TN22 HCQ</GrantOrContributionPurposeTxt>
          <Amt>297957</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D</GrantOrContributionPurposeTxt>
          <Amt>809757</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D</GrantOrContributionPurposeTxt>
          <Amt>131733</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEN-GURION UNIVERSITY OF THE NEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN-GURION BLVD 1</AddressLine1Txt>
            <CityNm>BEER SHEVA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY PREPAREDNESS FOR BEN GURION UNIVERSITY OF THE NEGEV</GrantOrContributionPurposeTxt>
          <Amt>450000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEN-GURION UNIVERSITY OF THE NEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN-GURION BLVD 1</AddressLine1Txt>
            <CityNm>BEER SHEVA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CD</GrantOrContributionPurposeTxt>
          <Amt>938641</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BERKSHIRE THEATRE GROUP INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>111 SOUTH STREET</AddressLine1Txt>
            <CityNm>PITTSFIELD</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR THE DAVID AND SUSIE AUERBACH REHEARSAL STUDIO</GrantOrContributionPurposeTxt>
          <Amt>17500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BETH ISRAEL DEACONESS MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>330 BROOKLINE AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155491</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE: THE OPTIMIZE TRIAL</GrantOrContributionPurposeTxt>
          <Amt>797851</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 CONCAR DRIVE OFFICE 03-155</AddressLine1Txt>
            <CityNm>SAN MATEO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94402</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1060000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 CONCAR DRIVE OFFICE 03-155</AddressLine1Txt>
            <CityNm>SAN MATEO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94402</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>940000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 CONCAR DRIVE OFFICE 03-155</AddressLine1Txt>
            <CityNm>SAN MATEO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94402</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETIC KETOACIDOSIS (DKA) CAMPAIGN PHASE 3</GrantOrContributionPurposeTxt>
          <Amt>149166</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIGHORN VALLEY HEALTH CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10 4TH STREET WEST SUITE B</AddressLine1Txt>
            <CityNm>HARDIN</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59034</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>260119</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BILLINGS CLINIC CODY ULTRASOUND PROJECT</GrantOrContributionPurposeTxt>
          <Amt>172365</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ECMO SERVICES AT BILLINGS CLINIC</GrantOrContributionPurposeTxt>
          <Amt>620341</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIPARTISAN POLICY CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1225 I ST NW 1000</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES</GrantOrContributionPurposeTxt>
          <Amt>622296</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1740266</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1975490</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>3480533</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1740267</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BNAI ZION MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>47 GOLOMB ST</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PURCHASE OF A CT SCANNER FOR BNAI ZION MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>1300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2601 ENTERPRISE ROAD</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89512</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND TRAINING INITIATIVE IN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>197208</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2601 ENTERPRISE ROAD</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89512</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>64655</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETESWISE FOR EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>344015</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABDOCS NATIONAL K12: SUPPLEMENT</GrantOrContributionPurposeTxt>
          <Amt>402980</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1006531</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS MULTIANALYTE SENSOR FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>1483787</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTIGATING THE ROLE OF THE HUMAN EXPOSOME IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>836979</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION &amp; EVALUATION OF ECHO FOR PEOPLE WITH DIABETES ON INTENSIVE INSULIN THERAPY (IIT)</GrantOrContributionPurposeTxt>
          <Amt>341879</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>379194</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON SYMPHONY ORCHESTRA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOULDER CITY HOSPITAL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 ADAMS BLVD</AddressLine1Txt>
            <CityNm>BOULDER CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BOULDER CITY HOSPITAL EQUIPMENT REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>34997</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>1915763</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMATIVE CONNECTIVITY IN RURAL ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>2648126</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HILLS ROAD</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1230080</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CAMPBELL COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>501 SOUTH BURMA AVE</AddressLine1Txt>
            <CityNm>GILLETTE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82717</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAMPBELL COUNTY HEALTH ULTRASOUND PROJECT</GrantOrContributionPurposeTxt>
          <Amt>599884</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CANDID</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>32 OLD SLIP 24TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25974</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARDIFF UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>30-36 NEWPORT RD</AddressLine1Txt>
            <CityNm>WALES</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D-PLUS: AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D</GrantOrContributionPurposeTxt>
          <Amt>944873</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARE-FOR-RARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DR VON HAUNERSCHES KINDERSPITAL</AddressLine1Txt>
            <AddressLine2Txt>KLINIKUM DER UNIVERSITAT MUNCHEN</AddressLine2Txt>
            <CityNm>MUNICH</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MUNICH STUDIES</GrantOrContributionPurposeTxt>
          <Amt>655603</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CASTLE ROCK SPECIAL HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1400 UINTA DRIVE</AddressLine1Txt>
            <CityNm>GREEN RIVER</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82935</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>117688</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING COMMUNITY RECOVERY AND RESILIENCE</GrantOrContributionPurposeTxt>
          <Amt>1617611</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE</GrantOrContributionPurposeTxt>
          <Amt>1845255</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY</GrantOrContributionPurposeTxt>
          <Amt>202791</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY</GrantOrContributionPurposeTxt>
          <Amt>200041</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONG-TERM RESPONSES TO SARS-COV-2 VACCINATION IN A DIVERSE INFLAMMATORY BOWEL DISEASE POPULATION: A MULTI-OMIC STUDY</GrantOrContributionPurposeTxt>
          <Amt>364763</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: CEDARS-SINAI</GrantOrContributionPurposeTxt>
          <Amt>115500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRAL MONTANA MEDICAL FACILITIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>408 WENDELL AVE</AddressLine1Txt>
            <CityNm>LEWISTOWN</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59457</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CANCER CENTER AT CENTRAL MONTANA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>3690035</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT</GrantOrContributionPurposeTxt>
          <Amt>95277</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD</GrantOrContributionPurposeTxt>
          <Amt>244860</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>221420</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHEYENNE HEALTH &amp; WELLNESS CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2508 E FOX FARM RD 1-1A</AddressLine1Txt>
            <CityNm>CHEYENNE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82007</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>78892</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHEYENNE REGIONAL MEDICAL CENTER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>214 EAST 23RD STREET</AddressLine1Txt>
            <CityNm>CHEYENNE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHEYENNE REGIONAL MEDICAL CENTER WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1490918</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHI HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12809 WEST DODGE ROAD</AddressLine1Txt>
            <CityNm>OMAHA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68154</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY</GrantOrContributionPurposeTxt>
          <Amt>2165669</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>374591</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOLECULAR AND SPATIAL SINGLE-CELL REMODELING IN PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>374591</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI)</GrantOrContributionPurposeTxt>
          <Amt>665654</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL GLUCOSE BINDERS FOR THE DEVELOPMENT OF GLUCOSE RESPONSIVE INSULIN (GRI)</GrantOrContributionPurposeTxt>
          <Amt>666216</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: BOSTON STUDIES</GrantOrContributionPurposeTxt>
          <Amt>1399726</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM FOR THE PREVENTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1255105</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF NOVEL GLUCOSE RESPONSIVE GLUCAGON (GRG) DELIVERY SYSTEM FOR THE PREVENTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1072041</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SABAN RESEARCH INSTITUTE</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90027</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE</GrantOrContributionPurposeTxt>
          <Amt>679025</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1009535</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECISION CROHNS DISEASE MANAGEMENT UTILIZING PREDICTIVE PROTEIN PANELS</GrantOrContributionPurposeTxt>
          <Amt>88791</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL</GrantOrContributionPurposeTxt>
          <Amt>402142</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1421241</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S MERCY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2401 GILLHAM ROAD</AddressLine1Txt>
            <CityNm>KANSAS CITY</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>64108</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RAPID LEARNING LAB</GrantOrContributionPurposeTxt>
          <Amt>1399624</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREEN FUND</GrantOrContributionPurposeTxt>
          <Amt>305108</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CIVICA FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2912 WEST EXECUTIVE PARKWAY</AddressLine1Txt>
            <CityNm>LEHI</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84043</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AFFORDABLE INSULIN</GrantOrContributionPurposeTxt>
          <Amt>2500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CIVICA FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2912 WEST EXECUTIVE PARKWAY</AddressLine1Txt>
            <CityNm>LEHI</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84043</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AFFORDABLE INSULIN</GrantOrContributionPurposeTxt>
          <Amt>2500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDICAL EQUIPMENT FOR EMEK MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>1103070</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT</GrantOrContributionPurposeTxt>
          <Amt>138626</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY SUPPORT FOR SOROKA MEDICAL CENTER: MEDICAL EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A PHOTON COUNTING DETECTOR-CT DEVICE FOR SOROKA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>2159000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>418217</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>452465</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE INFLAMMATORY BOWEL DISEASE MEDITERRANEAN DIET (IBDMED) MICROBIOME-TARGETING NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL AND PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>667139</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE INFLAMMATORY BOWEL DISEASE MEDITERRANEAN DIET (IBDMED) MICROBIOME-TARGETING NUTRITIONAL EDUCATION PROGRAM FOR CD CONTROL AND PREVENTION</GrantOrContributionPurposeTxt>
          <Amt>243216</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MARKET SHAPING TO IMPROVE ACCESS TO DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>1243053</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION</GrantOrContributionPurposeTxt>
          <Amt>3057795</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COMMONWEALTH HEALTHCARE CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1178 HINEMLU ST GARAPAN</AddressLine1Txt>
            <CityNm>SAIPAN</CityNm>
            <CountryCd>CQ</CountryCd>
            <ForeignPostalCd>96950</ForeignPostalCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CNMI CHCC MRI/MEDICAL EQUIPMENT UPGRADE PROJECT</GrantOrContributionPurposeTxt>
          <Amt>6440191</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COMMUNITY CENTERS INCDBA BARBARA'S HOUSE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2 ST ROCH AVENUE</AddressLine1Txt>
            <CityNm>GREENWICH</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06830</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>45000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COMMUNITY SERVICE SOCIETY OF NEW YORK (CSS)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>633 THIRD AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KEEP NEW YORK COVERED (KNYC)</GrantOrContributionPurposeTxt>
          <Amt>550000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONSORCI INSTITUT D'INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ROSSELL 149</AddressLine1Txt>
            <CityNm>BARCELONA</CityNm>
            <CountryCd>SP</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY DETECTION OF PERIANAL FISTULIZING DISEASE- PATHOPHYSIOLOGY AND IMAGING</GrantOrContributionPurposeTxt>
          <Amt>261570</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONVERGENT IMPACT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3223 ARAPAHOE AVE</AddressLine1Txt>
            <CityNm>BOULDER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80303</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1795546</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORK UNIVERSITY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WESTERN ROAD</AddressLine1Txt>
            <CityNm>CORK</CityNm>
            <CountryCd>EI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS</GrantOrContributionPurposeTxt>
          <Amt>642744</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORNELL UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 22</AddressLine1Txt>
            <CityNm>ITHACA</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>148510022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPONSORSHIP FOR THE 25TH ANNIVERSARY ADHERENT INVASIVE E. COLI (AIEC) MEETING</GrantOrContributionPurposeTxt>
          <Amt>15000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORPORATION FOR SUPPORTIVE HOUSING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>61 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>1200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COUNCIL ON FOUNDATIONS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1255 23RD ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>34000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COUNCIL ON THE ENVIRONMENT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>100 GOLD ST SUITE 3300</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>15000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COZAD HOSPITAL DISTRICT NO 2</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 EAST 12TH STREET</AddressLine1Txt>
            <CityNm>COZAD</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69130</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>141545</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CRITICAL PATH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1840 E RIVER ROAD</AddressLine1Txt>
            <CityNm>TUCSON</CityNm>
            <StateAbbreviationCd>AZ</StateAbbreviationCd>
            <ZIPCd>85718</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D CONSORTIUM 2.0</GrantOrContributionPurposeTxt>
          <Amt>266741</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD VENTURES ACADEMIC INCUBATOR</GrantOrContributionPurposeTxt>
          <Amt>1180400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING AWARDS PROGRAM - CLASS OF 2021</GrantOrContributionPurposeTxt>
          <Amt>1067400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>712850</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>595677</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>588266</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SYSTEMATIZING IMPROVEMENT INTERVENTIONS OF URGENT CARE MANAGEMENT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>588266</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPONSORSHIP FOR THE 2024 CROHNS &amp; COLITIS CONGRESS PRESENTED BY THE CROHNS &amp; COLITIS FOUNDATION AND THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE</GrantOrContributionPurposeTxt>
          <Amt>284646</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CD PATIENTS LIVING IN CANADA</GrantOrContributionPurposeTxt>
          <Amt>562426</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS UK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 BISHOPS SQUARE</AddressLine1Txt>
            <CityNm>HATFIELD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 &amp; 2022 OPERATING SUPPORT FOR CROHN'S AND COLITIS UK: KNOWLEDGE AND EVIDENCE PERSONNEL</GrantOrContributionPurposeTxt>
          <Amt>75900</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S COLITIS CURE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 OCONNELL STREET</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF "CCCARE-P", A PEDIATRIC-SPECIFIC CROHNS DISEASE ELECTRONIC MEDICAL RECORD TO DRIVE CARE CONSISTENCY AND ENHANCE TRANSITIONS IN CARE</GrantOrContributionPurposeTxt>
          <Amt>115418</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROOK COUNTY MEDICAL SERVICES DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>713 W OAK ST</AddressLine1Txt>
            <CityNm>SUNDANCE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82729</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>437000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DARTMOUTH- HITCHCOCK CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE MEDICAL CENTER DRIVE</AddressLine1Txt>
            <CityNm>LEBANON</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03756</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>509790</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DE LA SALLE SOLIDARIETA INTERNAZIONALE - ETS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>VIA AUREALIA 476</AddressLine1Txt>
            <CityNm>ROME</CityNm>
            <CountryCd>IT</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ETHIOPIAN CATHOLIC UNIVERSITY DIAGNOSTIC LABORATORY</GrantOrContributionPurposeTxt>
          <Amt>94780</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DE LA SALLE SOLIDARIETA INTERNAZIONALE - ETS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>VIA AUREALIA 476</AddressLine1Txt>
            <CityNm>ROME</CityNm>
            <CountryCd>IT</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPAND DEVELOPMENT OF LASALLIAN UNIVERSITY OF AFRICA</GrantOrContributionPurposeTxt>
          <Amt>784080</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DIABETES NSW</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>26 ARUNDEL ST</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES, THROUGH EXPANSION AND COUNTRY-SPECIFIC DATA-DRIVEN INITIATIVES</GrantOrContributionPurposeTxt>
          <Amt>1700835</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DREAMED DIABETES LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>14 KAPLAN ST</AddressLine1Txt>
            <CityNm>PETAH TIKVA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1350000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUKE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O OFFICE OF RESEARCH SUPPORT</AddressLine1Txt>
            <CityNm>DURHAM</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>277054677</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UTILIZING AMINO ACIDS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE IN PANCREATIC ALPHA CELLS TO PREVENT INSULIN-INDUCED HYPOGLYCEMIA IN T1D</GrantOrContributionPurposeTxt>
          <Amt>203497</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUKE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O OFFICE OF RESEARCH SUPPORT</AddressLine1Txt>
            <CityNm>DURHAM</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>277054677</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UTILIZING AMINO ACIDS AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE IN PANCREATIC ALPHA CELLS TO PREVENT INSULIN-INDUCED HYPOGLYCEMIA IN T1D</GrantOrContributionPurposeTxt>
          <Amt>71503</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUNDY COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1313 N CHEYENNE ST</AddressLine1Txt>
            <CityNm>BENKELMAN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69021</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>29310</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>EHLERS-DANLOS RESEARCH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1829 REISTERSTOWN ROAD</AddressLine1Txt>
            <CityNm>PIKESVILLE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21208</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>EMORY UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1599 CLIFTON ROAD NE</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303224250</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>313686</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>EZRATH NASHIM SARAH HERZOG MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>92 GIVAT SHAUL ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONSTRUCTION OF A NEW MENTAL HEALTH FACILITY AT HERZOG MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>2384174</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FAIRVIEW HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2450 RIVERSIDE AVE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55454</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE</GrantOrContributionPurposeTxt>
          <Amt>1960000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FAIRVIEW HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2450 RIVERSIDE AVE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55454</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE</GrantOrContributionPurposeTxt>
          <Amt>4889200</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FEDERAL INSTITUTE OF TECHNOLOGY ZURICH ETHZ</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RAMISTRASSE 101</AddressLine1Txt>
            <CityNm>ZURICH</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPATIAL BIOLOGY OF CROHNS COLITIS</GrantOrContributionPurposeTxt>
          <Amt>536228</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FJC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 WEST 39TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC FUND TO END YOUTH &amp; FAMILY HOMELESSNESS, A PROJECT OF FJC.</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FJC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 WEST 39TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 BEDFORD STREET</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FIRST SENIOR MENTOR PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CAMPUS BIOTECH</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1275100</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRANCISCAN CARE SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>430 N MONITOR ST</AddressLine1Txt>
            <CityNm>WEST POINT</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68788</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>17093</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRANCISCAN CARE SERVICES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>430 N MONITOR ST</AddressLine1Txt>
            <CityNm>WEST POINT</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68788</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT FRANCISCAN HEALTHCARE</GrantOrContributionPurposeTxt>
          <Amt>42729</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRIENDS OF CRAWFORD PARK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7 RYE RIDGE PLAZA</AddressLine1Txt>
            <CityNm>RYE BROOK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10573</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FRIENDS OF THE ISRAEL DEFENSE FORCES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>60 EAST 42 STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10165</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPACT! SCHOLARSHIP PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>503200</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FUENTE LATINA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7300 BISCAYNE BLVD SUITE 200</AddressLine1Txt>
            <CityNm>MIAMI</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33138</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEDIA FELLOWSHIPS TO ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FUND FOR PUBLIC HOUSING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>90 CHURCH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10007</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPING AND ACTIVATING GREENSPACE USING THE CONNECTED COMMUNITIES' PARTICIPATORY PROCESS AT FOUR NYCHA DEVELOPMENTS</GrantOrContributionPurposeTxt>
          <Amt>1630000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GALILEE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>GALILEE MEDICAL CENTER</AddressLine1Txt>
            <CityNm>NAHARIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PURCHASING A CT SCANNER FOR GALILEE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>991768</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GALILEE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>GALILEE MEDICAL CENTER</AddressLine1Txt>
            <CityNm>NAHARIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>2200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GATES PHILANTHROPY PARTNERS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 60555</AddressLine1Txt>
            <CityNm>CITY OF INDUSTRY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91716</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POLIO ERADICATION FUND SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEISINGER CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>100 NORTH ACADEMY AVE</AddressLine1Txt>
            <CityNm>DANVILLE</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>178223057</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDY OF PRE-IMPLEMENTATION OUTCOMES REQUIRED TO IMPLEMENT PREVENTIVESCREENING AT WELL-CHILD VISITS</GrantOrContributionPurposeTxt>
          <Amt>72007</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLCOME GENOME CAMPUS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>397123</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLCOME GENOME CAMPUS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>251522</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGETOWN UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>37TH O STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20057</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCING ACCESS TO HIGH QUALITY, AFFORDABLE DIABETES CARE THROUGH PRIVATE HEALTH INSURANCE REGULATION</GrantOrContributionPurposeTxt>
          <Amt>418301</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 10TH STREET NW</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303320420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>485617</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 10TH STREET NW</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303320420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>480848</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GHANA RURAL INTEGRATED DEVELOPMENT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>7774 10 SIDEROAD</AddressLine1Txt>
            <CityNm>MILTON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LEYAATA HOSPITAL MEDICAL HOUSING</GrantOrContributionPurposeTxt>
          <Amt>751636</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GIRLS WITH GUTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6024 RIDGE AVENUE</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19128</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2021 &amp; 2022 OPERATING SUPPORT TO PROVIDE POST-OPERATIVE AND INFUSION KITS FOR WOMEN WITH INFLAMMATORY BOWEL DISEASE</GrantOrContributionPurposeTxt>
          <Amt>77164</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GLENROCK HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>925 WEST BIRCH</AddressLine1Txt>
            <CityNm>GLENROCK</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>63635</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GLOBAL SOLIDARITY FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>425 LEXINGTON AVE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JOB CREATION IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>1508200</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRANTMAKERS FOR EFFECTIVE ORGANIZATIONS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1310 L STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>18920</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GRANTMAKERS IN HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 CONNECTICUT AVENUE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>24640</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GUARDIAN ORG FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>900 17TH STREET NW SUITE 250</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A GROWING CRISIS: NON-COMMUNICABLE DISEASES, AN INDEPENDENT JOURNALISM SERIES BY THE GUARDIAN</GrantOrContributionPurposeTxt>
          <Amt>625000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HADASSAH MEDICAL ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EIN KEREM ADDRESS KALMAN YAAKOV MAN</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUIPPING HADASSAH HOSPITAL'S OPERATING ROOMS</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HADASSAH MEDICAL ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EIN KEREM ADDRESS KALMAN YAAKOV MAN</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING AND EQUIPPING A NEW COMPREHENSIVE DIAGNOSTIC AND INTERVENTIONAL IMAGING CENTER</GrantOrContributionPurposeTxt>
          <Amt>1136000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALTH ADVOCACY SUMMIT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1962 DOCKSIDE DRIVE</AddressLine1Txt>
            <CityNm>GREENWOOD</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>46143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS AND COLITIS YOUNG ADULTS NETWORK LEARNING COMMUNITY, ROUNDTABLE ON ADOLESCENTS AND YOUNG ADULTS WITH IBD</GrantOrContributionPurposeTxt>
          <Amt>60060</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEALTH RESEARCH ALLIANCE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>65 TW ALEXANDER DRIVE</AddressLine1Txt>
            <CityNm>RESEARCH TRIANGLE PARK</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>27709</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>44300</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HEBREW UNIVERSITY OF JERUSALEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OFFICE OF THE PRESIDENT</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>METHYLATION PATTERNS OF CELL-FREE DNA AS A NOVEL BIOMARKER IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>362703</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELEN KELLER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE DAG HAMMARSKJOLD PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT</GrantOrContributionPurposeTxt>
          <Amt>1441293</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELEN KELLER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE DAG HAMMARSKJOLD PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A CONTINUED PATH TO RESILIENCE AND EMPOWERMENT</GrantOrContributionPurposeTxt>
          <Amt>1652490</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>778887</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>745207</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>1310340</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>2240499</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>1956717</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1849482</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1044591</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>2114441</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>2929862</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HENRY J KAISER FAMILY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>185 BERRY STREET NO 2000</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>KAISER HEALTH NEWS RURAL HEALTH DESK</GrantOrContributionPurposeTxt>
          <Amt>1458159</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV AND GENTOFTE HOSPITAL</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D</GrantOrContributionPurposeTxt>
          <Amt>145339</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV AND GENTOFTE HOSPITAL</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS &amp; GIP IN PANCREATIC CELLS</GrantOrContributionPurposeTxt>
          <Amt>81534</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HOLY ROSARY HEALTHCARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2600 WILSON STREET</AddressLine1Txt>
            <CityNm>MILES CITY</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59301</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOLY ROSARY HEALTHCARE COMPREHENSIVE CANCER CENTER</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HOT SPRINGS COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>150 E ARAPAHOE ST</AddressLine1Txt>
            <CityNm>THERMOPOLIS</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82443</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>346794</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HUMAN CELL ATLAS INCORPORATED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN ST</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2023 HUMAN CELL ATLAS GENERAL MEETING</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HUMBOLDT COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1000 N 15TH ST</AddressLine1Txt>
            <CityNm>HUMBOLDT</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50548</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>117600</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>305349</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEXT PHASE OF STEM CELL TRANSPLANT FOR REFRACTORY CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>404688</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE: PREDICT AND PREVENT</GrantOrContributionPurposeTxt>
          <Amt>1623623</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPATIAL MAPPING OF FIBROMUSCULAR CROHNS DISEASE: FROM GENETIC TO SENESCENT SIGNALS</GrantOrContributionPurposeTxt>
          <Amt>1085802</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE MELODY TRIAL: MODULATING EARLY LIFE MICROBIOME THROUGH DIETARY INTERVENTION IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>759619</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE FOR NYCS MOST VULNERABLE MEMBERS, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS.</GrantOrContributionPurposeTxt>
          <Amt>672617</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICHUD HATZALAH ISRAEL 1221 (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>78 YIRMIYAHU ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROVIDING SUPPORT FOR EMERGENCY PREPAREDNESS</GrantOrContributionPurposeTxt>
          <Amt>600000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICHUD HATZALAH ISRAEL 1221 (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>78 YIRMIYAHU ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY FUNDING FOR RESPONSE TO ATTACKS ON ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>1300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICHUD HATZALAH ISRAEL 1221 (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>78 YIRMIYAHU ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROVIDING SUPPORT, RECOVERY AND RESPECTFUL HANDLING OF FALLEN WAR VICTIMS</GrantOrContributionPurposeTxt>
          <Amt>350000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDA COUNTY IOWA COMMUNITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>701 EAST SECOND STREET</AddressLine1Txt>
            <CityNm>IDA GROVE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51445</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>114569</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>11424</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>60914</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUTE FOR COMMUNITY LIVING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 BROAD STREET</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT</GrantOrContributionPurposeTxt>
          <Amt>749790</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSULIN FOR LIFE USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2555 SW 76TH STREET</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>32608</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSULIN FOR LIFE USA STRENGTHENING ORGANIZATIONAL CAPACITY</GrantOrContributionPurposeTxt>
          <Amt>341606</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 STATE STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEED FUNDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>714053</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)</GrantOrContributionPurposeTxt>
          <Amt>379100</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)</GrantOrContributionPurposeTxt>
          <Amt>672500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CD. USE-IT: A PROSPECTIVE, MULTICENTER STUDY</GrantOrContributionPurposeTxt>
          <Amt>375221</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL WATER MANAGEMENT INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>127 SUNIL MAWATHA</AddressLine1Txt>
            <CityNm>BATTARAMULLA</CityNm>
            <CountryCd>CE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA</GrantOrContributionPurposeTxt>
          <Amt>1999629</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IOWA DEPARTMENT OF PUBLIC HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>321 EAST 12TH</AddressLine1Txt>
            <CityNm>DES MOINES</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50319</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IOWA FIRST RESPONDER AED INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>58968</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ISRAEL EMERGENCY ALLIANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 341069</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90034</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT OF LEGAL EFFORTS TO COMBAT ANTISEMITISM, AND SOCIAL MEDIA EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IVINSON MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>255 N 30TH ST</AddressLine1Txt>
            <CityNm>LARAMIE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>550348</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE IN DIABETES INITIATIVE: PEDIATRIC STUDY</GrantOrContributionPurposeTxt>
          <Amt>283542</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDUCATIONAL INTERVENTION TO SUPPORT DIABETES GUIDANCE FOR EXERCISE (EDGE)</GrantOrContributionPurposeTxt>
          <Amt>620243</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)</GrantOrContributionPurposeTxt>
          <Amt>1449344</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY AND JDRF CO-FUNDED WORKSHOPS</GrantOrContributionPurposeTxt>
          <Amt>49192</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JOINING FORCES: BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AUTOIMMUNITY SCREENING FOR KIDS (ASK) PROGRAM TRANSITION TOWARDS A SUSTAINABLE SCREENING FOR T1D AND CELIAC DISEASE IN COLORADO (ASK RENEWAL 2022)</GrantOrContributionPurposeTxt>
          <Amt>555046</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JERUSALEM COLLEGE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>21 HAVAAD HALEUMI ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY FACULTY OF LIFE AND HEALTH SCIENCES BUILDING</GrantOrContributionPurposeTxt>
          <Amt>1300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JERUSALEM COLLEGE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>21 HAVAAD HALEUMI ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY SUPPORT FOR STUDENTS AT THE JERUSALEM COLLEGE OF TECHNOLOGY.</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING</GrantOrContributionPurposeTxt>
          <Amt>567091</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>568782</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNSON COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>497 WEST LOTT STREET</AddressLine1Txt>
            <CityNm>BUFFALO</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82834</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JOHNSON COUNTY HEALTHCARE CENTER ULTRASOUND EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>476613</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOSLIN DIABETES CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE JOSLIN PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02215</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES</GrantOrContributionPurposeTxt>
          <Amt>941354</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JUVENILE DIABETES RESEARCH FOUNDATION CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>235 YORKLAND BLVD SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JDRF CANADA PSYCHOSOCIAL HEALTH INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>19000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KAISER FOUNDATION HEALTH PLAN OF GEORGIA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1375 PEACHTREE STREET NE</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>30309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF THE T1DES PILOT TO A PUBLIC HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>291280</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDENT1FI</GrantOrContributionPurposeTxt>
          <Amt>855018</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN ENTEROCHROMAFFIN CELL AND MACROPHAGE ATLAS OF THE HUMAN GUT</GrantOrContributionPurposeTxt>
          <Amt>246662</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE: THE OATS STUDY</GrantOrContributionPurposeTxt>
          <Amt>770816</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KIMBALL COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 S BURG STREET</AddressLine1Txt>
            <CityNm>KIMBALL</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69145</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PINE BLUFFS HEALTH CLINIC: WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>5252</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>447521</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHN'S DISEASE: A RANDOMIZED CONTROLLED TRIAL</GrantOrContributionPurposeTxt>
          <Amt>531295</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING THE ROLE OF FOOD ADDITIVE EMULSIFIERS IN CROHN'S DISEASE: A RANDOMIZED CONTROLLED TRIAL</GrantOrContributionPurposeTxt>
          <Amt>195494</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KMR ADVANCEMENT OF MEDICAL CENTERS LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>8 HAALIYAH ST</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROPOSAL FOR BUILDING OF PRINCIPAL INFRASTRUCTURE FOR ALL 20 FLOORS OF THE HELMSLEY HEALTH DISCOVERY TOWER</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LIFESCAPE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2011 W 26TH ST SUITE 201</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57105</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>7500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LIVING GOODS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1423 BROADWAY 1054</AddressLine1Txt>
            <CityNm>OAKLAND</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94612</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGITIZING COMMUNITY HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1100222</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LIVING WATER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4001 GREENBRIAR DRIVE</AddressLine1Txt>
            <CityNm>STAFFORD</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77477</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING INTEGRATED WASH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>2838602</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LUCAS COUNTY HEALTH CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1200 NORTH 7TH STREET</AddressLine1Txt>
            <CityNm>CHARITON</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50049</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AVERA ECARE EMERGENCY VIRTUAL HEALTH AT LUCAS COUNTY HEALTH CENTER</GrantOrContributionPurposeTxt>
          <Amt>17970</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MACCABI HEALTHCARE SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 HAMERED ST</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOBILE MAMMOGRAPHY UNIT</GrantOrContributionPurposeTxt>
          <Amt>31500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MACCABI HEALTHCARE SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 HAMERED ST</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>URGENT PROCUREMENT OF MEDICAL EQUIPMENT FOR WOUNDED SOLDIERS AND CIVILIANS</GrantOrContributionPurposeTxt>
          <Amt>492958</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MADISON COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 W HUTCHINGS STREET</AddressLine1Txt>
            <CityNm>WINTERSET</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50273</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EEMERGENCY AT MADISON COUNTY HEALTH CARE SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>15187</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MARY C WHEELER SCHOOL INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>216 HOPE STREET</AddressLine1Txt>
            <CityNm>PROVIDENCE</CityNm>
            <StateAbbreviationCd>RI</StateAbbreviationCd>
            <ZIPCd>02906</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT: THE WHEELER FUND.</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PEN-PLUS EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>9013397</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2023 WOMEN'S HEALTH LUNCHEON</GrantOrContributionPurposeTxt>
          <Amt>20000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INVESTIGATION OF ANTI-GM-CSF AUTOANTIBODIES AS A DISEASE DETERMINANT IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>499459</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 FRANCIS STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING A GLOBAL PARTNERSHIP TO ACHIEVE UNIVERSAL ACCESS FOR T1D AND OTHER SEVERE CHRONIC NONCOMMUNICABLE DISEASES</GrantOrContributionPurposeTxt>
          <Amt>1785375</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBES, MOLECULES, AND CHEMISTRY: DYSBIOSIS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1728414</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WIRELESS INFRARED IMAGING CAPSULE FOR PINPOINTING INFLAMMATION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>752326</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHN'S DISEASE IN SOUTH ASIANS: DEFINING DISEASE BIOLOGY FOR PREVENTION AND BETTER TREATMENT</GrantOrContributionPurposeTxt>
          <Amt>705894</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>77 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02139</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS</GrantOrContributionPurposeTxt>
          <Amt>251447</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MILITARY SCIENCES MEDICAL TRAINING 2022-2024</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>334407</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MDECINS SANS FRONTIERES USA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 RECTOR STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICAL UNIVERSITY OF SOUTH CAROLINA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>179 ASHLEY AVENUE</AddressLine1Txt>
            <CityNm>CHARLESTON</CityNm>
            <StateAbbreviationCd>SC</StateAbbreviationCd>
            <ZIPCd>29425</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>412500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICINE BOW RURAL HEALTH CARE DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>514 IDAHO DR</AddressLine1Txt>
            <CityNm>MEDICINE BOW</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82329</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>19017</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICINES DEVELOPMENT FOR GLOBAL HEALTH (MDGH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>18 KAVANAGH STREET SOUTHBANK</AddressLine1Txt>
            <CityNm>SOUTHBANK</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCING THE FIGHT AGAINST ONCHOCERCIASIS</GrantOrContributionPurposeTxt>
          <Amt>1014170</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICINES FOR HUMANITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>800 HINGHAM STREET</AddressLine1Txt>
            <CityNm>ROCKLAND</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02370</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAI MBELEKI II EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>436472</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEMORIAL HOSPITAL OF CARBON COUNTY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2221 W ELM STREET</AddressLine1Txt>
            <CityNm>RAWLINS</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82301</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MEMORIAL HOSPITAL OF CARBON COUNTY ULTRASOUND EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>598152</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEMORIAL HOSPITAL OF CONVERSE COUNTY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>111 S 5TH STREET</AddressLine1Txt>
            <CityNm>DOUGLAS</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82633</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>559262</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEMORIAL HOSPITAL OF SWEETWATER COUNTY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1200 COLLEGE DRIVE</AddressLine1Txt>
            <CityNm>ROCK SPRINGS</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82901</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>551594</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 27837</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HIRING ADDITIONAL TRANSLATORS/ANALYSTS</GrantOrContributionPurposeTxt>
          <Amt>420000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 27837</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE INTERCONNECTED IRAN-RUSSIA-CHINA AXIS</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MIDDLE EAST MEDIA AND RESEARCH INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 27837</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETED ADS FOR UNIVERSITY CAMPUS NEWSPAPERS</GrantOrContributionPurposeTxt>
          <Amt>108500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINERAL COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 SOUTH A STREET</AddressLine1Txt>
            <CityNm>HAWTHORNE</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89415</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USDA COMMUNITY FACILITY DIRECT LOAN PROGRAM APPLICATION</GrantOrContributionPurposeTxt>
          <Amt>350000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONROE COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6580 165TH STREET</AddressLine1Txt>
            <CityNm>ALBIA</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52531</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPHARMACY AT MONROE COUNTY HOSPITAL &amp; CLINICS</GrantOrContributionPurposeTxt>
          <Amt>7031</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONTANA PEDIATRICS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>259 W FRONT STREET</AddressLine1Txt>
            <CityNm>MISSOULA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59802</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1086286</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONUMENT HEALTH STURGIS HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2140 JUNCTION AVE</AddressLine1Txt>
            <CityNm>STURGIS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57785</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EEMERGENCY AT MONUMENT HEALTH STURGIS HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>16568</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONUMENT HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>353 FAIRMONT BLVD</AddressLine1Txt>
            <CityNm>RAPID CITY</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NICU EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>2066019</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL ASSOCIATION OF SCHOOL NURSES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 WAYNE AVE</AddressLine1Txt>
            <CityNm>SILVER SPRING</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20910</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT</GrantOrContributionPurposeTxt>
          <Amt>891762</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL COMMITTEE FOR QUALITY ASSURANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NCQA DIABETES RECOGNITION PROGRAM REFRESH &amp; DIABETES MEASURE DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>885819</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BERING LAND BRIDGE VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>1163270</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BADLANDS NATIONAL PARK CEDAR PASS VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>1850000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL PARK FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 K ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LITTLE BIGHORN BATTLEFIELD NATIONAL MONUMENT VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>869558</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATURAL AREAS CONSERVANCY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1234 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACTIVATING AND SUSTAINING NYC NATURE TRAIL NETWORK (PHASE 3)</GrantOrContributionPurposeTxt>
          <Amt>336672</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NCD ALLIANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>31-33 AVENUE GIUSEPPE MOTTA</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2023-2025 PARTNERSHIP</GrantOrContributionPurposeTxt>
          <Amt>1911525</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NCD ALLIANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>31-33 AVENUE GIUSEPPE MOTTA</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT - NCD ALLIANCE SUPPORTERS GROUP</GrantOrContributionPurposeTxt>
          <Amt>42500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEBRASKA METHODIST HOSPITAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8701 WEST DODGE ROAD</AddressLine1Txt>
            <CityNm>OMAHA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68114</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NICU EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>290000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 CENTENNIAL MALL SOUTH</AddressLine1Txt>
            <CityNm>LINCOLN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEBRASKA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>309887</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4126 TECHNOLOGY WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEVADA VIRTUAL CRISIS CARE</GrantOrContributionPurposeTxt>
          <Amt>1230038</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4126 TECHNOLOGY WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEVADA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>223920</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA HEALTH CENTERS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3325 RESEARCH WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>QUALITY ULTRASOUND SERVICES AND TRAINING PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>81967</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA RURAL HOSPITAL PARTNERS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4600 KIETZKE LANE</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89502</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL NEVADA HOSPITALS</GrantOrContributionPurposeTxt>
          <Amt>27500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW DESTINY HOUSING CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12 W 37TH STREET 7TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING AFTERCARE INTERVENTIONTO IMPROVE HOUSING AND HEALTH STABILITYFOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS</GrantOrContributionPurposeTxt>
          <Amt>398456</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW GROUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>70 ACORN LANE</AddressLine1Txt>
            <CityNm>LEVITTOWN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11756</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW VENTURE FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1828 L STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAMPS PROJECT (2022 - 2024)</GrantOrContributionPurposeTxt>
          <Amt>1468813</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY BALLET INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DAVID H KOCH THEATER</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10023</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR NEW COMBINATIONS FUND</GrantOrContributionPurposeTxt>
          <Amt>15000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 WORTH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC</GrantOrContributionPurposeTxt>
          <Amt>867832</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>550 1ST AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10016</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>3692303</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>665 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10012</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANALYSIS OF MEDICAID AND RELATED DATA ON CARE TO HOMELESS SHELTER PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>100123</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NIOBRARA COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>921 S BALLANCEE AVE</AddressLine1Txt>
            <CityNm>LUSK</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82225</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>147400</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTH BIG HORN HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1115 LANE 12</AddressLine1Txt>
            <CityNm>LOVELL</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82431</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH BIG HORN HOSPITAL WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>153800</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTH DAKOTA DEPARTMENT OF HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 E BOULEVARD AVENUE</AddressLine1Txt>
            <CityNm>BISMARCK</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>585050200</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH DAKOTA LAW ENFORCEMENT AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>27500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NURU INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2020 PENNSYLVANIA AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF AGRIBUSINESS COOPERATIVES</GrantOrContributionPurposeTxt>
          <Amt>2250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OAKLAND UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2200 NORTH SQUIRREL ROAD</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 1)</GrantOrContributionPurposeTxt>
          <Amt>738313</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK ROAD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NICH BAY AREA EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>749644</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK ROAD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NICH BAY AREA EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>654234</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PALO ALTO VETERANS INSTITUTE FOR RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3801 MIRANDA AVENUE</AddressLine1Txt>
            <CityNm>PALO ALTO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>943040038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>292821</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PALO ALTO VETERANS INSTITUTE FOR RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3801 MIRANDA AVENUE</AddressLine1Txt>
            <CityNm>PALO ALTO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>943040038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>292821</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PANORAMA GLOBAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2101 FOURTH AVENUE SUITE 2100</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PANORAMA - TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND</GrantOrContributionPurposeTxt>
          <Amt>1167087</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PANORAMA GLOBAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2101 FOURTH AVENUE SUITE 2100</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PANORAMA - TYPE 1 DIABETES GLOBAL ACCESS MICRO-GRANT FUND</GrantOrContributionPurposeTxt>
          <Amt>64900</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PATH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2201 WESTLAKE AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE</GrantOrContributionPurposeTxt>
          <Amt>967457</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PAWNEE COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>600 I STREET</AddressLine1Txt>
            <CityNm>PAWNEE CITY</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AT PAWNEE COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>7139</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PENNINGTON COUNTY HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>321 KANSAS CITY STREET</AddressLine1Txt>
            <CityNm>RAPID CITY</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PENNINGTON COUNTY CRISIS STABILIZATION UNIT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PERKINS COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>900 LINCOLN AVE</AddressLine1Txt>
            <CityNm>GRANT</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69140</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES FOR PERKINS COUNTY HEALTH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>36761</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PHILANTHROPY NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>320 EAST 43RD STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>39250</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PHILLIPS COUNTY HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>311 S 8TH AVENUE EAST</AddressLine1Txt>
            <CityNm>MALTA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59538</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AND TELE-PHARMACY AT PHILLIPS COUNTY</GrantOrContributionPurposeTxt>
          <Amt>64193</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PIONEER MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 WEST 7TH AVE</AddressLine1Txt>
            <CityNm>BIG TIMBER</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59011</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT PIONEER MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>24968</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PLATTE VALLEY HEALTHCARE PROJECT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 W MAIN ST</AddressLine1Txt>
            <CityNm>SARATOGA</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82331</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORTH PLATTE VALLEY MEDICAL CENTER ULTRASOUND PROJECT</GrantOrContributionPurposeTxt>
          <Amt>64362</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PORT CHESTER CARVER CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 WESTCHESTER AVE</AddressLine1Txt>
            <CityNm>PORT CHESTER</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10573</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>POWELL VALLEY HEALTH CARE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>777 AVE H</AddressLine1Txt>
            <CityNm>POWELL</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82435</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>349300</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PRESIDENT AND FELLOWS OF HARVARD COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1033 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021385366</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRE-SYMPTOMATIC AUTOANTIBODY AND VIRAL PROFILE OF US MILITARY PERSONNEL WITH ADULT-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>146368</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROJECT CONCERN ZAMBIA LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLOT 37/1P</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS</GrantOrContributionPurposeTxt>
          <Amt>975702</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PULITZER CENTER ON CRISIS REPORTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1779 MASSACHUSETTS AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20036</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING RESILIENCE THROUGH JOURNALISM AND EDUCATION</GrantOrContributionPurposeTxt>
          <Amt>310123</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RAMBAM HEALTH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HAALIA HASNIA 8</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CROHN'S</GrantOrContributionPurposeTxt>
          <Amt>1186800</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACHANOTHER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 NE 3RD ST STE 106-307</AddressLine1Txt>
            <CityNm>BEND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>97701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>2667559</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>403877</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A SYSTEM BIOLOGY APPROACH TO UNDERSTANDING PERSISTENT SYMPTOMS IN QUIESCENT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>142264</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>187370</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USING NATURAL LANGUAGE PROCESSING OF CLINICAL DOCUMENTATION TO IMPROVE PERSONALIZATION OF CARE IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>369880</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MINNESOTA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>4885390</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THERAPEUTIC USE OF PEPTIDE:MHC MABS FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>272555</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL DEVELOPMENT OF A MONOCLONAL ANTIBODY TO SERPINB13</GrantOrContributionPurposeTxt>
          <Amt>308267</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.</GrantOrContributionPurposeTxt>
          <Amt>988042</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPING OXYGEN SUPER-SATURATED SALINE FOR DEPLOYMENT IN MEDICAL EMERGENCIES</GrantOrContributionPurposeTxt>
          <Amt>190677</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)</GrantOrContributionPurposeTxt>
          <Amt>502750</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF UNIVERSITY OF CALIFORNIA BERKELEY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>190 DOE</AddressLine1Txt>
            <CityNm>BERKELEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94720</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPING MICROBIOME EDITING TOOLS TO ADVANCE UNDERSTANDING OF THE MICROBIAL INFLUENCE ON CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1225929</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RENOWN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1155 MILL ST</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89502</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>2211453</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RIVER'S EDGE HOSPITAL AND CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 N SUNRISE DRIVE</AddressLine1Txt>
            <CityNm>ST PETER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56082</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES FOR RIVER'S EDGE HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>43913</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ROUNDABOUT THEATRE COMPANY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>231 W 39TH STREET 1200</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAFE WATER NETWORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>122 EAST 42ND STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10168</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING AFFORDABLE SAFELY MANAGED WATER SUPPLY</GrantOrContributionPurposeTxt>
          <Amt>1552050</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAGE BIONETWORKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2901 THIRD AVE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981213014</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTENSION OF VEOIBD DATA COORDINATION TO ACCELERATE DISCOVERY OF PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>73424</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAINT LOUIS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>221 NORTH GRAND BOULEVARD</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63103</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>608000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAVE A LAB RESCUE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>165 ELLERY AVE</AddressLine1Txt>
            <CityNm>MIDDLETOWN</CityNm>
            <StateAbbreviationCd>RI</StateAbbreviationCd>
            <ZIPCd>02842</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SCHWARTZREISMAN SCIENCE EDUCATION CENTER REHOVOT (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERZL ST 234</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SCHWARTZREISMAN SCIENCE EDUCATION CENTER REHOVOT (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERZL ST 234</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CAMPUS FOR SCIENCE EDUCATION IN NETIVOT</GrantOrContributionPurposeTxt>
          <Amt>1982305</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SEATTLE CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 5731 M/S S-200</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981455005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)</GrantOrContributionPurposeTxt>
          <Amt>602243</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY SURGICAL WING</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LINEAR ACCELERATORS FOR THE RADIOTHERAPY INSTITUTE</GrantOrContributionPurposeTxt>
          <Amt>5200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF INFLAMMATORY BOWEL DISEASES IN PERSONS AT RISK: THE PIONIR TRIAL (PREVENTING IBD ONSET IN INDIVIDUALS AT RISK)</GrantOrContributionPurposeTxt>
          <Amt>174719</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT</GrantOrContributionPurposeTxt>
          <Amt>934083</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHALVA - ISRAEL ASSOC TO RELIEVE THE HANDICAPPED CHILD AND FAMILY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 SHALVA ROAD</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUIPMENT AND INFRASTRUCTURE FOR NATIONAL CRISIS CENTER</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHARE TRUST INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>310 DEDHAM ST</AddressLine1Txt>
            <CityNm>DOVER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION</GrantOrContributionPurposeTxt>
          <Amt>1114361</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHERIDAN COUNTY MEMORIAL HOSPITAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1401 WEST 5TH ST</AddressLine1Txt>
            <CityNm>SHERIDAN</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>675676</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHERIDAN COUNTY MEMORIAL HOSPITAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1401 WEST 5TH ST</AddressLine1Txt>
            <CityNm>SHERIDAN</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SHERIDAN MEMORIAL HOSPITAL EMPATH AND CRISIS STABILIZATION UNIT</GrantOrContributionPurposeTxt>
          <Amt>2500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIGHTSAVERS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 BOSTON PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02108</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRACHOMA ELIMINATION IN ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>2193748</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O MONTANA MEDICAL ASSOCIATION</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O MONTANA MEDICAL ASSOCIATION</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SNV NETHERLANDS DEVELOPMENT ORGANISATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PARKSTRAAT 83</AddressLine1Txt>
            <CityNm>DEN HAAG</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTHY FUTURE FOR ALL (HF4A) IMPROVING WATER, SANITATION, HYGIENE AND NUTRITION</GrantOrContributionPurposeTxt>
          <Amt>962857</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOCIAL SCIENCE RESEARCH COUNCIL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE PIERREPONT PLAZA 15TH FLOOR</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA2GO.NYC REVAMP AND DATA CLINIC</GrantOrContributionPurposeTxt>
          <Amt>261421</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOCIETY FOR THE PRESERVATION OF NEW ENGLAND ANTIQUITIES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>151 ESSEX STREET</AddressLine1Txt>
            <CityNm>HAVERHILL</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01832</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>35000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOLIDARIDAD NETWORK FOUNDATION LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>163 KUDU ROAD</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOOVES FOR SUSTAINABILITY (H4S)</GrantOrContributionPurposeTxt>
          <Amt>795998</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH BIG HORN COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>388 US HWY 20 SOUTH</AddressLine1Txt>
            <CityNm>BASIN</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82410</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THREE RIVERS HEALTH ULTRASOUND PROJECT</GrantOrContributionPurposeTxt>
          <Amt>199845</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH LINCOLN HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>711 ONYX ST</AddressLine1Txt>
            <CityNm>KEMMERER</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>83101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>291933</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH LINCOLN HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>711 ONYX ST</AddressLine1Txt>
            <CityNm>KEMMERER</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>83101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AT SOUTH LINCOLN MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>26976</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTHCENTRAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4501 DIPLOMACY DR</AddressLine1Txt>
            <CityNm>ANCHORAGE</CityNm>
            <StateAbbreviationCd>AL</StateAbbreviationCd>
            <ZIPCd>99508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>903283</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SPLASH INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7511 GREENWOOD AVE NORTH</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98103</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WASH IN SCHOOLS FOR EVERYONE</GrantOrContributionPurposeTxt>
          <Amt>597840</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST LUKE HEALTH CARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>28W609 HICKORY LN</AddressLine1Txt>
            <CityNm>WEST CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60185</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOPE CENTER FOR WOMEN AND CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>3026254</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST JOHN'S HOSPITAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>555 E BROADWAY</AddressLine1Txt>
            <CityNm>JACKSON</CityNm>
            <StateAbbreviationCd>MS</StateAbbreviationCd>
            <ZIPCd>83001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>273054</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST PETER'S HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2475 BROADWAY STREET</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSCRANIAL MAGNETIC STIMULATION (TMS) SUITE</GrantOrContributionPurposeTxt>
          <Amt>288057</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>4925243</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1443217</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STAR VALLEY MEDICAL CENTER CHARITABLE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 ADAMS</AddressLine1Txt>
            <CityNm>AFTON</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>83110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STAR VALLEY HEALTH ULTRASOUND PROJECT</GrantOrContributionPurposeTxt>
          <Amt>320890</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STATE OF NEVADA DEPARTMENT OF DIVISION OF STATE PARKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 S STEWART ST SUITE 5005</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALLEY OF FIRE VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>3500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STATE OF NEVADA DEPARTMENT OF DIVISION OF STATE PARKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 S STEWART ST SUITE 5005</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ICE AGE FOSSIL STATE PARK TRAILS AND OUTDOOR AMENITIES</GrantOrContributionPurposeTxt>
          <Amt>3500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING ACCESS TO MEDICINE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NARITAWEG 227 SUITE A</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO T1D CARE</GrantOrContributionPurposeTxt>
          <Amt>875000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60/II</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE III</GrantOrContributionPurposeTxt>
          <Amt>1245075</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING PHARMACCESS INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AHTC TOWER C4 PAASHEUVELWEG 25</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFECARE: A BUSINESS MODEL FOR HEALTHCARE QUALITY</GrantOrContributionPurposeTxt>
          <Amt>774350</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING THE OCEAN CLEANUP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BATAVIERENSTRAAT 15</AddressLine1Txt>
            <CityNm>ROTTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SUBLETTE COUNTY HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 627</AddressLine1Txt>
            <CityNm>PINEDALE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82941</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUBLETTE COUNTY HOSPITAL DISTRICT RADIOLOGY EQUIPMENT PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1017308</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SUPPORTIVE HOUSING NETWORK OF NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>247 W 37TH ST</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCH. QUALITY IMPROVEMENT COLLAB. AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>650000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCH. QUALITY IMPROVEMENT COLLAB. AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>2567417</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCH. QUALITY IMPROVEMENT COLLAB. AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>1920614</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DRIVING EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH TD THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLAB. AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>1283708</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITAET MUENCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ARCISSTRABE 21</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COST-EFFECTIVENESS OF PUBLIC HEALTH SCREENING FOR PRE-SYMPTOMATIC TYPE 1 DIABETES WITH AND WITHOUT TREATMENT FOR PREVENTION OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>127031</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITAT DRESDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZSTR 10</AddressLine1Txt>
            <CityNm>DRESDEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FR1DA IN SACHSEN</GrantOrContributionPurposeTxt>
          <Amt>60079</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITAT DRESDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HELMHOLTZSTR 10</AddressLine1Txt>
            <CityNm>DRESDEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENOMIC INFLUENCE OF MATERNAL TYPE 1 DIABETES - UNDERSTANDING PROTECTION AGAINST TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>210829</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WEIZMAN 6</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS</GrantOrContributionPurposeTxt>
          <Amt>346330</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL-AVIV UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL AVIV UNIVERSITY</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY MEDICAL SIMULATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ACADEMIC COLLEGE AT TEL-HAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HAI COLLEGE</AddressLine1Txt>
            <CityNm>UPPER GALILEE</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY RESEARCH AND INNOVATION WING IN THE TEL-HAI COMPUTER SCIENCE BUILDING.</GrantOrContributionPurposeTxt>
          <Amt>900000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASPEN INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2300 N STREET</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING VISIONARY AND EFFECTIVE TEAMS TO ACCELERATE PROGRESS AGAINST TYPE 1 DIABETES (T1D) AND OTHER NON-COMMUNICABLE DISEASES (NCDS)</GrantOrContributionPurposeTxt>
          <Amt>998081</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2012100 HALUTZ</AddressLine1Txt>
            <CityNm>RAMAT HANEGEV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RAMAT HANEGEV SENIOR CITIZEN CENTER</GrantOrContributionPurposeTxt>
          <Amt>136393</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2012100 HALUTZ</AddressLine1Txt>
            <CityNm>RAMAT HANEGEV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY PREPAREDNESS FOR COMMUNITIES IN THE RAMAT HANEGEV COUNCIL REGION OF SOUTHERN ISRAEL</GrantOrContributionPurposeTxt>
          <Amt>432000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BANQUET</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>900 E 8TH ST</AddressLine1Txt>
            <CityNm>SIOUX FALLS</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57103</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BINYAMIN FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>445 CENTRAL AVENUE</AddressLine1Txt>
            <CityNm>CEDARHURST</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11516</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY PREPAREDNESS FOR COMMUNITIES IN BINYAMIN REGIONAL COUNCIL</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NOVEL THERAPEUTIC APPROACHES FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CENTER FOR EFFECTIVE PHILANTHROPY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>675 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02139</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>49800</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CHINESE UNIVERSITY OF HONG KONG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PI CHIU BUILDING</AddressLine1Txt>
            <CityNm>SHATIN</CityNm>
            <CountryCd>HK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD GIVES-21: GLOBAL IBD VISUALIZATION OF EPIDEMIOLOGY STUDIES IN THE 21ST CENTURY</GrantOrContributionPurposeTxt>
          <Amt>249337</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENETIC PROTECTION BY HLA-DQ6 IN T1D</GrantOrContributionPurposeTxt>
          <Amt>116445</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>165000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CHARITABLE TRUST GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>1031896</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>429712</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE MILESTONE INITIATIVE: EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA</GrantOrContributionPurposeTxt>
          <Amt>331133</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>1355310</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN INTESTINAL ULTRASOUND INDEX AND A HISTOPATHOLOGY INDEX FOR STRICTURING SMALL BOWEL CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>111750</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE DIATRIBE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>804 HAIGHT STREET</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94117</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIATRIBE LEARN MENTAL HEALTH SERIES</GrantOrContributionPurposeTxt>
          <Amt>100285</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE END FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2 PARK AVENUE 18TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10016</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>REACHING THE LAST MILE FUND EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>4130500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>QUANTITATIVE PROTEOMIC PROFILING OF FIBROSTENOTIC CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>247654</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VISUALIZATION OF COVID-19 VACCINE SEROLOGY IN CROHNS DISEASE: A KNOWLEDGE TRANSLATION STRATEGY</GrantOrContributionPurposeTxt>
          <Amt>89047</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD</GrantOrContributionPurposeTxt>
          <Amt>137153</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD</GrantOrContributionPurposeTxt>
          <Amt>126154</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CHANGING EPIDEMIOLOGY AND DEMOGRAPHICS OF CROHNS DISEASE IN THE WESTERN WORLD OVER THE NEXT DECADE</GrantOrContributionPurposeTxt>
          <Amt>121036</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CHANGING EPIDEMIOLOGY AND DEMOGRAPHICS OF CROHNS DISEASE IN THE WESTERN WORLD OVER THE NEXT DECADE</GrantOrContributionPurposeTxt>
          <Amt>191883</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HEALTH &amp; HOUSING CONSORTIUM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>STADIUM STATION</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10452</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC HEALTH &amp; HOUSING CONSORTIUM: STRATEGIZING FOR SUSTAINABILITY</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOLE IN THE WALL GANG FUND INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>555 LONG WHARF DRIVE</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06511</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOPE CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 KANSAS CITY STREET</AddressLine1Txt>
            <CityNm>RAPID CITY</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOSPITAL FOR SICK CHILDREN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>555 UNIVERSITY AVE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES</GrantOrContributionPurposeTxt>
          <Amt>548276</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION</GrantOrContributionPurposeTxt>
          <Amt>380592</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE JEWISH AGENCY FOR ISRAEL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>48 KING GEORGE STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE JEWISH AGENCY SECURITY FUND (THE FUND)</GrantOrContributionPurposeTxt>
          <Amt>161477</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE LANIADO KIRIAT SANZ HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DIVREI KHAYIM ST 16</AddressLine1Txt>
            <CityNm>NATANIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW MATERNITY FLOOR C</GrantOrContributionPurposeTxt>
          <Amt>2150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE LEGATUM INSTITUTE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O GENEVA GLOBAL 1536 E LANCASTER</AddressLine1Txt>
            <AddressLine2Txt>AVE</AddressLine2Txt>
            <CityNm>PAOLI</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19301</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO CONCLUDE PHASE TWO OF THE PROJECT: THE PRODUCTION, DISSEMINATION AND PROMOTION OF THE UNITED STATES PROSPERITY INDEX</GrantOrContributionPurposeTxt>
          <Amt>71831</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MAX STERN ACADEMIC COLLEGE OF EMEK YEZREEL LTD (CC)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>YEZREEL VALLEY</AddressLine1Txt>
            <CityNm>YEZREEL VALLEY</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>OPPORTUNITY FOR SUCCESS SCHOLARSHIPS FOR ETHIOPIAN-ISRAELIS PURSUING NURSING DEGREES</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MILKEN INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1250 FOURTH STREET</AddressLine1Txt>
            <CityNm>SANTA MONICA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90401</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FASTERCURES LEADERSLINK PROGRAM EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE NATURE CONSERVANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4245 NORTH FAIRFAX DRIVE SUITE 100</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FUTURE FOREST NYC PHASE III</GrantOrContributionPurposeTxt>
          <Amt>352196</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>229044195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS</GrantOrContributionPurposeTxt>
          <Amt>206088</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 THEORY SUITE 200</AddressLine1Txt>
            <CityNm>IRVINE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>926971050</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>461893</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCLA OFFICE OF CONTRACTS AND GRANTS</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>900951406</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>568851</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 GILMAN DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92093</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN</GrantOrContributionPurposeTxt>
          <Amt>545759</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)</GrantOrContributionPurposeTxt>
          <Amt>241173</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)</GrantOrContributionPurposeTxt>
          <Amt>241173</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS</GrantOrContributionPurposeTxt>
          <Amt>648749</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SANTA BARBARA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UC SANTA BARBARA</AddressLine1Txt>
            <CityNm>SANTA BARBARA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>93106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>832906</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ASK THE EXPERTS</GrantOrContributionPurposeTxt>
          <Amt>575810</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>413258</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FAILED GENETIC PROTECTION: T1D IN THE PRESENCE OF DQB1*06:02</GrantOrContributionPurposeTxt>
          <Amt>266200</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)</GrantOrContributionPurposeTxt>
          <Amt>453311</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION</GrantOrContributionPurposeTxt>
          <Amt>676014</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D</GrantOrContributionPurposeTxt>
          <Amt>179943</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>501000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREPARE 4 AID: PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY</GrantOrContributionPurposeTxt>
          <Amt>1441282</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETIC KETOACIDOSIS TRENDS AND RESOURCE UTILIZATION AT DIAGNOSIS OF TYPE 1 DIABETES IN THE UNITED STATES</GrantOrContributionPurposeTxt>
          <Amt>157700</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SCRIPPS RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10550 NORTH TORREY PINES ROAD</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GUT-RETAINED NRF2/ARE ACTIVATORS FOR IBD</GrantOrContributionPurposeTxt>
          <Amt>2265175</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SCRIPPS RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10550 NORTH TORREY PINES ROAD</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSLATION OF MICROBIOTA MECHANISMS ON NOD2 FOR CROHNS DISEASE THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>494231</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SDEROT DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 BAR LEV STREET</AddressLine1Txt>
            <CityNm>SDEROT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ESTABLISHING A WARM HOME COMPLEX FOR CHILDREN AT RISK IN SDEROT</GrantOrContributionPurposeTxt>
          <Amt>2421222</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HASHOMER</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY FUNDING FOR EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>976000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HASHOMER</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CENTER FOR INNOVATIVE SURGICAL TRAINING</GrantOrContributionPurposeTxt>
          <Amt>4395700</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HASHOMER</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE &amp; OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)</GrantOrContributionPurposeTxt>
          <Amt>704764</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SONIA NABETA FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4705 5TH STREET UNIT 405</AddressLine1Txt>
            <CityNm>LONG ISLAND CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT BODA-BODA</GrantOrContributionPurposeTxt>
          <Amt>184889</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TEL AVIV JAFFA ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RABENU YERUHAM ST 2 POB 8401</AddressLine1Txt>
            <CityNm>TEL AVIV YAFFO</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS</GrantOrContributionPurposeTxt>
          <Amt>266667</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TEL AVIV JAFFA ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RABENU YERUHAM ST 2 POB 8401</AddressLine1Txt>
            <CityNm>TEL AVIV YAFFO</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCHOLARSHIP SUPPORT FOR ULTRA-ORTHODOX (HAREDI) MEN PURSUING B.S. DEGREES IN NURSING</GrantOrContributionPurposeTxt>
          <Amt>253818</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>334798</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>351258</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDING HEALTH QUESTIONS TO THE POVERTY TRACKER TO SURVEY THEHEALTHCARE NEEDS AND UTILIZATION PREFERENCES OF LOW-INCOMENEW YORKERS</GrantOrContributionPurposeTxt>
          <Amt>143021</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE UNIVERSITY OF ADELAIDE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA EXPANDED SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>163010</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE UNIVERSITY OF ADELAIDE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA SCIENCE CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>181471</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE UNIVERSITY OF ADELAIDE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>217136</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNO-PHARMACOGENOMICS TO UNDERSTAND AND PREDICT RESPONSE TO BIOLOGICS IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>106296</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNO-PHARMACOGENOMICS TO UNDERSTAND AND PREDICT RESPONSE TO BIOLOGICS IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>106296</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND</GrantOrContributionPurposeTxt>
          <Amt>784751</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>212881</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>444246</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN TYPE 1 DIABETES.</GrantOrContributionPurposeTxt>
          <Amt>159623</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING ALPHA CELL DYSFUNCTION AND CORRECTING GLUCAGON SECRETION IN TYPE 1 DIABETES.</GrantOrContributionPurposeTxt>
          <Amt>179714</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC)</GrantOrContributionPurposeTxt>
          <Amt>172204</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF MANCHESTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OXFORD RD</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION</GrantOrContributionPurposeTxt>
          <Amt>1113915</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CUMBRAE STEWART BUILDING 72</AddressLine1Txt>
            <CityNm>BRISBANE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1261871</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CUMBRAE STEWART BUILDING 72</AddressLine1Txt>
            <CityNm>BRISBANE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>156746</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5323 HARRY HINES BOULEVARD</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>753909020</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNE CHECKPOINT ENGINEERED BETA CELL AS AN ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF TYPE I DIABETES</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF WESTERN AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>35 STIRLING HIGHWAY</AddressLine1Txt>
            <CityNm>CRAWLEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM ASSESSMENTS OF ENDIA CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>58241</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE QUANTUM MATERIALS DEVICES FABRICATION LAB</GrantOrContributionPurposeTxt>
          <Amt>1750000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DECODING THE CLINICAL IMPACT OF HOST AND MICROBIAL INTESTINAL PROTEOMIC LANDSCAPE IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>961620</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DECODING PERSONALIZED NUTRITIONAL, MICROBIOME AND HOST PATTERNS IMPACTING CLINICAL AND PROGNOSTIC FEATURES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>947483</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TOWNSEND HEALTH SYSTEMS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>110 NORTH OAK</AddressLine1Txt>
            <CityNm>TOWNSEND</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59644</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT BILLINGS CLINIC BROADWATER</GrantOrContributionPurposeTxt>
          <Amt>15112</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRICKLE UP PROGRAM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 WEST 27TH STREET 12TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>25000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TROPICAL GASTROENTEROLOGY AND NUTRITION LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>26 COPPER ROAD</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>1ST CONVENING OF THE IBD AFRICA GENETICS CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>29471</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES AND FRIENDS OF AGRICULTURAL RESEARCH AT THE VOLCANI CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HA MACABIM 68 PO BOX 15159</AddressLine1Txt>
            <CityNm>RISHON LEZION</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROTECTING FARMERS AND AGRICULTURAL WORKERS ACROSS THE WESTERN NEGEV</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 EAST 3RD STREET</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOLECULAR DESIGN AND TESTING OF GLUCOSE-RESPONSIVE THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>1128685</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 EAST 3RD STREET</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE EFFORT TO VALIDATE MICRORNA AS BIOMARKERS OF T1D</GrantOrContributionPurposeTxt>
          <Amt>426380</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS</GrantOrContributionPurposeTxt>
          <Amt>407000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>293370</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ULTRA PROCESSED WESTERN DIET, THE GUT MICROBIOME, AND DIETARY XENOBIOTIC EXPOSURE IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>285079</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TZAFON MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE BARUCH PADEH MEDICAL CENTER</AddressLine1Txt>
            <AddressLine2Txt>PORIYA</AddressLine2Txt>
            <CityNm>TIBERIAS</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VASCULAR ANGIOGRAPHY INSTITUTE</GrantOrContributionPurposeTxt>
          <Amt>752574</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TZAFON MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE BARUCH PADEH MEDICAL CENTER</AddressLine1Txt>
            <AddressLine2Txt>PORIYA</AddressLine2Txt>
            <CityNm>TIBERIAS</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY REHABILITATION CENTER OF THE NORTH</GrantOrContributionPurposeTxt>
          <Amt>5431730</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED JEWISH APPEAL FEDERATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>130 EAST 59TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED JEWISH APPEAL FEDERATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>130 EAST 59TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED NATIONS DEVELOPMENT PROGRAMME</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 UNITED NATIONS PLAZA</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO HEALTHCARE FOR PEOPLE LIVING WITH DIABETES AND OTHER NCDS</GrantOrContributionPurposeTxt>
          <Amt>339777</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED STATES AFRICAN DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1400 I STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LIVELIHOOD IMPROVEMENT PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>1283255</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED STATES FUND FOR UNICEF</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 MAIDEN LANE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>784421</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM</GrantOrContributionPurposeTxt>
          <Amt>450921</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE DE GENEVE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RUE MICHEL SERVET 1</AddressLine1Txt>
            <CityNm>GENEVE</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL TESTING OF S100A9 TO IMPROVE GLYCEMIC CONTROL IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1373247</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE LIBRE DE BRUXELLES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE FRANKLIN ROOSEVELT 50</AddressLine1Txt>
            <CityNm>BRUSSELS</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING</GrantOrContributionPurposeTxt>
          <Amt>213582</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P C</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 MAIN STREET</AddressLine1Txt>
            <CityNm>BUFFALO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>14203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>272233</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>GOWER STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPIT-C: USING SALIVA TO PREDICT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>60000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY HOSPITALS HEALTH SYSTEM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11100 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS</GrantOrContributionPurposeTxt>
          <Amt>707339</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1800 W CHARLESTON BLVD</AddressLine1Txt>
            <CityNm>LAS VEGAS</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>719072</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BIRMINGHAM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INSTITUTE OF IMMUNOLOGY AND</AddressLine1Txt>
            <AddressLine2Txt>IMMUNOTHERAPY</AddressLine2Txt>
            <CityNm>BIRMINGHAM</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING AN OPTIMISED ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>506886</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BIRMINGHAM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INSTITUTE OF IMMUNOLOGY AND</AddressLine1Txt>
            <AddressLine2Txt>IMMUNOTHERAPY</AddressLine2Txt>
            <CityNm>BIRMINGHAM</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR TYPE 1 DIABETES: AN EXPERIMENTAL MEDICINE STUDY</GrantOrContributionPurposeTxt>
          <Amt>80506</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?</GrantOrContributionPurposeTxt>
          <Amt>1045519</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?</GrantOrContributionPurposeTxt>
          <Amt>583311</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2)</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - ANOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>713088</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CINCINNATI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>51 GOODMAN DRIVE SUITE 500</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45221</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>416500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>B CELL SIGNATURES IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>251607</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>669554</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>307674</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2: FROM OBSERVATION TO MECHANISM</GrantOrContributionPurposeTxt>
          <Amt>345527</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERATING AUTOANTIGEN-SPECIFIC ANTIBODY-PRODUCING HYBRIDOMAS AS A RENEWABLE SOURCE OF ISLET AUTOANTIBODIES</GrantOrContributionPurposeTxt>
          <Amt>54094</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC): A NATIONAL NEEDS ASSESSMENT</GrantOrContributionPurposeTxt>
          <Amt>741600</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF GLASGOW COURT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY AVENUE</AddressLine1Txt>
            <CityNm>GLASGOW</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE: THE BIOPIC STUDY</GrantOrContributionPurposeTxt>
          <Amt>1231291</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DIVISION OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION IOWA (SIM-IA)</GrantOrContributionPurposeTxt>
          <Amt>33833</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 LAKE AVENUE NORTH</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01655</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS</GrantOrContributionPurposeTxt>
          <Amt>881959</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MELBOURNE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 4 ALAN GILBERT BUILDING</AddressLine1Txt>
            <CityNm>VICTORIA</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANIMAL AND CLINICAL EVALUATION OF A NOVEL CONTINUOUS KETONE SENSOR</GrantOrContributionPurposeTxt>
          <Amt>880551</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MELBOURNE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 4 ALAN GILBERT BUILDING</AddressLine1Txt>
            <CityNm>VICTORIA</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>203056</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS</GrantOrContributionPurposeTxt>
          <Amt>893092</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>149796</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>581625</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CROHN'S-LIKE DISEASE OF THE POUCH</GrantOrContributionPurposeTxt>
          <Amt>260103</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH DAKOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SCHOOL OF MEDICINE HEALTH SCIENCES</AddressLine1Txt>
            <CityNm>GRAND FORKS</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION (SIM) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>14808</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES</GrantOrContributionPurposeTxt>
          <Amt>373873</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>IN</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>143127</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF OULU</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO BOX 8000</AddressLine1Txt>
            <CityNm>OULU</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING</GrantOrContributionPurposeTxt>
          <Amt>137453</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3420 FORBES AVENUE</AddressLine1Txt>
            <CityNm>PITTSBURGH</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>152603203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>280115</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3420 FORBES AVENUE</AddressLine1Txt>
            <CityNm>PITTSBURGH</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>152603203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>243196</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3420 FORBES AVENUE</AddressLine1Txt>
            <CityNm>PITTSBURGH</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>152603203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ANALOGUE VS HUMAN INSULIN FOR YOUTH WITH TYPE 1 DIABETES IN LOW-RESOURCE SETTINGS: A RANDOMIZED CONTROLLED TRIAL (ANHUT1D TRIAL)</GrantOrContributionPurposeTxt>
          <Amt>998931</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3925 WEST BRAKER LANE</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>787595316</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN</GrantOrContributionPurposeTxt>
          <Amt>198646</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3925 WEST BRAKER LANE</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>787595316</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN</GrantOrContributionPurposeTxt>
          <Amt>196411</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TOLEDO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3000 ARLINGTON AVENUE</AddressLine1Txt>
            <CityNm>TOLEDO</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>436142595</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH</GrantOrContributionPurposeTxt>
          <Amt>91848</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TOLEDO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3000 ARLINGTON AVENUE</AddressLine1Txt>
            <CityNm>TOLEDO</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>436142595</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES CAR TREG THERAPEUTIC APPROACH</GrantOrContributionPurposeTxt>
          <Amt>18632</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF UTAH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>201 S PRESIDENTS CIRCLE</AddressLine1Txt>
            <CityNm>SALT LAKE CITY</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84112</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INDUCTION OF PERIPHERAL TOLERANCE TO BETA CELL ANTIGENS BY SPECIFIC TARGETING OF LANGERIN+ DENDRITIC CELLS</GrantOrContributionPurposeTxt>
          <Amt>290806</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF VIRGINIA LAW SCHOOL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>580 MASSIE ROAD</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22903</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR THE CATHERINE MURPHY KEATING '87 RESTRICTED FUND</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF VIRGINIA LAW SCHOOL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>580 MASSIE ROAD</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22903</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR THE CATHERINE MURPHY KEATING '87 RESTRICTED FUND</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WASHINGTON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981959472</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DESIGN OF ISLET TARGETED AGONISTS OF PD1 AND CTLA4</GrantOrContributionPurposeTxt>
          <Amt>378764</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WASHINGTON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981959472</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SKIN PATHOLOGY IN PEOPLE WITH T1D: IMPACT OF INSULIN INFUSION VIA PUMP</GrantOrContributionPurposeTxt>
          <Amt>111932</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WESTERN ONTARIO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>339 WINDERMERE RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>919293</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WYOMING FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>222 S 22ND ST</AddressLine1Txt>
            <CityNm>LARAMIE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND TRAINING INITIATIVE IN WYOMING</GrantOrContributionPurposeTxt>
          <Amt>641903</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UPPSALA UNIVERSITET</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BOX 256</AddressLine1Txt>
            <CityNm>UPPSALA</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALPHA-CELL SIGNALING FOR GLUCAGON SECRETION</GrantOrContributionPurposeTxt>
          <Amt>229347</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UPTIME GLOBAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>23-38 HYTHE BRIDGE STREET</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RESULTS-BASED SAFE WATER SERVICES</GrantOrContributionPurposeTxt>
          <Amt>350000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MRI OF THE PANCREAS IN T1D</GrantOrContributionPurposeTxt>
          <Amt>196582</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MRI OF THE PANCREAS IN T1D</GrantOrContributionPurposeTxt>
          <Amt>176459</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>36595</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL SINGLE CELL STRATEGIES FOR A CROHN'S DISEASE GUT CELL ATLAS</GrantOrContributionPurposeTxt>
          <Amt>290049</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>68349</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN ADMINISTRATIVE CORE AND COLLABORATIVE DATA REPOSITORY FOR THE GUT CELL ATLAS</GrantOrContributionPurposeTxt>
          <Amt>496512</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCREENING HUMAN ISLETS TO IDENTIFY SMALL MOLECULES ENHANCING GLUCAGON SECRETION UNDER HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>221931</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEWAPPROACHES TO PREVENT HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>170401</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY</GrantOrContributionPurposeTxt>
          <Amt>145749</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SPONSORED PROGRAMS ADMINISTRATION</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>372032417</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1888240</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FEASIBILITY PILOT TO DESIGN A VALUE BASED PAYMENT ECOSYSTEM TO IMPROVE HEALTH AND EQUITY FOR MEDICAID BENEFICIARIES LIVING WITH T1D AND T2D</GrantOrContributionPurposeTxt>
          <Amt>705194</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VETERANS MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>40 1ST STREET SE</AddressLine1Txt>
            <CityNm>WAUKON</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52172</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECARE PHARMACY AND EMERGENCY SERVICES AT VETERANS MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>30504</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VILLAGES OF HOPE AFRICA SOCIETY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2450 MILLTOWER COURT</AddressLine1Txt>
            <CityNm>MISSISSAUGA</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INFRASTRUCTURE IMPROVEMENTS AND EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>253122</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VIVLI INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 MIDDLESEX TURNPIKE SUITE 6</AddressLine1Txt>
            <CityNm>BURLINGTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>018034914</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA SHARING PLATFORM FOR T1-DEXI DATASETS</GrantOrContributionPurposeTxt>
          <Amt>120000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WARREN MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>905 2ND ST</AddressLine1Txt>
            <CityNm>FRIEND</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68359</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT FRIEND COMMUNITY HEALTHCARE SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>25335</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>CAMPUS BOX 1054</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>631304862</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>338970</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>CAMPUS BOX 1054</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>631304862</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING</GrantOrContributionPurposeTxt>
          <Amt>330000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WATER4 INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2405 NW 10TH STREET</AddressLine1Txt>
            <CityNm>OKLAHOMA CITY</CityNm>
            <StateAbbreviationCd>OK</StateAbbreviationCd>
            <ZIPCd>73107</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING THE NUMA MODEL TO DELIVER SAFE, SUSTAINABLE WATER</GrantOrContributionPurposeTxt>
          <Amt>1673164</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WEST PARK HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>707 SHERIDAN AVENUE</AddressLine1Txt>
            <CityNm>CODY</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82414</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CODY REGIONAL HEALTH ULTRASOUND PROJECT</GrantOrContributionPurposeTxt>
          <Amt>466486</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WILDLIFE CONSERVATION SOCIETY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2300 SOUTHERN BOULEVARD</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10460</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT FOR ELEPHANTS</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WIND RIVER FAMILY AND COMMUNITY HEALTH CARE SYSTEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>14 GREAT PLAINS RD</AddressLine1Txt>
            <CityNm>ARAPAHOE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82510</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING ULTRASOUND REVITALIZATION INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>391802</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WNET FOR THE WLIW-21 PUBLIC BROADCASTING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>825 EIGHTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100197435</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORLD HEALTH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE APPIA 20</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS</GrantOrContributionPurposeTxt>
          <Amt>2862039</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WYOMING COMMUNITY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1472 NORTH 5TH STREET</AddressLine1Txt>
            <CityNm>LARAMIE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82072</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENHANCING ULTRASOUND CAPABILITIES IN WYOMING</GrantOrContributionPurposeTxt>
          <Amt>361581</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WYOMING DEPARTMENT OF HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>6101 YELLOWSTONE RD SUITE 400</AddressLine1Txt>
            <CityNm>CHEYENNE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82009</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WYOMING FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>16000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YAD SARAH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>124 HERZL BLVD</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY EQUIPMENT PURCHASES</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>414595</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPOSOMICS FOR EARLY LIFE CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>298606</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>792237</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YITZHAK SHAMIR MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEER YAAKOV</AddressLine1Txt>
            <CityNm>TZRIFIN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SHAMIR UNDERGROUND EMERGENCY HOSPITAL EQUIPMENT</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUNG MEN'S CHRISTIAN ASSOCIATION RETIREMENT FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10271</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>7500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUNG MEN'S CHRISTIAN ASSOCIATION RETIREMENT FUND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10271</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>10000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUTH DEVELOPMENT ORGANIZATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15 UNION STREET 563</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING PROJECT SUPPORT 2022</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ZIV MEDICAL CENTER ZEFAT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RAMBAM ST</AddressLine1Txt>
            <CityNm>ZEFAT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY EQUIPMENT FOR ZIV MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ZIV MEDICAL CENTER ZEFAT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RAMBAM ST</AddressLine1Txt>
            <CityNm>ZEFAT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRESSURE CHAMBER FOR HYPERBARIC THERAPY, ZIV MEDICAL CENTER, SAFED.</GrantOrContributionPurposeTxt>
          <Amt>2120034</Amt>
        </GrantOrContributionPdDurYrGrp>
        <TotalGrantOrContriPdDurYrAmt>445672622</TotalGrantOrContriPdDurYrAmt>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUTE FOR MONITORING PEACE AND CULTURAL TOLERANCE IN SCHOOL EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 JABOTINSKY ST</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING EDUCATION FOR PEACE: A NATIONWIDE AWARENESS CAMPAIGN ON INCITEMENT IN PALESTINIAN/UNRWA TEXTBOOKS.</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3103 BEE CAVES ROAD</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>78746</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PF</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY</GrantOrContributionPurposeTxt>
          <Amt>1446574</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACADEMISCH ZIEKENHUIS LEIDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 ALBINUSDREEF</AddressLine1Txt>
            <CityNm>LEIDEN</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)</GrantOrContributionPurposeTxt>
          <Amt>238910</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACADEMISCH ZIEKENHUIS LEIDEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 ALBINUSDREEF</AddressLine1Txt>
            <CityNm>LEIDEN</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFETY AND EFFICACY OF IMMUNE INTERVENTION WITH TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH EARLY T1D (D-SENSE II)</GrantOrContributionPurposeTxt>
          <Amt>93238</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACTION4DIABETES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>9 PARKFIELD ROAD</AddressLine1Txt>
            <CityNm>TAUNTON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHILIPPINES T1D TASK FORCE</GrantOrContributionPurposeTxt>
          <Amt>222500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ACTION4DIABETES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>9 PARKFIELD ROAD</AddressLine1Txt>
            <CityNm>TAUNTON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PHILIPPINES T1D TASK FORCE</GrantOrContributionPurposeTxt>
          <Amt>284390</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 MORRIS PARK AVENUE</AddressLine1Txt>
            <CityNm>BRONX</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>104611975</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENHANCING THE COMMUNITY HEALTH WORKER MODEL TO PROMOTE DIABETES TECHNOLOGY USE IN ADULTS FROM UNDERREPRESENTED MINORITY GROUPS WITH T1D PILOT STUDY</GrantOrContributionPurposeTxt>
          <Amt>173613</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALIMENTIV INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NEXT GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>259951</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1825 EYE STREET NW 401</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION</GrantOrContributionPurposeTxt>
          <Amt>539349</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ALLIANCE OF COMMUNITY HEALTH PLANS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1825 EYE STREET NW 401</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATING WITH HEALTH PLANS TO OVERCOME BARRIERS TO COVERAGE AND UTILIZATION OF CONTINUOUS GLUCOSE MONITORING : LAYING THE FOUNDATION</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>225500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE: OMICROHN</GrantOrContributionPurposeTxt>
          <Amt>1532103</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A PROSPECTIVE RANDOMIZED STUDY OF TREATMENT SELECTION BASED ON EPIGENETIC MARKERS IN CROHNS DISEASE: OMICROHN</GrantOrContributionPurposeTxt>
          <Amt>1476985</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMC MEDICAL RESEARCH BV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MEIBERGDREEF 9</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION OF BIOMARKERS FOR PATIENT STRATIFICATION IN PERIANAL FISTULIZING DISEASE</GrantOrContributionPurposeTxt>
          <Amt>306900</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN COLLEGE OF DIABETOLOGY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 87633</AddressLine1Txt>
            <CityNm>FAYETTEVILLE</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>28304</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVE THE DIABETES TRAINING OPPORTUNITIES FOR PCPS</GrantOrContributionPurposeTxt>
          <Amt>1200436</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING AND MENTORSHIP PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>805382</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING AND MENTORSHIP PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>805382</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN DIABETES ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2451 CRYSTAL DRIVE SUITE 900</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2022-2024 TYPE 1 DIABETES CAMP INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>399368</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN GASTROENTEROLOGICAL ASSOCIATION INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4930 DEL RAY AVE</AddressLine1Txt>
            <CityNm>BETHESDA</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20814</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMPLIFYING LEARNING FROM THE CEDARS-SINAI ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION</GrantOrContributionPurposeTxt>
          <Amt>64189</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MISSION: LIFELINE STROKE IOWA</GrantOrContributionPurposeTxt>
          <Amt>2521277</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POST-ACUTE STROKE CARE: IMPLEMENTING QUALITY STANDARDS IN MONTANA, NEBRASKA AND NORTH DAKOTA</GrantOrContributionPurposeTxt>
          <Amt>379458</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH</GrantOrContributionPurposeTxt>
          <Amt>6966024</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>871217</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AMERICAN HEART ASSOCIATION CENTER FOR TELEHEALTH</GrantOrContributionPurposeTxt>
          <Amt>4816553</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN HEART ASSOCIATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>7272 GREENVILLE AVENUE</AddressLine1Txt>
            <CityNm>DALLAS</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>75231</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEARTCORPS: AHA'S RURAL PUBLIC HEALTH WORKFORCE DEVELOPMENT INITIATIVE</GrantOrContributionPurposeTxt>
          <Amt>850098</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AMERICAN PHARMACISTS ASSOCIATION FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2215 CONSTITUTION AVE NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROJECT IMPACT CGM: EXPANDING ACCESS TO CGM THROUGH COMMUNITY PHARMACIES</GrantOrContributionPurposeTxt>
          <Amt>1502893</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANN &amp; ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 EAST CHICAGO AVENUE BOX 205</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60611</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D</GrantOrContributionPurposeTxt>
          <Amt>2325006</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANN &amp; ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 EAST CHICAGO AVENUE BOX 205</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60611</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D</GrantOrContributionPurposeTxt>
          <Amt>1542882</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANN &amp; ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 EAST CHICAGO AVENUE BOX 205</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60611</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION AND DISSEMINATION OF TOOLS TO HARNESS CGM DATA TO ACCELERATE ADOPTION OF POPULATION HEALTH IN T1D</GrantOrContributionPurposeTxt>
          <Amt>1245216</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANTHOS HOME INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>238 SEELEY ST</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11218</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANTHOS HOME INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>238 SEELEY ST</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11218</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ANTHOS HOME INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>238 SEELEY ST</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11218</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LAUNCHING ANTHOS HOME, WITH SPECIALIZED FOCUS ON HOUSING HIGH-NEED PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>APHP ST ANTOINE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>184 RUE DU FAUBOURG SAINT-ANTOINE</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE AS RELAY AFTER ANTI-TNF WITHDRAWAL (MIRACLE)</GrantOrContributionPurposeTxt>
          <Amt>421681</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ARAD MUNICIPALITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 HAPALMACH STREET</AddressLine1Txt>
            <CityNm>ARAD</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ARAD OCCUPATIONAL REHABILITATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>106764</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 SOUTH WACKER DRIVE SUITE 600</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60606</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF THE DANATECH PLATFORM</GrantOrContributionPurposeTxt>
          <Amt>855546</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION SANTE DIABETE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>5 RUE FEDERICO GARCIA LORCA</AddressLine1Txt>
            <CityNm>GRENOBLE</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS</GrantOrContributionPurposeTxt>
          <Amt>587221</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION SANTE DIABETE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>5 RUE FEDERICO GARCIA LORCA</AddressLine1Txt>
            <CityNm>GRENOBLE</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS</GrantOrContributionPurposeTxt>
          <Amt>325558</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ASSOCIATION SANTE DIABETE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>5 RUE FEDERICO GARCIA LORCA</AddressLine1Txt>
            <CityNm>GRENOBLE</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHEN THE CARE AND SUPPORT OF PATIENTS WITH TYPE 1 DIABETES IN MALI, BURKINA FASO, AND THE UNION OF THE COMOROS</GrantOrContributionPurposeTxt>
          <Amt>587221</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 2</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY.</GrantOrContributionPurposeTxt>
          <Amt>209377</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 2</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY.</GrantOrContributionPurposeTxt>
          <Amt>315421</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 2</AddressLine1Txt>
            <CityNm>FITZROY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSPLANTATION (FMT) IN CROHN'S DISEASE: THE MIRO (MICROBIOTA RESTORATION) STUDY.</GrantOrContributionPurposeTxt>
          <Amt>315421</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BALLAD RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3525 JOHN HOPKINS COURT</AddressLine1Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>315380</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BALLAD RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3525 JOHN HOPKINS COURT</AddressLine1Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD127-HIGH T-CELL POPULATIONS IN AUTOANTIBODY POSITIVE CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>243390</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAR ILAN UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>MAX VE-ANNA WEBB ST</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE LEONA M. AND HARRY B. HELMSLEY ENERGY PROTOTYPE LAB AT BAR-ILAN UNIVERSITY</GrantOrContributionPurposeTxt>
          <Amt>3348125</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BAYLOR COLLEGE OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREDICTIVE ANALYTICS AND TARGETED INTERVENTIONS: SHIFTING THE PARADIGM FROM REACTIVE TO PROACTIVE DIABETES CARE</GrantOrContributionPurposeTxt>
          <Amt>547540</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1201 NINTH AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981012795</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LINKING DISEASE MECHANISM AND CLINICAL TRIAL DESIGN VIA RAPIDLY CONDUCTED IMMUNOTHERAPY TRIALS IN T1D</GrantOrContributionPurposeTxt>
          <Amt>288200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEN-GURION UNIVERSITY OF THE NEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN-GURION BLVD 1</AddressLine1Txt>
            <CityNm>BEER SHEVA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONSTRUCTION OF THE LEONA B. AND HARRY M. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING</GrantOrContributionPurposeTxt>
          <Amt>5785714</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEN-GURION UNIVERSITY OF THE NEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN-GURION BLVD 1</AddressLine1Txt>
            <CityNm>BEER SHEVA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COBMINDEX GOES FORWARD- A SMARTPHONE APPLICATION FOR ADDED PSYCHOLOGICAL WELLBEING IN CROHN'S DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>765436</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEN-GURION UNIVERSITY OF THE NEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEN-GURION BLVD 1</AddressLine1Txt>
            <CityNm>BEER SHEVA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONSTRUCTION OF THE LEONA B. AND HARRY M. HELMSLEY CHARITABLE TRUST COMPUTER SCIENCE BUILDING</GrantOrContributionPurposeTxt>
          <Amt>10542857</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BETH ISRAEL DEACONESS MEDICAL CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>330 BROOKLINE AVENUE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155491</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROACTIVE OPTIMIZATION OF INFLIXIMAB USING A PHARMACOKINETIC DASHBOARD VERSUS STANDARD OF CARE IN PATIENTS WITH CROHNS DISEASE: THE OPTIMIZE TRIAL</GrantOrContributionPurposeTxt>
          <Amt>797851</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 CONCAR DRIVE OFFICE 03-155</AddressLine1Txt>
            <CityNm>SAN MATEO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94402</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BEYOND TYPE 1</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 CONCAR DRIVE OFFICE 03-155</AddressLine1Txt>
            <CityNm>SAN MATEO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94402</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ECMO SERVICES AT BILLINGS CLINIC</GrantOrContributionPurposeTxt>
          <Amt>449629</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ECMO SERVICES AT BILLINGS CLINIC</GrantOrContributionPurposeTxt>
          <Amt>485826</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BILLINGS CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2917 TENTH AVENUE NORTH</AddressLine1Txt>
            <CityNm>BILLINGS</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BILLINGS CLINIC SURGICAL INTENSIVE CARE UNIT</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIPARTISAN POLICY CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1225 I ST NW 1000</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES</GrantOrContributionPurposeTxt>
          <Amt>609887</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BIPARTISAN POLICY CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1225 I ST NW 1000</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING RURAL HEALTH CARE DELIVERY AND SERVICES</GrantOrContributionPurposeTxt>
          <Amt>633819</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>4470844</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>4470843</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BLUE CIRCLE HEALTH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>THE CORPORATION TRUST CENTER 1209</AddressLine1Txt>
            <AddressLine2Txt>ORANGE STREET</AddressLine2Txt>
            <CityNm>WILMINGTON</CityNm>
            <StateAbbreviationCd>DE</StateAbbreviationCd>
            <ZIPCd>19801</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF BLUE CIRCLE HEALTH</GrantOrContributionPurposeTxt>
          <Amt>3975887</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2601 ENTERPRISE ROAD</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89512</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND TRAINING INITIATIVE IN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>197208</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF REGENTS NEVADA SYSTEM OF HIGHER EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2601 ENTERPRISE ROAD</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89512</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CARDIORESPIRATORY CARE SCIENCE DEGREE PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>137345</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>758218</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABETESWISE FOR EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>835639</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABDOCS NATIONAL K12: SUPPLEMENT</GrantOrContributionPurposeTxt>
          <Amt>402980</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBIOME-BASED THERAPEUTICS FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1006687</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF PERSONALIZED DECISION SUPPORT TOOL USING NETIOB TO HELP MANAGE EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1069498</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>443 VIA ORTEGA</AddressLine1Txt>
            <CityNm>STANFORD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIABDOCS NATIONAL K12: SUPPLEMENT</GrantOrContributionPurposeTxt>
          <Amt>193790</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 EIGHTH AVENUE 5TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>567155</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BREAKING GROUND HOUSING DEVELOPMENT FUND CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 EIGHTH AVENUE 5TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING AND EVALUATING THE HEALTH EFFECTS OF ACCELERATED PLACEMENTS INTO PERMANENT SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>585924</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>2306101</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIDGES TO PROSPERITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1031 33RD STREET</AddressLine1Txt>
            <CityNm>DENVER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMATIVE CONNECTIVITY IN RURAL ZAMBIA</GrantOrContributionPurposeTxt>
          <Amt>2359636</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HILLS ROAD</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE UK IBD BIORESOURCE: TRANSLATING TODAYS SCIENCE INTO TOMORROWS TREATMENTS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>657605</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARDIFF UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>30-36 NEWPORT RD</AddressLine1Txt>
            <CityNm>CARDIFF</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D-PLUS: AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D</GrantOrContributionPurposeTxt>
          <Amt>892873</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARDIFF UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>30-36 NEWPORT RD</AddressLine1Txt>
            <CityNm>CARDIFF</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D-PLUS: AN ADAPTIVE TRIAL PLATFORM FOR THE STUDY OF COMBINATION THERAPIES IN NEW-ONSET T1D</GrantOrContributionPurposeTxt>
          <Amt>632664</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CARE-FOR-RARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DR VON HAUNERSCHES KINDERSPITAL</AddressLine1Txt>
            <AddressLine2Txt>KLINIKUM DER UNIVERSITAT MUNCHEN</AddressLine2Txt>
            <CityNm>MUNICH</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MUNICH STUDIES</GrantOrContributionPurposeTxt>
          <Amt>667252</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE</GrantOrContributionPurposeTxt>
          <Amt>1337724</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING COMMUNITY RECOVERY AND RESILIENCE</GrantOrContributionPurposeTxt>
          <Amt>1808630</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELPING MOTHERS AND NEWBORNS SURVIVE AND THRIVE</GrantOrContributionPurposeTxt>
          <Amt>1273764</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CATHOLIC RELIEF SERVICES-USCCB</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>228 W LEXINGTON ST</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING COMMUNITY RECOVERY AND RESILIENCE</GrantOrContributionPurposeTxt>
          <Amt>1073759</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: CEDARS-SINAI</GrantOrContributionPurposeTxt>
          <Amt>115500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY</GrantOrContributionPurposeTxt>
          <Amt>219514</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MULTIDISCIPLINARY PREHABILITATION PROGRAM FOR PATIENTS WITH IBD UNDERGOING ABDOMINAL SURGERY</GrantOrContributionPurposeTxt>
          <Amt>211815</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION</GrantOrContributionPurposeTxt>
          <Amt>519768</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CEDARS-SINAI MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>8700 BEVERLY BLVD</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90048</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE ADVANCED DIETARY IBD EDUCATION AND TRAINING (DIET) PROGRAM: BEYOND MALNUTRITION</GrantOrContributionPurposeTxt>
          <Amt>733694</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR HEALTH CARE STRATEGIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 AMERICAN METRO BLVD</AddressLine1Txt>
            <CityNm>HAMILTON</CityNm>
            <StateAbbreviationCd>NJ</StateAbbreviationCd>
            <ZIPCd>08619</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN</GrantOrContributionPurposeTxt>
          <Amt>1002514</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR HEALTH CARE STRATEGIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 AMERICAN METRO BLVD</AddressLine1Txt>
            <CityNm>HAMILTON</CityNm>
            <StateAbbreviationCd>NJ</StateAbbreviationCd>
            <ZIPCd>08619</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFYING OPPORTUNITIES TO SUPPORT T1D AUTOANTIBODY SCREENING IN MEDICAID PROGRAMS AND HEALTH CARE SYSTEMS THAT SERVE MEDICAID BENEFICIARIES</GrantOrContributionPurposeTxt>
          <Amt>149672</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTER FOR HEALTH CARE STRATEGIES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 AMERICAN METRO BLVD</AddressLine1Txt>
            <CityNm>HAMILTON</CityNm>
            <StateAbbreviationCd>NJ</StateAbbreviationCd>
            <ZIPCd>08619</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM MEDICAID ACCESS ACCELERATOR - TARGETED RESOURCES AND TECHNICAL ASSISTANCE TO IMPROVE CARE FOR PEOPLE LIVING WITH DIABETES WHO USE INSULIN</GrantOrContributionPurposeTxt>
          <Amt>626707</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT</GrantOrContributionPurposeTxt>
          <Amt>103796</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CENTRE HOSPITALIER REGIONAL DE NANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>29 AVENUE MAL DE LATTRE TASSIGNY</AddressLine1Txt>
            <CityNm>NANCY</CityNm>
            <CountryCd>FR</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREVENTION OF EXTRA-INTESTINAL MANIFESTATIONS AND COMORBIDITIES IN CROHNS DISEASE: THE NEMO PROJECT</GrantOrContributionPurposeTxt>
          <Amt>153102</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE CELLULAR LANDSCAPE OF MONOGENIC INFLAMMATORY BOWEL DISEASE IN VEOIBD</GrantOrContributionPurposeTxt>
          <Amt>244860</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>202677</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERROGATING THE MECHANISM OF HYPERSENSITIVITY TO ANTIBODY-BASED DRUGS FOR DEVELOPMENT OF A NOVEL ANTI-TNF BIOLOGIC FOR CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>93443</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHANCELLOR MASTERS &amp; SCHOLARS OF THE UNIVERSITY OF OXFORD</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY OFFICES WELLINGTON</AddressLine1Txt>
            <AddressLine2Txt>SQUARE</AddressLine2Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ALPHA CELL FUNCTION IN PEOPLE WITH TYPE 1 DIABETES WITH AND WITHOUT SEVERE HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>515981</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHI HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12809 WEST DODGE ROAD</AddressLine1Txt>
            <CityNm>OMAHA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68154</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY</GrantOrContributionPurposeTxt>
          <Amt>229460</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHI HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12809 WEST DODGE ROAD</AddressLine1Txt>
            <CityNm>OMAHA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68154</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ECMO SUPPORT AT CHI HEALTH CREIGHTON UNIVERSITY MEDICAL CENTER-BERGAN MERCY</GrantOrContributionPurposeTxt>
          <Amt>229460</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ATTN RESEARCH FINANCE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: BOSTON STUDIES</GrantOrContributionPurposeTxt>
          <Amt>1470081</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SABAN RESEARCH INSTITUTE</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90027</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BEYOND COYOT1: EXPANSION OF PATIENT-CENTERED VIRTUAL CARE</GrantOrContributionPurposeTxt>
          <Amt>684686</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ARTIFICIAL INTELLIGENCE PREDICTION OF MEANINGFUL OUTCOMES IN NEWLY DIAGNOSED SMALL BOWEL CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1093319</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ROLE OF PPAR-ALPHA IN PROMOTING BRUSH BORDER MATURITY OF INTESTINAL ENTEROCYTES</GrantOrContributionPurposeTxt>
          <Amt>439601</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL</GrantOrContributionPurposeTxt>
          <Amt>963282</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL</GrantOrContributionPurposeTxt>
          <Amt>1016595</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPARISON OF STANDARD-OF-CARE VS. A PATIENT-CENTRIC NONCONTRAST ABBREVIATED MR ENTEROGRAPHY PROTOCOL</GrantOrContributionPurposeTxt>
          <Amt>407932</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3333 BURNET AVENUE</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45229</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DELIVERY SYSTEM REDESIGN TO IMPROVE CARE FOR LOW-INCOME YOUTH WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>725157</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CHILDREN'S HOSPITAL OF PHILADELPHIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2716 SOUTH STREET</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191462305</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LEVERAGING HLA PROTECTION AND HUMORAL IMMUNITY TO DEVELOP MICROBIAL THERAPEUTICS THAT PREVENT T1D</GrantOrContributionPurposeTxt>
          <Amt>228375</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREEN FUND</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CITY PARKS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>830 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC GREEN FUND</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM MANAGEMENT</GrantOrContributionPurposeTxt>
          <Amt>145605</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLINICAL TRIAL TO EVALUATE A NOVEL MDI-BGM DECISION SUPPORT SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>1472591</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: BIOMARKER-BASED MULTIDISCIPLINARY TEAM APPROACH TO IMPROVE EARLY CROHN'S DISEASE OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>463512</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>3358835</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLALIT HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 ARLOZOROV STREET</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A NEW NEONATAL CENTER FOR ISRAELS SOUTHERN PERIPHERY AT SOROKA MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>2541165</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION</GrantOrContributionPurposeTxt>
          <Amt>2811261</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CLINTON HEALTH ACCESS INITIATIVE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>383 DORCHESTER AVENUE SUITE 400</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02127</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING MEDICAL OXYGEN PRODUCTION AND UTILIZATION</GrantOrContributionPurposeTxt>
          <Amt>1166919</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONVERGENT IMPACT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3223 ARAPAHOE AVE</AddressLine1Txt>
            <CityNm>BOULDER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80303</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>992300</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CONVERGENT IMPACT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3223 ARAPAHOE AVE</AddressLine1Txt>
            <CityNm>BOULDER</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>80303</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATIVE ON HOUSING FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1212300</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COREWELL HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>100 MICHIGAN ST NE</AddressLine1Txt>
            <CityNm>GRAND RAPIDS</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>49503</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO ROBOTIC PCI AND ESTABLISHING A MULTI-STATE NETWORK TO STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS</GrantOrContributionPurposeTxt>
          <Amt>3104271</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COREWELL HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>100 MICHIGAN ST NE</AddressLine1Txt>
            <CityNm>GRAND RAPIDS</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>49503</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING ACCESS TO ROBOTIC PCI AND ESTABLISHING A MULTI-STATE NETWORK TO STUDY THE FEASIBILITY OF TELEROBOTIC HEART ATTACK AND STROKE INTERVENTIONS</GrantOrContributionPurposeTxt>
          <Amt>2081202</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORK UNIVERSITY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WESTERN ROAD</AddressLine1Txt>
            <CityNm>CORK</CityNm>
            <CountryCd>EI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS</GrantOrContributionPurposeTxt>
          <Amt>663503</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORK UNIVERSITY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WESTERN ROAD</AddressLine1Txt>
            <CityNm>CORK</CityNm>
            <CountryCd>EI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDOSCOPIC MULTIMODAL ASSESSMENT USING ADVANCED IMAGING INTEGRATED AI TO PREDICT RECURRENCE IN POST-OPERATIVE CROHNS DISEASE - PROSPERS</GrantOrContributionPurposeTxt>
          <Amt>941943</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORPORATION FOR SUPPORTIVE HOUSING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>61 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORPORATION FOR SUPPORTIVE HOUSING</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>61 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10006</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH-ENRICHED SERVICES PILOTS FOR SUPPORTIVE HOUSING</GrantOrContributionPurposeTxt>
          <Amt>800000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COZAD HOSPITAL DISTRICT NO 2</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 EAST 12TH STREET</AddressLine1Txt>
            <CityNm>COZAD</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69130</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>35283</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COZAD HOSPITAL DISTRICT NO 2</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>300 EAST 12TH STREET</AddressLine1Txt>
            <CityNm>COZAD</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69130</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AT COZAD COMMUNITY HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>17570</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CRITICAL PATH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1840 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>TUCSON</CityNm>
            <StateAbbreviationCd>AZ</StateAbbreviationCd>
            <ZIPCd>85718</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSLATIONAL THERAPEUTICS ACCELERATOR: DEVELOPING KINASE INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE TO TREAT T1D</GrantOrContributionPurposeTxt>
          <Amt>500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CRITICAL PATH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1840 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>TUCSON</CityNm>
            <StateAbbreviationCd>AZ</StateAbbreviationCd>
            <ZIPCd>85718</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T1D CONSORTIUM 2.0</GrantOrContributionPurposeTxt>
          <Amt>266741</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD VENTURES ACADEMIC INCUBATOR</GrantOrContributionPurposeTxt>
          <Amt>1180400</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>342493</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>744245</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>APPLICATION OF MACHINE LEARNING TO PRECISION NUTRITION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>626728</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S &amp; COLITIS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 THIRD AVENUE SUITE 510</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10017</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING ENROLLMENT IN IBD CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>375484</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF NATIONWIDE TELEMEDICINE NETWORK TO MITIGATE GEOGRAPHIC DISPARITIES IN ACCESS TO HEALTHCARE FOR CD PATIENTS LIVING IN CANADA</GrantOrContributionPurposeTxt>
          <Amt>374912</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CROHN'S AND COLITIS CANADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>60 ST CLAIR AVE EAST SUITE 600</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTING A MULTIMODAL RCT INTERVENTION TO IMPROVE THE TRANSITION OF PATIENTS WITH CROHNS DISEASE FROM PEDIATRIC TO ADULT CARE</GrantOrContributionPurposeTxt>
          <Amt>297612</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DARTMOUTH- HITCHCOCK CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE MEDICAL CENTER DRIVE</AddressLine1Txt>
            <CityNm>LEBANON</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03756</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING FOR DARTMOUTH-HITCHCOCK'S VIRTUAL IBD TELEMEDICINE NETWORK PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>525177</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DIABETES NSW</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>26 ARUNDEL ST</AddressLine1Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVEMENTS IN OUTCOMES FOR YOUNG PEOPLE WITH DIABETES IN LESS-RESOURCED COUNTRIES, THROUGH EXPANSION AND COUNTRY-SPECIFIC DATA-DRIVEN INITIATIVES</GrantOrContributionPurposeTxt>
          <Amt>4299165</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DUNDY COUNTY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1313 N CHEYENNE ST</AddressLine1Txt>
            <CityNm>BENKELMAN</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69021</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT DUNDY COUNTY HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>11725</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>EMORY UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1599 CLIFTON ROAD NE</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303224250</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>302430</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>EMORY UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1599 CLIFTON ROAD NE</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303224250</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CARDIAC ARREST REGISTRY TO ENHANCE SURVIVAL (CARES) HELMSLEY STATE EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>283099</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FAIRVIEW HEALTH SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2450 RIVERSIDE AVE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55454</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPROVING SURVIVAL OUTCOMES THROUGH UNIVERSITY OF MINNESOTA MEDICAL CENTER ECMO CENTER OF EXCELLENCE</GrantOrContributionPurposeTxt>
          <Amt>3176500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FEDERAL INSTITUTE OF TECHNOLOGY ZURICH ETHZ</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RAMISTRASSE 101</AddressLine1Txt>
            <CityNm>ZURICH</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPATIAL BIOLOGY OF CROHNS COLITIS</GrantOrContributionPurposeTxt>
          <Amt>421278</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FJC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 WEST 39TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FJC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 WEST 39TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NYC FUND TO END YOUTH &amp; FAMILY HOMELESSNESS, A PROJECT OF FJC.</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FJC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>225 WEST 39TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE WELLNESS CLASSROOM, A PROJECT OF FJC - A FOUNDATION OF PHILANTHROPIC FUNDS</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY (FIRST)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 BEDFORD STREET</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FIRST SENIOR MENTOR PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOR INSPIRATION AND RECOGNITION OF SCIENCE AND TECHNOLOGY (FIRST)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 BEDFORD STREET</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FIRST SENIOR MENTOR PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CAMPUS BIOTECH</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACESS TO CGMS FOR EQUITY IN DIABETES MANAGEMENT - THE ACCEDE PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1118735</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GALILEE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>GALILEE MEDICAL CENTER</AddressLine1Txt>
            <CityNm>NAHARIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOVATION OF TWO FLOORS OF THE INTERNAL MEDICINE BUILDING AT GALILEE MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>2200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GATES PHILANTHROPY PARTNERS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 60555</AddressLine1Txt>
            <CityNm>CITY OF INDUSTRY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91716</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POLIO ERADICATION FUND SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GATES PHILANTHROPY PARTNERS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 60555</AddressLine1Txt>
            <CityNm>CITY OF INDUSTRY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91716</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POLIO ERADICATION FUND SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLCOME GENOME CAMPUS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>402672</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLCOME GENOME CAMPUS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>187672</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GENOME RESEARCH LIMITED FOR THE WELLCOME SANGER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WELLCOME GENOME CAMPUS</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCIBD-RESPONSE: MASSIVE-SCALE SINGLE-CELL RNA-SEQUENCING TO IDENTIFY TRANSCRIPTOMIC PREDICTORS OF RESPONSE TO BIOLOGIC THERAPIES IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>143892</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGETOWN UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>37TH O STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20057</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCING ACCESS TO HIGH QUALITY, AFFORDABLE DIABETES CARE THROUGH PRIVATE HEALTH INSURANCE REGULATION</GrantOrContributionPurposeTxt>
          <Amt>432998</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>GEORGIA TECH RESEARCH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>505 10TH STREET NW</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>303320420</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOIII FI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONGITUDINAL TRACKING AND REFERENCE-BASED INTERPRETATION OF SINGLE-CELL CHARACTERISTICS IN TREATMENT NAVE PATIENTS WITH CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>485616</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOSAMPLE RFP</GrantOrContributionPurposeTxt>
          <Amt>1046486</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EUROPEAN PRE-T1D REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>196089</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>1000684</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1188316</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>1927629</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>2029929</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FR1DA ORAL INSULIN INTERVENTION TRIAL AMENDMENT</GrantOrContributionPurposeTxt>
          <Amt>228040</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>1042232</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1188316</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>2348061</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>2466113</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>3500510</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD DRIED BLOOD SPOT OMICS TO PREDICT HEALTH AND AUTOIMMUNITY OUTCOMES IN CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>162877</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOSAMPLE RFP</GrantOrContributionPurposeTxt>
          <Amt>95294</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD COORDINATION CENTER CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>1042232</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1466731</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-03 STUDY: THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>2466114</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>3500510</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>4557698</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1466732</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>3640094</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>4557698</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1348365</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>3640094</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>5772918</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1348365</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>3982146</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>5772917</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1761496</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>3982146</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>5928622</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>1761496</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>5928622</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>4903870</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-04 STUDY: SUPPLEMENTATION WITH B. INFANTIS FOR MITIGATION OF TYPE 1 DIABETES AUTOIMMUNITY (SINT1A)</GrantOrContributionPurposeTxt>
          <Amt>526471</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>4903869</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>3470012</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>3470011</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>1676154</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GPPAD-05 STUDY: ANTI-VIRAL ACTION AGAINST TYPE 1 DIABETES AUTOIMMUNITY (AVANT1A)</GrantOrContributionPurposeTxt>
          <Amt>1676153</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HELMHOLTZ ZENTRUM MUNCHEN (GMBH)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEUTSCHES FORSCHUNGSZENTRUM FUR</AddressLine1Txt>
            <AddressLine2Txt>GESUNDHEIT UND UMWELT GMBH</AddressLine2Txt>
            <CityNm>NEUHERBERG</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CONTINUATION 2 OF THE GPPAD-02-STUDY: IDENTIFICATION OF INFANTS WITH INCREASED TYPE 1 DIABETES RISK FOR ENROLLMENT INTO PRIMARY PREVENTION TRIALS</GrantOrContributionPurposeTxt>
          <Amt>1310183</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV AND GENTOFTE HOSPITAL</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING GIP/GLP-2 RECEPTORS TO PREVENT HYPOGLYCEMIA IN T1D</GrantOrContributionPurposeTxt>
          <Amt>140000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HERLEV OG GENTOFTE HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERLEV AND GENTOFTE HOSPITAL</AddressLine1Txt>
            <CityNm>HERLEV</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UTILIZATION OF INTERACTION BETWEEN AMINO ACIDS &amp; GIP IN PANCREATIC CELLS</GrantOrContributionPurposeTxt>
          <Amt>135722</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HIGH QUALITY MEDICAL EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4117 PENFIELD CT S</AddressLine1Txt>
            <CityNm>AFTON</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>1705225</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HIGH QUALITY MEDICAL EDUCATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4117 PENFIELD CT S</AddressLine1Txt>
            <CityNm>AFTON</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>2112639</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HILLEL YAFFE MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HA-SHALOM ST</AddressLine1Txt>
            <CityNm>HADERA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EYE INSTITUTE AND AMBULATORY SURGERY CENTER</GrantOrContributionPurposeTxt>
          <Amt>3158400</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HUMBOLDT COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1000 N 15TH ST</AddressLine1Txt>
            <CityNm>HUMBOLDT</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50548</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>39438</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HUMBOLDT COUNTY MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1000 N 15TH ST</AddressLine1Txt>
            <CityNm>HUMBOLDT</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>50548</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HUMBOLDT COUNTY MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>15775</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES: MOUNT SINAI STUDIES</GrantOrContributionPurposeTxt>
          <Amt>220000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROMOTE BIRTH EQUITY THROUGH COMMUNITY-BASED DOULA CARE, AN ADAPTATION FOR NYCS COMMUNITY MEMBERS, HOMELESS AND JUSTICE-INVOLVED PREGNANT PERSONS.</GrantOrContributionPurposeTxt>
          <Amt>779716</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE: PREDICT AND PREVENT</GrantOrContributionPurposeTxt>
          <Amt>1974021</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SPATIAL MAPPING OF FIBROMUSCULAR CROHNS DISEASE: FROM GENETIC TO SENESCENT SIGNALS</GrantOrContributionPurposeTxt>
          <Amt>920802</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 GUSTAVE L LEVY PL</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE PRE-DISEASE PHASE OF CROHNS DISEASE: PREDICT AND PREVENT</GrantOrContributionPurposeTxt>
          <Amt>587152</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDA COUNTY IOWA COMMUNITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>701 EAST SECOND STREET</AddressLine1Txt>
            <CityNm>IDA GROVE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51445</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>44685</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>IDA COUNTY IOWA COMMUNITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>701 EAST SECOND STREET</AddressLine1Txt>
            <CityNm>IDA GROVE</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>51445</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT HORN MEMORIAL HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>17875</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INNODIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HERESTRAAT 49</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INNODIA NONPROFIT LAUNCH</GrantOrContributionPurposeTxt>
          <Amt>434183</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>108203</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BIOBANKING FOR THE PRIMARY ORAL INSULIN TRIAL</GrantOrContributionPurposeTxt>
          <Amt>164873</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>113757</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>109309</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>114864</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUT INTEGRATED BIOBANK OF LUXEMBOURG</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 RUE LOUIS RECH</AddressLine1Txt>
            <CityNm>DUDELANGE</CityNm>
            <CountryCd>LU</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GPPAD BIOBANK - SINT1A</GrantOrContributionPurposeTxt>
          <Amt>112522</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUTE FOR COMMUNITY LIVING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 BROAD STREET</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT</GrantOrContributionPurposeTxt>
          <Amt>749790</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSTITUTE FOR COMMUNITY LIVING INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 BROAD STREET</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10004</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING A THREE-YEAR IMT/ACT STEP-DOWN PROJECT</GrantOrContributionPurposeTxt>
          <Amt>749790</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 STATE STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEED FUNDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>893663</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL ALLIANCE FOR DIABETES ACTION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>75 STATE STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEED FUNDING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>971684</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)</GrantOrContributionPurposeTxt>
          <Amt>488553</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)</GrantOrContributionPurposeTxt>
          <Amt>645000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE EXTENT STUDY (CALCULATING THE LEMANN INDEX USING INTESTINAL ULTRASOUND)</GrantOrContributionPurposeTxt>
          <Amt>688466</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
            <CityNm>MUNSTER</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION GLOBALLY (IBUS EIUS ED)</GrantOrContributionPurposeTxt>
          <Amt>296500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL WATER MANAGEMENT INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>127 SUNIL MAWATHA</AddressLine1Txt>
            <CityNm>BATTARAMULLA</CityNm>
            <CountryCd>CE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA</GrantOrContributionPurposeTxt>
          <Amt>2449440</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INTERNATIONAL WATER MANAGEMENT INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>127 SUNIL MAWATHA</AddressLine1Txt>
            <CityNm>BATTARAMULLA</CityNm>
            <CountryCd>CE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGITAL INNOVATIONS FOR A WATER SECURE AFRICA</GrantOrContributionPurposeTxt>
          <Amt>1550680</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ISRAEL CENTER ON ADDICTION RA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2 HATZORAN ST</AddressLine1Txt>
            <CityNm>NETANYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ICA'S EMERGENCY MENTAL HEALTH SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>55000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE IN DIABETES INITIATIVE: LARGE ADULT STUDY</GrantOrContributionPurposeTxt>
          <Amt>159838</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>410774</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING</GrantOrContributionPurposeTxt>
          <Amt>273882</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDUCATIONAL INTERVENTION TO SUPPORT DIABETES GUIDANCE FOR EXERCISE (EDGE)</GrantOrContributionPurposeTxt>
          <Amt>805385</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>413871</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)</GrantOrContributionPurposeTxt>
          <Amt>1256044</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LEVERAGING NEW ULTRA-RAPID INSULINS WITH AID FOR EXERCISE MANAGEMENT WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>191816</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>357597</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY DATA REPOSITORY TO ASSESS MANAGEMENT OF TYPE 1 DIABETES WITH DIABETES TECHNOLOGY (PRAM-T1D)</GrantOrContributionPurposeTxt>
          <Amt>1223066</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF THE RELATIONSHIP OF GLUCOSE METRICS VIA CONTINUOUS GLUCOSE MONITORING WITH DIABETIC RETINOPATHY</GrantOrContributionPurposeTxt>
          <Amt>188007</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LEVERAGING NEW ULTRA-RAPID INSULINS WITH AID FOR EXERCISE MANAGEMENT WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1025846</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15310 AMBERLY DRIVE SUITE 350</AddressLine1Txt>
            <CityNm>TAMPA</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33647</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VIRTUAL DIABETES SPECIALTY CLINIC (VDISC) - A STUDY EVALUATING REMOTE INITIATION OF CONTINUOUS GLUCOSE MONITORING</GrantOrContributionPurposeTxt>
          <Amt>194126</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>80-84 CHANDOS STREET ST LEONARDS</AddressLine1Txt>
            <AddressLine2Txt>2065 NSW AUSTRALIA</AddressLine2Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA FOLLOW UP 2023-2025 + SAMPLES ANALYSIS RFA</GrantOrContributionPurposeTxt>
          <Amt>1196912</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>80-84 CHANDOS STREET ST LEONARDS</AddressLine1Txt>
            <AddressLine2Txt>2065 NSW AUSTRALIA</AddressLine2Txt>
            <CityNm>SYDNEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDIA FOLLOW UP 2023-2025 + SAMPLES ANALYSIS RFA</GrantOrContributionPurposeTxt>
          <Amt>997843</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE</GrantOrContributionPurposeTxt>
          <Amt>133332</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CO-FUNDED DEVELOPMENT OF A 3--HYDROXYBUTYRATE BINDING PROTEIN BASED CONTINUOUS KETONE MONITORING MICROSENSOR</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY AND JDRF CO-FUNDED WORKSHOPS</GrantOrContributionPurposeTxt>
          <Amt>105404</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JOINING FORCES: BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CO-FUNDED DEVELOPMENT OF A MICRONEEDLE SENSOR FOR SIMULTANEOUS CONTINUOUS MONITORING OF KETONES AND GLUCOSE</GrantOrContributionPurposeTxt>
          <Amt>133334</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY AND JDRF CO-FUNDED WORKSHOPS</GrantOrContributionPurposeTxt>
          <Amt>145404</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JDRF INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 VESEY STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10281</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>JOINING FORCES: BUILDING A SHARED 'GRAND ACCESS STRATEGY' FOR SAVING T1D LIVES</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JERUSALEM COLLEGE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>21 HAVAAD HALEUMI ST</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY SUPPORT FOR STUDENTS AT THE JERUSALEM COLLEGE OF TECHNOLOGY.</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERED CYTOKINE/ANTIBODY FUSION PROTEIN TO TREAT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>750000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN APTAMER-BASED BIOSENSOR FOR CONTINUOUS INSULIN MONITORING</GrantOrContributionPurposeTxt>
          <Amt>742901</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>733 NORTH BROADWAY MRB 117</AddressLine1Txt>
            <CityNm>BALTIMORE</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETED, SUSTAINED RELEASE ANTIFIBROTIC THERAPIES FOR CROHNS DISEASE PATIENTS</GrantOrContributionPurposeTxt>
          <Amt>571287</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOSLIN DIABETES CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE JOSLIN PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02215</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES</GrantOrContributionPurposeTxt>
          <Amt>287280</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>JOSLIN DIABETES CENTER INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE JOSLIN PLACE</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02215</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN INTEGRATED CARE MODEL FOR OLDER ADULTS WITH INSULIN-TREATED DIABETES</GrantOrContributionPurposeTxt>
          <Amt>569990</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KAISER FOUNDATION HEALTH PLAN OF GEORGIA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1375 PEACHTREE STREET NE</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>30309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF THE T1DES PILOT TO A PUBLIC HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>255687</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FAT AS A VILLAIN IN CROHN'S DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>1456556</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMBODY: EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY</GrantOrContributionPurposeTxt>
          <Amt>221407</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDS 2024 BRUGES</GrantOrContributionPurposeTxt>
          <Amt>50000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY OF DIET WITH BIOLOGICALS FOR CROHNS DISEASE: THE OATS STUDY</GrantOrContributionPurposeTxt>
          <Amt>490041</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDENT1FI</GrantOrContributionPurposeTxt>
          <Amt>1551603</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FAT AS A VILLAIN IN CROHN'S DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>1344948</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMBODY: EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY</GrantOrContributionPurposeTxt>
          <Amt>199460</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMBODY: EFFECTS OF A MINDFULNESS BASED INTERVENTION ON IBD DISABILITY</GrantOrContributionPurposeTxt>
          <Amt>205983</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDENT1FI</GrantOrContributionPurposeTxt>
          <Amt>1574759</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KATHOLIEKE UNIVERSITEIT TE LEUVEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WAAISTRAAT 6 BOX 5105</AddressLine1Txt>
            <CityNm>LEUVEN</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EDENT1FI</GrantOrContributionPurposeTxt>
          <Amt>1018620</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T CELL RECEPTOR SEQUENCING IN TYPE 1 DIABETES - BIOMARKER DISCOVERY AND TECHNOLOGY DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>115097</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6+) SUBJECTS</GrantOrContributionPurposeTxt>
          <Amt>278644</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)</GrantOrContributionPurposeTxt>
          <Amt>825146</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>384292</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>369984</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HYPO - RESOLVE - EVALUATION OF BIOLOGICAL, SOCIAL AND ECONOMIC IMPACT OF HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>307779</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1147254</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1296483</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1325562</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHARACTERISING NOGO AUTOIMMUNITY IN GENETICALLY PROTECTED (HLA-DQ6+) SUBJECTS</GrantOrContributionPurposeTxt>
          <Amt>208787</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>778535</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL DRIVERS OF INFANT ISLET AUTOIMMUNITY (PISA STUDY)</GrantOrContributionPurposeTxt>
          <Amt>781151</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1069889</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MULTIPEPT1DE PROOF-OF-CONCEPT STUDY: STAGE III</GrantOrContributionPurposeTxt>
          <Amt>1079926</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KING'S COLLEGE LONDON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>150 STAMFORD STREET</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RESOLVING HARMFUL ACCUMULATION OF INNATE LYMPHOID CELLS DURING CROHNS DISEASE.</GrantOrContributionPurposeTxt>
          <Amt>325389</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRABE 17</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>925603</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>FEODOR-LYNEN-STRABE 17</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FECAL MICROBIOTA TRANSFER FOR MAINTENANCE OF REMISSION AFTER INDUCTION TREATMENT WITH EXCLUSIVE ENTERAL NUTRITION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>931293</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LIVING WATER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4001 GREENBRIAR DRIVE</AddressLine1Txt>
            <CityNm>STAFFORD</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>77477</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING INTEGRATED WASH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>2574349</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LIVING WATER INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4001 GREENBRIAR DRIVE</AddressLine1Txt>
            <CityNm>STAFFORD</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>77477</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SCALING INTEGRATED WASH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>2432337</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MACCABI HEALTHCARE SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>27 HAMERED ST</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MOBILE MAMMOGRAPHY UNIT</GrantOrContributionPurposeTxt>
          <Amt>31500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAINEHEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>22 BRAMHALL STREET</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>ME</StateAbbreviationCd>
            <ZIPCd>04102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING RURAL DIABETES CARE IN MAINE</GrantOrContributionPurposeTxt>
          <Amt>596795</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAINEHEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>22 BRAMHALL STREET</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>ME</StateAbbreviationCd>
            <ZIPCd>04102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRANSFORMING RURAL DIABETES CARE IN MAINE</GrantOrContributionPurposeTxt>
          <Amt>848894</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASS GENERAL BRIGHAM FOR THE MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>021142696</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBES, MOLECULES, AND CHEMISTRY: DYSBIOSIS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1722621</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>77 MASSACHUSETTS AVENUE</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02139</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPUTATIONAL MODELING TO IMPROVE GLUCOSE-RESPONSIVE GLUCAGON DESIGNS</GrantOrContributionPurposeTxt>
          <Amt>348553</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FEASIBILITY OF OFF-SITE REMOTE CONTROL ROBOTIC PERCUTANEOUS CORONARY INTERVENTIONS: A PILOT ANIMAL FEASIBILITY STUDY</GrantOrContributionPurposeTxt>
          <Amt>385906</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MAYO CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 FIRST STREET SW</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55905</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>151705</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICAL UNIVERSITY OF SOUTH CAROLINA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>179 ASHLEY AVENUE</AddressLine1Txt>
            <CityNm>CHARLESTON</CityNm>
            <StateAbbreviationCd>SC</StateAbbreviationCd>
            <ZIPCd>29425</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICAL UNIVERSITY OF SOUTH CAROLINA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>179 ASHLEY AVENUE</AddressLine1Txt>
            <CityNm>CHARLESTON</CityNm>
            <StateAbbreviationCd>SC</StateAbbreviationCd>
            <ZIPCd>29425</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERED DENDRITIC CELL BASED ROBUST ANTIGEN SPECIFIC THERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>137500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEDICINES FOR HUMANITY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>800 HINGHAM STREET</AddressLine1Txt>
            <CityNm>ROCKLAND</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02370</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAI MBELEKI II EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>322909</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MILLE LACS HEALTH SYSTEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 ELM STREET NORTH</AddressLine1Txt>
            <CityNm>ONAMIA</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56359</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>17020</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MILLE LACS HEALTH SYSTEM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>200 ELM STREET NORTH</AddressLine1Txt>
            <CityNm>ONAMIA</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56359</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT MILLE LACS HEALTH SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>6809</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA ACADEMY OF FAMILY PHYSICIANS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1400 VANBUREN ST STE 215</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>2016319</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA ACADEMY OF FAMILY PHYSICIANS FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1400 VANBUREN ST STE 215</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55413</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>POINT-OF-CARE ULTRASOUND (POCUS) TRAINING FOR MINNESOTA RURAL PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>1801545</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA RURAL HEALTH ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>27011 460TH AVE</AddressLine1Txt>
            <CityNm>HENNING</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56551</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>318700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA RURAL HEALTH ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>27011 460TH AVE</AddressLine1Txt>
            <CityNm>HENNING</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56551</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>378700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA STATE COLLEGES AND UNIVERSITIES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>30 E 7TH STREET</AddressLine1Txt>
            <CityNm>ST PAUL</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>217428</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MINNESOTA STATE COLLEGES AND UNIVERSITIES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>30 E 7TH STREET</AddressLine1Txt>
            <CityNm>ST PAUL</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING RURAL SONOGRAPHY EXPERTISE IN MINNESOTA</GrantOrContributionPurposeTxt>
          <Amt>205285</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MONTANA PEDIATRICS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>259 W FRONT STREET</AddressLine1Txt>
            <CityNm>MISSOULA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59802</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING A STATEWIDE MODEL OF CARE FOR CHILDREN WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>536186</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL ACADEMY OF SCIENCES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>500 5TH STREET NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20001</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING MINORITY SERVING INSTITUTIONS</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL ASSOCIATION OF SCHOOL NURSES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 WAYNE AVE</AddressLine1Txt>
            <CityNm>SILVER SPRING</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20910</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT</GrantOrContributionPurposeTxt>
          <Amt>946275</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL ASSOCIATION OF SCHOOL NURSES INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 WAYNE AVE</AddressLine1Txt>
            <CityNm>SILVER SPRING</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20910</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PROVIDING COORDINATED CARE AND CAPTURING OUTCOMES FOR STUDENTS WITH T1D SCHOOL NURSE-LED PILOT PROJECT</GrantOrContributionPurposeTxt>
          <Amt>927791</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL COMMITTEE FOR QUALITY ASSURANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NCQA DIABETES RECOGNITION PROGRAM REFRESH &amp; DIABETES MEASURE DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>621487</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATIONAL COMMITTEE FOR QUALITY ASSURANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1100 13TH ST NW</AddressLine1Txt>
            <CityNm>WASHINGTON</CityNm>
            <StateAbbreviationCd>DC</StateAbbreviationCd>
            <ZIPCd>20005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NCQA DIABETES RECOGNITION PROGRAM REFRESH &amp; DIABETES MEASURE DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>753478</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NATURAL AREAS CONSERVANCY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1234 FIFTH AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10029</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACTIVATING AND SUSTAINING NYC NATURE TRAIL NETWORK (PHASE 3)</GrantOrContributionPurposeTxt>
          <Amt>363328</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NCD ALLIANCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>31-33 AVENUE GIUSEPPE MOTTA</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>2023-2025 PARTNERSHIP</GrantOrContributionPurposeTxt>
          <Amt>1582350</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4126 TECHNOLOGY WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEVADA VIRTUAL CRISIS CARE</GrantOrContributionPurposeTxt>
          <Amt>1239092</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4126 TECHNOLOGY WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEVADA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>60670</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA HEALTH CENTERS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3325 RESEARCH WAY</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89706</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>QUALITY ULTRASOUND SERVICES AND TRAINING PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>14249</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEVADA RURAL HOSPITAL PARTNERS FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4600 KIETZKE LANE</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89502</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SONOGRAPHER AND TECHNOLOGIST TRAINING FOR RURAL NEVADA HOSPITALS</GrantOrContributionPurposeTxt>
          <Amt>27500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW DESTINY HOUSING CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>12 W 37TH STREET 7TH FLOOR</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING AFTERCARE INTERVENTIONTO IMPROVE HOUSING AND HEALTH STABILITYFOR FORMERLY HOMELESS DOMESTIC VIOLENCE SURVIVORS</GrantOrContributionPurposeTxt>
          <Amt>183350</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK CITY HEALTH AND HOSPITALS CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 WORTH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10013</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPRESSCARE TELE-BEHAVIORAL HEALTH SERVICE LAUNCH AND TAILORED SERVICE STRATEGIES FOR HIGH NEEDS PATIENTS IN NYC</GrantOrContributionPurposeTxt>
          <Amt>614668</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>550 1ST AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10016</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>2756847</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>550 1ST AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10016</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TAMALE EDUCATION AND INNOVATION CENTER FOR HEALTH</GrantOrContributionPurposeTxt>
          <Amt>1360453</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>NORTHERN WESTCHESTER HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>400 EAST MAIN STREET</AddressLine1Txt>
            <CityNm>MOUNT KISCO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10549</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMERGENCY DEPARTMENT RAPID ACCESS EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>400000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OAKLAND UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2200 NORTH SQUIRREL ROAD</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)</GrantOrContributionPurposeTxt>
          <Amt>1139629</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OAKLAND UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2200 NORTH SQUIRREL ROAD</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)</GrantOrContributionPurposeTxt>
          <Amt>1019181</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OAKLAND UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2200 NORTH SQUIRREL ROAD</AddressLine1Txt>
            <CityNm>ROCHESTER</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48309</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A COMPREHENSIVE STUDY OF T1D EXOMES (PHASE 2)</GrantOrContributionPurposeTxt>
          <Amt>1129765</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK ROAD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1783316</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>OREGON HEALTH &amp; SCIENCE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3181 SW SAM JACKSON PARK ROAD</AddressLine1Txt>
            <CityNm>PORTLAND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>972393098</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>AN MDI DECISION SUPPORT SYSTEM WITH CDCES AND BEHAVIORAL HEALTH SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>1795816</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PALO ALTO VETERANS INSTITUTE FOR RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3801 MIRANDA AVENUE</AddressLine1Txt>
            <CityNm>PALO ALTO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>943040038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELL ATLAS OF HUMAN INTESTINAL LYMPHOID TISSUES AND CHANGES IN CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>318978</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1 LETTERMAN DRIVE</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94129</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING AUTOIMMUNE DIABETES FOLLOWING CERTAIN CANCER IMMUNOTHERAPIES.</GrantOrContributionPurposeTxt>
          <Amt>358140</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PATH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2201 WESTLAKE AVENUE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DIABETES CAREPAK PROJECT: ENABLING HIGH-QUALITY DIABETES SELF-CARE</GrantOrContributionPurposeTxt>
          <Amt>871123</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PENNINGTON COUNTY HEALTH AND HUMAN SERVICES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>321 KANSAS CITY STREET</AddressLine1Txt>
            <CityNm>RAPID CITY</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>57701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PENNINGTON COUNTY CRISIS STABILIZATION UNIT</GrantOrContributionPurposeTxt>
          <Amt>1000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PERKINS COUNTY HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>900 LINCOLN AVE</AddressLine1Txt>
            <CityNm>GRANT</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>69140</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES FOR PERKINS COUNTY HEALTH SERVICES</GrantOrContributionPurposeTxt>
          <Amt>14706</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PHILLIPS COUNTY HOSPITAL ASSOCIATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>311 S 8TH AVENUE EAST</AddressLine1Txt>
            <CityNm>MALTA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59538</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AND TELE-PHARMACY AT PHILLIPS COUNTY</GrantOrContributionPurposeTxt>
          <Amt>25448</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PIONEER MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>301 WEST 7TH AVE</AddressLine1Txt>
            <CityNm>BIG TIMBER</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59011</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-PHARMACY AT PIONEER MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>9988</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROJECT CONCERN ZAMBIA LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLOT 37/1P</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS</GrantOrContributionPurposeTxt>
          <Amt>1004026</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>PROJECT CONCERN ZAMBIA LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLOT 37/1P</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EMPOWERED CHILDREN AND ADOLESCENTS PROGRAM PLUS</GrantOrContributionPurposeTxt>
          <Amt>1590680</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RAMBAM HEALTH CORPORATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>HAALIA HASNIA 8</AddressLine1Txt>
            <CityNm>HAIFA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MICROBIAL AND DIETARY EFFECTS ON IMMUNE COMPOSITION AND FUNCTION IN PATIENTS WITH CROHN'S</GrantOrContributionPurposeTxt>
          <Amt>746990</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACHANOTHER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 NE 3RD ST STE 106-307</AddressLine1Txt>
            <CityNm>BEND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>97701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>627684</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REACHANOTHER FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 NE 3RD ST STE 106-307</AddressLine1Txt>
            <CityNm>BEND</CityNm>
            <StateAbbreviationCd>OR</StateAbbreviationCd>
            <ZIPCd>97701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING PEDIATRIC NEUROSURGERY CAPACITY IN ETHIOPIA</GrantOrContributionPurposeTxt>
          <Amt>190186</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>92033</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HEALTH ECONOMIC ANALYSIS OF AUTOMATED INSULIN DELIVERY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>458831</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MICHIGAN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3003 SOUTH STATE STREET</AddressLine1Txt>
            <CityNm>ANN ARBOR</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48109</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EVALUATION OF A GUT-SPECIFIC ANTIFIBROTIC THERAPEUTIC IN PRE-CLINICAL MODELS OF CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>92033</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MINNESOTA FIRST RESPONDER AED PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1296918</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)</GrantOrContributionPurposeTxt>
          <Amt>502750</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.</GrantOrContributionPurposeTxt>
          <Amt>1454586</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THERAPEUTIC USE OF PEPTIDE:MHC MABS FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>220565</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING ANTIGEN-SPECIFIC REGULATORY T CELLS FOR USE IN TYPE 1 DIABETES (PHASE 3)</GrantOrContributionPurposeTxt>
          <Amt>502750</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THERAPEUTIC USE OF PEPTIDE:MHC MABS FOR T1D</GrantOrContributionPurposeTxt>
          <Amt>166880</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF THE UNIVERSITY OF MINNESOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>401 EAST RIVER ROAD</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>554552070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STANDARDIZED MICROBIOTA TRANSPLANT THERAPY IN CROHNS DISEASE. PILOT TRIAL.</GrantOrContributionPurposeTxt>
          <Amt>585172</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGENTS OF UNIVERSITY OF CALIFORNIA BERKELEY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>190 DOE</AddressLine1Txt>
            <CityNm>BERKELEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94720</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPING MICROBIOME EDITING TOOLS TO ADVANCE UNDERSTANDING OF THE MICROBIAL INFLUENCE ON CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1054179</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGION HOVEDSTADEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KONGENS VNGE 2</AddressLine1Txt>
            <CityNm>HILLEROD</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?</GrantOrContributionPurposeTxt>
          <Amt>375228</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>REGION HOVEDSTADEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>KONGENS VNGE 2</AddressLine1Txt>
            <CityNm>HILLEROD</CityNm>
            <CountryCd>DA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAN MICROCHIMERISM EXPLAIN DIFFERENCES IN PARENTAL TYPE 1 DIABETES CONFERRED RISK OF OFFSPRING TYPE 1 DIABETES?</GrantOrContributionPurposeTxt>
          <Amt>113358</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RENOWN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1155 MILL ST</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89502</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>1091987</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RENOWN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1155 MILL ST</AddressLine1Txt>
            <CityNm>RENO</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89502</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RENOWN HEALTH TO BRING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) TO NORTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>243019</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RESEARCH TRIANGLE INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3040 EAST CORNWALLIS ROAD</AddressLine1Txt>
            <CityNm>RESEARCH TRIANGLE PARK</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>277092194</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS: A STATEWIDE IMPLEMENTATION STUDY</GrantOrContributionPurposeTxt>
          <Amt>1110288</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RESEARCH TRIANGLE INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3040 EAST CORNWALLIS ROAD</AddressLine1Txt>
            <CityNm>RESEARCH TRIANGLE PARK</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>277092194</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USING GENOME SEQUENCING AND GENETIC RISK SCORES TO IDENTIFY NEWBORNS WITH SERIOUS HEALTH CONDITIONS: A STATEWIDE IMPLEMENTATION STUDY</GrantOrContributionPurposeTxt>
          <Amt>826376</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RIVER'S EDGE HOSPITAL AND CLINIC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1900 N SUNRISE DRIVE</AddressLine1Txt>
            <CityNm>ST PETER</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>56082</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES FOR RIVER'S EDGE HOSPITAL</GrantOrContributionPurposeTxt>
          <Amt>17567</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAGE BIONETWORKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2901 THIRD AVE</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981213014</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTENSION OF VEOIBD DATA COORDINATION TO ACCELERATE DISCOVERY OF PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>75165</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAINT LOUIS UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>221 NORTH GRAND BOULEVARD</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>63103</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFY AND VALIDATE POTENTIAL THERAPEUTIC TARGETS TO PREVENT HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>608523</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1305 W 18TH ST</AddressLine1Txt>
            <CityNm>SIOUX FALL</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>571040569</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PLEDGE PHASE 3</GrantOrContributionPurposeTxt>
          <Amt>1118635</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SANFORD RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1305 W 18TH ST</AddressLine1Txt>
            <CityNm>SIOUX FALL</CityNm>
            <StateAbbreviationCd>SD</StateAbbreviationCd>
            <ZIPCd>571040569</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PLEDGE PHASE 3</GrantOrContributionPurposeTxt>
          <Amt>1086430</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SAPIR ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DN HOF ASHKELON</AddressLine1Txt>
            <CityNm>REGIONAL COUNCIL SHAAR HA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PLANNING FOR SAPIR ACADEMIC COLLEGE LAW SCHOOL BUILDING</GrantOrContributionPurposeTxt>
          <Amt>303000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SCRIPPS HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10140 CAMPUS POINT DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>1262800</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SCRIPPS HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10140 CAMPUS POINT DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>1636800</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SCRIPPS HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10140 CAMPUS POINT DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CROHNS FISTULIZING PROGRAM INVESTIGATOR INITIATED CLINICAL TRIALS</GrantOrContributionPurposeTxt>
          <Amt>888800</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SEATTLE CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 5731 M/S S-200</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981455005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)</GrantOrContributionPurposeTxt>
          <Amt>609141</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SEATTLE CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 5731 M/S S-200</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981455005</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANDING USE OF ENGINEERED TREGS IN T1D THERAPY (PHASE 4)</GrantOrContributionPurposeTxt>
          <Amt>616923</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY SURGICAL WING</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAELI IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: COMBINING MULTI-TIER ADMINISTRATIVE DATA FOR FACILITATING DISEASE FREE MANAGEMENT</GrantOrContributionPurposeTxt>
          <Amt>989083</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHAARE ZEDEK MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>12 SHMUEL BAIT STREET</AddressLine1Txt>
            <CityNm>JERUSALEM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF THE HELMSLEY SURGICAL WING</GrantOrContributionPurposeTxt>
          <Amt>3500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHARE TRUST INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>310 DEDHAM ST</AddressLine1Txt>
            <CityNm>DOVER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION</GrantOrContributionPurposeTxt>
          <Amt>1540658</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHARE TRUST INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>310 DEDHAM ST</AddressLine1Txt>
            <CityNm>DOVER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02030</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>BUILDING COMMUNITY DRIVEN COLLECTIVE ACTION</GrantOrContributionPurposeTxt>
          <Amt>1540658</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHATTERPROOF A NONPROFIT CORP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 MERRITT 7 CORPORATE PARK 1ST</AddressLine1Txt>
            <AddressLine2Txt>FLOOR</AddressLine2Txt>
            <CityNm>NORWALK</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06851</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SHATTERPROOF A NONPROFIT CORP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 MERRITT 7 CORPORATE PARK 1ST</AddressLine1Txt>
            <AddressLine2Txt>FLOOR</AddressLine2Txt>
            <CityNm>NORWALK</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>06851</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>170000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O MONTANA MEDICAL ASSOCIATION</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O MONTANA MEDICAL ASSOCIATION</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SIMULATION IN MOTION MONTANA INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O MONTANA MEDICAL ASSOCIATION</AddressLine1Txt>
            <CityNm>HELENA</CityNm>
            <StateAbbreviationCd>MT</StateAbbreviationCd>
            <ZIPCd>59601</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIM-MT BUSINESS DEVELOPMENT AND SUSTAINABILITY</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOCIAL SCIENCE RESEARCH COUNCIL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>ONE PIERREPONT PLAZA 15TH FLOOR</AddressLine1Txt>
            <CityNm>BROOKLYN</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11201</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA2GO.NYC REVAMP AND DATA CLINIC</GrantOrContributionPurposeTxt>
          <Amt>336025</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOLIDARIDAD NETWORK FOUNDATION LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>163 KUDU ROAD</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOOVES FOR SUSTAINABILITY (H4S)</GrantOrContributionPurposeTxt>
          <Amt>468562</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOLIDARIDAD NETWORK FOUNDATION LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>163 KUDU ROAD</AddressLine1Txt>
            <CityNm>LUSAKA</CityNm>
            <CountryCd>ZA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOOVES FOR SUSTAINABILITY (H4S)</GrantOrContributionPurposeTxt>
          <Amt>273384</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTH LINCOLN HOSPITAL DISTRICT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>711 ONYX ST</AddressLine1Txt>
            <CityNm>KEMMERER</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>83101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY AT SOUTH LINCOLN MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>10791</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SOUTHCENTRAL FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4501 DIPLOMACY DR</AddressLine1Txt>
            <CityNm>ANCHORAGE</CityNm>
            <StateAbbreviationCd>AK</StateAbbreviationCd>
            <ZIPCd>99508</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FWWI NU'IJU TRANSFORMATIONAL LIVING COMMUNITY PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>818171</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST LUKE HEALTH CARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>28W609 HICKORY LN</AddressLine1Txt>
            <CityNm>WEST CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60185</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOPE CENTER FOR WOMEN AND CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>5201874</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST LUKE HEALTH CARE FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>28W609 HICKORY LN</AddressLine1Txt>
            <CityNm>WEST CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60185</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HOPE CENTER FOR WOMEN AND CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>4790316</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>124981</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>172840</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH - ST. ROSE DOMINICAN - SIENA CAMPUS ECMO PROGRAM</GrantOrContributionPurposeTxt>
          <Amt>101195</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST ROSE DOMINICAN HEALTH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>102 E LAKE MEAD PARKWAY</AddressLine1Txt>
            <CityNm>HENDERSON</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89015</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>SOI</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIGNITY HEALTH-ST. ROSE DOMINICAN - SIENA CAMPUS CATH LAB REVITALIZATION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>87671</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>9 PRINCES ST</AddressLine1Txt>
            <CityNm>MELBOURNE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?</GrantOrContributionPurposeTxt>
          <Amt>298224</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>9 PRINCES ST</AddressLine1Txt>
            <CityNm>MELBOURNE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WHICH CHECKPOINTS MAINTAIN IMMUNE TOLERANCE TO BETA-CELLS IN GENETICALLY AT-RISK PEOPLE WHO DONT HAVE T1D?</GrantOrContributionPurposeTxt>
          <Amt>255857</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STATE OF NEVADA DEPARTMENT OF DIVISION OF STATE PARKS</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>901 S STEWART ST SUITE 5005</AddressLine1Txt>
            <CityNm>CARSON CITY</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89701</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VALLEY OF FIRE VISITOR CENTER</GrantOrContributionPurposeTxt>
          <Amt>3500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60/II</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV</GrantOrContributionPurposeTxt>
          <Amt>1300026</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60/II</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV</GrantOrContributionPurposeTxt>
          <Amt>998988</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING HEALTH ACTION INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OVERTOOM 60/II</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDRESSING THE CHALLENGE AND CONSTRAINTS OF INSULIN SOURCES AND SUPPLY (ACCISS) STUDY PHASE IV</GrantOrContributionPurposeTxt>
          <Amt>1200977</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING PHARMACCESS INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AHTC TOWER C4 PAASHEUVELWEG 25</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFECARE: A BUSINESS MODEL FOR HEALTHCARE QUALITY</GrantOrContributionPurposeTxt>
          <Amt>686565</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING PHARMACCESS INTERNATIONAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AHTC TOWER C4 PAASHEUVELWEG 25</AddressLine1Txt>
            <CityNm>AMSTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SAFECARE: A BUSINESS MODEL FOR HEALTHCARE QUALITY</GrantOrContributionPurposeTxt>
          <Amt>538692</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING THE OCEAN CLEANUP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BATAVIERENSTRAAT 15</AddressLine1Txt>
            <CityNm>ROTTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STICHTING THE OCEAN CLEANUP</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BATAVIERENSTRAAT 15</AddressLine1Txt>
            <CityNm>ROTTERDAM</CityNm>
            <CountryCd>NL</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP AND SCALE TECHNOLOGIES TO RID THE OCEANS OF PLASTICS</GrantOrContributionPurposeTxt>
          <Amt>5000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STIFTELSEN FOR UTBILDNING (IOIBD)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEPT OF GASTROENTEROLOGY</AddressLine1Txt>
            <CityNm>OREBRO</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD</GrantOrContributionPurposeTxt>
          <Amt>132000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>STIFTELSEN FOR UTBILDNING (IOIBD)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DEPT OF GASTROENTEROLOGY</AddressLine1Txt>
            <CityNm>OREBRO</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE IOIBD CLINICAL EXPERIENCE EXCHANGE TO FOSTER INVESTIGATIVE CAREERS IN IBD</GrantOrContributionPurposeTxt>
          <Amt>132000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SUPPORTIVE HOUSING NETWORK OF NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>247 W 37TH ST</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>SUPPORTIVE HOUSING NETWORK OF NEW YORK INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>247 W 37TH ST</AddressLine1Txt>
            <CityNm>NEW YORK CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10018</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TRAINING ACADEMY AND COMMUNITY OF PRACTICE FOR SUPPORTIVE HOUSING PROVIDERS</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>633709</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>2567417</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>650000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>T1D EXCHANGE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 FEDERAL STREET SUITE 440</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EQUITABLE HEALTH AND PSYCHOSOCIAL OUTCOMES FOR INDIVIDUALS LIVING WITH T1D THROUGH THE T1D EXCHANGE QUALITY IMPROVEMENT COLLABORATIVE AND REGISTRY</GrantOrContributionPurposeTxt>
          <Amt>1917417</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TECHNISCHE UNIVERSITAET MUENCHEN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>ARCISSTRABE 21</AddressLine1Txt>
            <CityNm>MUNCHEN</CityNm>
            <CountryCd>GM</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COST-EFFECTIVENESS OF PUBLIC HEALTH SCREENING FOR PRE-SYMPTOMATIC TYPE 1 DIABETES WITH AND WITHOUT TREATMENT FOR PREVENTION OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>151947</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WEIZMAN 6</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENETICS INSTITUTE AND GENOMICS CENTER</GrantOrContributionPurposeTxt>
          <Amt>1118516</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WEIZMAN 6</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IBD GENETICS RESEARCH ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 (PAR2) IN INFLAMMATORY GASTROINTESTINAL DISORDERS</GrantOrContributionPurposeTxt>
          <Amt>268340</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL AVIV SOURASKY MEDICAL CENTER - ICHILOV HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>WEIZMAN 6</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENETICS INSTITUTE AND GENOMICS CENTER</GrantOrContributionPurposeTxt>
          <Amt>1420270</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL-AVIV UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL AVIV UNIVERSITY</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY MEDICAL SIMULATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>6828500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL-AVIV UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL AVIV UNIVERSITY</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY MEDICAL SIMULATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>1524350</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TEL-AVIV UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL AVIV UNIVERSITY</AddressLine1Txt>
            <CityNm>TEL AVIV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HELMSLEY MEDICAL SIMULATION CENTER</GrantOrContributionPurposeTxt>
          <Amt>1324350</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ACADEMIC COLLEGE AT TEL-HAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HAI COLLEGE</AddressLine1Txt>
            <CityNm>UPPER GALILEE</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY RESEARCH AND INNOVATION WING IN THE TEL-HAI COMPUTER SCIENCE BUILDING.</GrantOrContributionPurposeTxt>
          <Amt>2600000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ACADEMIC COLLEGE AT TEL-HAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HAI COLLEGE</AddressLine1Txt>
            <CityNm>UPPER GALILEE</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH</GrantOrContributionPurposeTxt>
          <Amt>2664333</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ACADEMIC COLLEGE AT TEL-HAI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HAI COLLEGE</AddressLine1Txt>
            <CityNm>UPPER GALILEE</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY FELLOWSHIPS FOR SUSTAINABILITY AND HEALTH</GrantOrContributionPurposeTxt>
          <Amt>2078769</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2012100 HALUTZ</AddressLine1Txt>
            <CityNm>RAMAT HANEGEV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RAMAT HANEGEV SENIOR CITIZEN CENTER</GrantOrContributionPurposeTxt>
          <Amt>2775467</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ASSOCIATION FOR THE RESIDENT AND COMMUNITY IN RAMAT HANEGEV</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2012100 HALUTZ</AddressLine1Txt>
            <CityNm>RAMAT HANEGEV</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RAMAT HANEGEV SENIOR CITIZEN CENTER</GrantOrContributionPurposeTxt>
          <Amt>699190</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>971014</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>415 MAIN STREET</AddressLine1Txt>
            <CityNm>CAMBRIDGE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02142</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNCOVERING CROHN'S GENETIC RISK IN AFRICAN-AMERICAN AND HISPANIC/LATINO POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>1129976</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE HELMSLEY CHARITABLE TRUST GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>368500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENETIC PROTECTION BY HLA-DQ6 IN T1D</GrantOrContributionPurposeTxt>
          <Amt>235681</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 E DUARTE RD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CD318 MEDIATED REGULATION OF ISLET AUTOANTIGEN SPECIFIC T CELL IMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>371800</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NEXT-GENERATION BIOMARKER TOOL TO ACCELERATE THE DEVELOPMENT OF EFFECTIVE ANTI-FIBROTIC THERAPIES</GrantOrContributionPurposeTxt>
          <Amt>1321210</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE MILESTONE INITIATIVE: EDUCATION INNOVATION FOR ADVANCED IBD FELLOWS IN THE USA</GrantOrContributionPurposeTxt>
          <Amt>236313</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>387615</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>869476</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANOBIOLOGY OF THE INTESTINAL EPITHELIAL BARRIER DISRUPTION IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>342955</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE CLEVELAND CLINIC FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>719051</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD</GrantOrContributionPurposeTxt>
          <Amt>127077</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE GOVERNORS OF THE UNIVERSITY OF CALGARY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>2500 UNIVERSITY DRIVE NW</AddressLine1Txt>
            <CityNm>CALGARY</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INTERLEUKIN-4 ACTIVATED MACROPHAGES (M(IL4)) FOR PERSONALIZED CELLULAR IMMUNOTHERAPY TO TREAT IBD</GrantOrContributionPurposeTxt>
          <Amt>137417</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOSPITAL FOR SICK CHILDREN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>555 UNIVERSITY AVE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD): PRECISION MOLECULAR DIAGNOSES TO TARGETED THERAPIES-TORONTO STUDIES</GrantOrContributionPurposeTxt>
          <Amt>555480</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOSPITAL FOR SICK CHILDREN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>555 UNIVERSITY AVE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>248621</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE HOSPITAL FOR SICK CHILDREN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>555 UNIVERSITY AVE</AddressLine1Txt>
            <CityNm>TORONTO</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNE RESPONSES TO GUT MICROBES ASSOCIATED WITH T1D RISK AND PROGRESSION</GrantOrContributionPurposeTxt>
          <Amt>250415</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1032574</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION</GrantOrContributionPurposeTxt>
          <Amt>391212</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNRAVELING THE IMMUNOPATHOLOGY OF PERIANAL FISTULIZING CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1081289</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>EXHIBITION RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNOLOGICAL MECHANISMS UNDERLYING THE GENETIC BASIS FOR NATURAL T1D PROTECTION</GrantOrContributionPurposeTxt>
          <Amt>340788</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE LANIADO KIRIAT SANZ HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>DIVREI KHAYIM ST 16</AddressLine1Txt>
            <CityNm>NATANIYA</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEW MATERNITY FLOOR</GrantOrContributionPurposeTxt>
          <Amt>1350000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE MILKEN INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1250 FOURTH STREET</AddressLine1Txt>
            <CityNm>SANTA MONICA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90401</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FASTERCURES LEADERSLINK PROGRAM EXPANSION</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE NATURE CONSERVANCY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4245 NORTH FAIRFAX DRIVE SUITE 100</AddressLine1Txt>
            <CityNm>ARLINGTON</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>22203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FUTURE FOREST NYC PHASE III</GrantOrContributionPurposeTxt>
          <Amt>347804</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>CHARLOTTESVILLE</CityNm>
            <StateAbbreviationCd>VA</StateAbbreviationCd>
            <ZIPCd>229044195</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK PREDICTION: INTEGRATION OF PHYSIOLOGY WITH GENETICS</GrantOrContributionPurposeTxt>
          <Amt>115896</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AT IRVINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 THEORY SUITE 200</AddressLine1Txt>
            <CityNm>IRVINE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>926971050</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A MULTI-ANALYTE SENSOR - GLUCOSE, LACTATE, OXYGEN, KETONES, INSULIN FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>1729516</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCLA OFFICE OF CONTRACTS AND GRANTS</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>900951406</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE RESPONSIVE GLUCAGON (GRG) FOR THE REDUCTION OF HYPOGLYCEMIA FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>568027</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 GILMAN DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92093</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DRUGGABLE GPCROME IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1091471</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 GILMAN DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92093</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MECHANISM OF ACTION AND SAFETY STUDY OF LIVER TARGETED INSULIN</GrantOrContributionPurposeTxt>
          <Amt>471131</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 GILMAN DRIVE</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92093</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE DRUGGABLE GPCROME IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>1092733</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)</GrantOrContributionPurposeTxt>
          <Amt>269368</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREGNANCY IN INFLAMMATORY BOWEL DISEASE AND NEONATAL OUTCOMES (PIANO)</GrantOrContributionPurposeTxt>
          <Amt>269368</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS</GrantOrContributionPurposeTxt>
          <Amt>433333</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>490 ILLINOIS STREET FOURTH FLOOR</AddressLine1Txt>
            <CityNm>SAN FRANCISCO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94143</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IDENTIFICATION AND ANALYSIS OF EXTREME FORMS OF TYPE 1 DIABETES, ESTABLISHMENT OF A DATA COMMONS</GrantOrContributionPurposeTxt>
          <Amt>217916</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SANTA BARBARA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UC SANTA BARBARA</AddressLine1Txt>
            <CityNm>SANTA BARBARA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>93106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1027327</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SANTA BARBARA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UC SANTA BARBARA</AddressLine1Txt>
            <CityNm>SANTA BARBARA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>93106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXERCISE SPECIFIC AID ALGORITHM FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1116996</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMPLEMENT SYSTEM IN THE INITIATION AND PROGRESSION OF ISLET AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>124200</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPLORING THE GENOMIC MECHANISM BEHIND THE MATERNAL PROTECTION FROM T1D</GrantOrContributionPurposeTxt>
          <Amt>200584</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)</GrantOrContributionPurposeTxt>
          <Amt>994996</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>809568</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)</GrantOrContributionPurposeTxt>
          <Amt>1023372</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREPARE 4 AID: PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY</GrantOrContributionPurposeTxt>
          <Amt>1945286</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>501000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAPPING THE B CELL HETEROGENEITY IN TYPE 1 DIABETES AT THE SINGLE-CELL LEVEL</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM IN PRIMARY CARE - REFER OR LEARN: IMPLEMENTATION AND EVALUATION</GrantOrContributionPurposeTxt>
          <Amt>332512</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEEDS PATHWAY: SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY</GrantOrContributionPurposeTxt>
          <Amt>686820</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRENATAL AND OBSTETRIC MATERNAL EXPOSURES AND ISLET AUTOIMMUNITY IN EARLY LIFE (PROMISE)</GrantOrContributionPurposeTxt>
          <Amt>835489</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPACT OF MENSTRUATION ON GLYCEMIC RESPONSE AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>1239503</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)</GrantOrContributionPurposeTxt>
          <Amt>994512</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PREPARE 4 AID: PRIMARY CARE PRAGMATIC, REAL WORLD EXPERIENCE FOR AUTOMATED INSULIN DELIVERY</GrantOrContributionPurposeTxt>
          <Amt>1161486</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>T AND B CELL RECEPTOR ATLAS ACROSS TISSUES AND STAGES OF TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>501000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMPLEMENTATION OF EARLY STAGE T1D EDUCATION AND SUPPORT (ESTES)</GrantOrContributionPurposeTxt>
          <Amt>506760</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE REGENTS OF THE UNIVERSITY OF COLORADO DENVER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>UCD GRANTS AND CONTRACTS MAIL STOP</AddressLine1Txt>
            <AddressLine2Txt>F428</AddressLine2Txt>
            <CityNm>AURORA</CityNm>
            <StateAbbreviationCd>CO</StateAbbreviationCd>
            <ZIPCd>800452571</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEEDS PATHWAY: SHARED EMPOWERMENT FOR EARLY DEVICE SUCCESS OF DIABETES TECHNOLOGY</GrantOrContributionPurposeTxt>
          <Amt>598309</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SCRIPPS RESEARCH INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10550 NORTH TORREY PINES ROAD</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92037</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GUT-RETAINED NRF2/ARE ACTIVATORS FOR IBD</GrantOrContributionPurposeTxt>
          <Amt>1836022</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SDEROT DEVELOPMENT FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>6 BAR LEV STREET</AddressLine1Txt>
            <CityNm>SDEROT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SDEROT MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>993626</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HASHOMER</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE &amp; OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)</GrantOrContributionPurposeTxt>
          <Amt>756699</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SHEBA FUND FOR HEALTH SERVICES AND RESEARCH (RA)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>TEL-HASHOMER</AddressLine1Txt>
            <CityNm>RAMAT GAN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISRAEL IBD RESEARCH NUCLEUS (IIRN) CONSORTIUM: CAPSULE &amp; OMICS FOR PREDICTING EXACERBATION OF CROHNS DISEASE (CORE-CD)</GrantOrContributionPurposeTxt>
          <Amt>188118</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SONIA NABETA FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4705 5TH STREET UNIT 405</AddressLine1Txt>
            <CityNm>LONG ISLAND CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WORLD OF WARRIORS</GrantOrContributionPurposeTxt>
          <Amt>514210</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SONIA NABETA FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4705 5TH STREET UNIT 405</AddressLine1Txt>
            <CityNm>LONG ISLAND CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WORLD OF WARRIORS</GrantOrContributionPurposeTxt>
          <Amt>578470</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE SONIA NABETA FOUNDATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>4705 5TH STREET UNIT 405</AddressLine1Txt>
            <CityNm>LONG ISLAND CITY</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>11101</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>WORLD OF WARRIORS</GrantOrContributionPurposeTxt>
          <Amt>482110</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TEL AVIV JAFFA ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RABENU YERUHAM ST 2 POB 8401</AddressLine1Txt>
            <CityNm>TEL AVIV YAFFO</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS</GrantOrContributionPurposeTxt>
          <Amt>266667</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TEL AVIV JAFFA ACADEMIC COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RABENU YERUHAM ST 2 POB 8401</AddressLine1Txt>
            <CityNm>TEL AVIV YAFFO</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NEED-BASED SCHOLARSHIPS FOR NURSING STUDENTS</GrantOrContributionPurposeTxt>
          <Amt>266666</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TREVOR PROJECT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 69232</AddressLine1Txt>
            <CityNm>WEST HOLLYWOOD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90069</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LGBTQ+ YOUTH SUICIDE PREVENTION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1536740</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TREVOR PROJECT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 69232</AddressLine1Txt>
            <CityNm>WEST HOLLYWOOD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90069</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LGBTQ+ YOUTH SUICIDE PREVENTION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>1282735</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TREVOR PROJECT INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 69232</AddressLine1Txt>
            <CityNm>WEST HOLLYWOOD</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90069</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LGBTQ+ YOUTH SUICIDE PREVENTION PROJECT</GrantOrContributionPurposeTxt>
          <Amt>2081072</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>429646</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT FOR T1D TRANSITION PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADDING HEALTH QUESTIONS TO THE POVERTY TRACKER TO SURVEY THEHEALTHCARE NEEDS AND UTILIZATION PREFERENCES OF LOW-INCOMENEW YORKERS</GrantOrContributionPurposeTxt>
          <Amt>146689</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATORIAL PERTURBATION OF CELLULAR NETWORK IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>413263</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>615 WEST 131ST STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100273922</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORT FOR T1D TRANSITION PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE UNIVERSITY OF ADELAIDE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>54351</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF ADELAIDE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE UNIVERSITY OF ADELAIDE</AddressLine1Txt>
            <CityNm>ADELAIDE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PANCREATIC EXOCRINE FUNCTION AND THE PROGRESSION TO TYPE 1 DIABETES IN YOUNG CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>44540</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF CHICAGO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>5801 SOUTH ELLIS AVENUE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60637</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT AND DISSEMINATION OF AN IBD MONITORING AND PREVENTION PROGRAM WITH A FOCUS ON INTESTINAL ULTRASOUND</GrantOrContributionPurposeTxt>
          <Amt>333042</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN GUT CELL ATLAS - NORMAL INTESTINE AND CROHN'S DISEASE</GrantOrContributionPurposeTxt>
          <Amt>209222</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF EDINBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BHF CENTRE FOR CARDIOVASCULAR</AddressLine1Txt>
            <AddressLine2Txt>SCIENCES</AddressLine2Txt>
            <CityNm>EDINBURGH</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MITOCHONDRIAL DAMPS AS MECHANISTIC BIOMARKERS OF MUCOSAL INFLAMMATION IN CROHNS DISEASE (MUSIC)</GrantOrContributionPurposeTxt>
          <Amt>682311</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF MANCHESTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>OXFORD RD</AddressLine1Txt>
            <CityNm>MANCHESTER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>A MAP OF THE INTESTINE FOLLOWING REGULATORY T CELL INFUSION INTO PATIENTS WITH ACTIVE CROHNS DISEASE AT SINGLE-CELL AND SPATIAL RESOLUTION</GrantOrContributionPurposeTxt>
          <Amt>692839</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CUMBRAE STEWART BUILDING 72</AddressLine1Txt>
            <CityNm>BRISBANE</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY</GrantOrContributionPurposeTxt>
          <Amt>69271</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE UNIVERSITY OF WESTERN AUSTRALIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>35 STIRLING HIGHWAY</AddressLine1Txt>
            <CityNm>CRAWLEY</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CGM ASSESSMENTS OF ENDIA CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>35866</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EARLY CHILDHOOD DEVELOPMENT AND COMMUNITY CENTER AT THE WEIZMANN INSTITUTE OF SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>3000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>234 HERZEL ST</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS</GrantOrContributionPurposeTxt>
          <Amt>300000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF INDIANA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>509 E 3RD ST</AddressLine1Txt>
            <CityNm>BLOOMINGTON</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>474013654</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING METABOLIC DRIVERS OF B CELL DIFFERENTIATION IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>58372</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF RESEARCH SERVICES</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>191046205</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENGINEERING CAR REGULATORY T CELLS TO PROVIDE DURABLE TOLERANCE TO ALLOGENIC ISLET TRANSPLANTS</GrantOrContributionPurposeTxt>
          <Amt>407000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED JEWISH APPEAL FEDERATION OF JEWISH PHILANTHROPIES OF NY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>130 EAST 59TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10022</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERAL OPERATING SUPPORT</GrantOrContributionPurposeTxt>
          <Amt>5000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNITED STATES FUND FOR UNICEF</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>125 MAIDEN LANE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ACCELERATING GLOBAL FOCUS ON NCDS AND PEN-PLUS COUNTRY PROGRAMS</GrantOrContributionPurposeTxt>
          <Amt>869232</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>LONGITUDINAL STUDY OF THE GLUCAGON RESPONSE TO HYPOGLYCEMIA IN CHILDREN AND ADOLESCENTS WITH NEW-ONSET T1D: CHARACTERISTICS AND PREDICTIVE BIOMARKERS</GrantOrContributionPurposeTxt>
          <Amt>62567</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM</GrantOrContributionPurposeTxt>
          <Amt>304033</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE CATHOLIQUE DE LOUVAIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PLACE DE LUNIVERSITE 1</AddressLine1Txt>
            <CityNm>LOUVAINLANEUVE</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SEARCH FOR MECHANISMS RESPONSIBLE FOR THE IMPAIRED GLUCAGON SECRETION IN T1D AND FOR STRATEGIES TO CORRECT THEM</GrantOrContributionPurposeTxt>
          <Amt>152546</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE DE GENEVE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>RUE MICHEL SERVET 1</AddressLine1Txt>
            <CityNm>GENEVE</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL TESTING OF S100A9 TO IMPROVE GLYCEMIC CONTROL IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>1112238</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITE LIBRE DE BRUXELLES</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE FRANKLIN ROOSEVELT 50</AddressLine1Txt>
            <CityNm>BRUSSELS</CityNm>
            <CountryCd>BE</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERATION OF NEW ANTI- FXYD2A PROBES AND PRECLINICAL VALIDATION FOR HUMAN BETA CELL IMAGING</GrantOrContributionPurposeTxt>
          <Amt>213602</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY AT BUFFALO PEDIATRIC ASSOCIATES P C</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1001 MAIN STREET</AddressLine1Txt>
            <CityNm>BUFFALO</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>14203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FINANCIAL VIABILITY OF TELEHEALTH SERVICES FOR UNDERSERVED T1D PEDIATRIC POPULATIONS</GrantOrContributionPurposeTxt>
          <Amt>537700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY HOSPITALS HEALTH SYSTEM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11100 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS</GrantOrContributionPurposeTxt>
          <Amt>866199</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY HOSPITALS HEALTH SYSTEM INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>11100 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44106</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES FINANCIAL TOOLKIT FOR EMERGING ADULTS</GrantOrContributionPurposeTxt>
          <Amt>677700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1800 W CHARLESTON BLVD</AddressLine1Txt>
            <CityNm>LAS VEGAS</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>387094</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1800 W CHARLESTON BLVD</AddressLine1Txt>
            <CityNm>LAS VEGAS</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89102</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF AN EXTRACORPOREAL LIFE SUPPORT (ECLS) PROGRAM AT UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA</GrantOrContributionPurposeTxt>
          <Amt>84783</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BIRMINGHAM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INSTITUTE OF IMMUNOLOGY AND</AddressLine1Txt>
            <AddressLine2Txt>IMMUNOTHERAPY</AddressLine2Txt>
            <CityNm>BIRMINGHAM</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CREATING AN OPTIMISED ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>479888</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BIRMINGHAM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>INSTITUTE OF IMMUNOLOGY AND</AddressLine1Txt>
            <AddressLine2Txt>IMMUNOTHERAPY</AddressLine2Txt>
            <CityNm>BIRMINGHAM</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING THE EFFICACY AND MECHANISMS OF PEPTIDE IMMUNOTHERAPY FOR TYPE 1 DIABETES: AN EXPERIMENTAL MEDICINE STUDY</GrantOrContributionPurposeTxt>
          <Amt>152801</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BRISTOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>SENATE HOUSE</AddressLine1Txt>
            <CityNm>BRISTOL</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY</GrantOrContributionPurposeTxt>
          <Amt>431779</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF BRISTOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>SENATE HOUSE</AddressLine1Txt>
            <CityNm>BRISTOL</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TYPE 1 DIABETES RISK IN ADULTS (T1DRA) A GENERAL POPULATION STUDY</GrantOrContributionPurposeTxt>
          <Amt>358900</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CLOSED LOOP INSULIN DELIVERY IN NEWLY DIAGNOSED YOUTH WITH TYPE 1 DIABETES AGES 10 TO 18 YEARS (PART 2)</GrantOrContributionPurposeTxt>
          <Amt>353223</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?</GrantOrContributionPurposeTxt>
          <Amt>808734</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EPIGENETIC REGULATION OF INTESTINAL EPITHELIAL MHC CLASS 1 SIGNALLING - ANOVEL MECHANISM IN THE PATHOGENESIS OF CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>718215</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?</GrantOrContributionPurposeTxt>
          <Amt>820911</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES THE WESTERN DIET TRIGGER CROHN'S DISEASE VIA OSMOTIC STRESS?</GrantOrContributionPurposeTxt>
          <Amt>726752</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CAMBRIDGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>THE OLD SCHOOLS</AddressLine1Txt>
            <CityNm>OXFORD</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DOES BIOCHEMISTRY AT THE CENTRE OF LIFE DRIVE CROHN'S DISEASE?</GrantOrContributionPurposeTxt>
          <Amt>851645</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CINCINNATI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>51 GOODMAN DRIVE SUITE 500</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45221</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>416500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF CINCINNATI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>51 GOODMAN DRIVE SUITE 500</AddressLine1Txt>
            <CityNm>CINCINNATI</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>45221</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STUDIES ON THE ROLE OF C-PEPTIDE TO REGULATE BLOOD GLUCOSE DURING SLEEP AND EXERCISE</GrantOrContributionPurposeTxt>
          <Amt>429700</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF DUNDEE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NETHERGATE</AddressLine1Txt>
            <CityNm>DUNDEE</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HYPO-RESOLVE - UNDERSTANDING ORGAN SPECIFIC CONSEQUENCES OF HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>133804</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXTREMELY EARLY ONSET TYPE 1 DIABETES (EXE T1D) PHASE 2: FROM OBSERVATION TO MECHANISM</GrantOrContributionPurposeTxt>
          <Amt>672028</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADVANCING -CELL SPECIFIC THERAPY BY IDENTIFYING -CELL REACTIVE HIGH AFFINITY T CELL RECEPTORS</GrantOrContributionPurposeTxt>
          <Amt>126104</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>B CELL SIGNATURES IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>235821</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>692073</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STIMULATED GLUCAGON LEVELS AS A BIOMARKER OF HYPOGLYCEMIA RISK IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>95777</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNCOVERING NEW GENETIC MECHANISMS UNDERLYING EXTREME EARLY-ONSET TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>189671</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF EXETER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>NORTHCOTE HOUSE THE QUEENS DRIVE</AddressLine1Txt>
            <CityNm>EXETER</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>B CELL SIGNATURES IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>313168</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>665910</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENERATING AUTOANTIGEN-SPECIFIC ANTIBODY-PRODUCING HYBRIDOMAS AS A RENEWABLE SOURCE OF ISLET AUTOANTIBODIES</GrantOrContributionPurposeTxt>
          <Amt>64043</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>UNDERSTANDING T1D AND INSULIN-REQUIRING DIABETES IN FEDERALLY QUALIFIED HEALTH CENTERS (FQHC): A NATIONAL NEEDS ASSESSMENT</GrantOrContributionPurposeTxt>
          <Amt>757160</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF FLORIDA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>219 GRINTER HALL</AddressLine1Txt>
            <CityNm>GAINESVILLE</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>326115500</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>HUMAN ATLAS OF NEONATAL DEVELOPMENT AND EARLY LIFE-IMMUNITY (HANDEL-I) CONTINUATION</GrantOrContributionPurposeTxt>
          <Amt>569086</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF GLASGOW COURT</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>UNIVERSITY AVENUE</AddressLine1Txt>
            <CityNm>GLASGOW</CityNm>
            <CountryCd>UK</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COMBINATION THERAPY WITH BIOLOGICS AND PARTIAL ENTERAL NUTRITION IN ADULTS WITH ACTIVE ILEOCOLONIC CROHNS DISEASE: THE BIOPIC STUDY</GrantOrContributionPurposeTxt>
          <Amt>176239</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DIVISION OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION</GrantOrContributionPurposeTxt>
          <Amt>199968</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DIVISION OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPORTING THE RUPRI HEALTH PANEL TO BRING RESEARCH AND EXPERTISE TO INFORM POLICY DEVELOPMENT AND IMPLEMENTATION</GrantOrContributionPurposeTxt>
          <Amt>204566</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF IOWA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>DIVISION OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>IOWA CITY</CityNm>
            <StateAbbreviationCd>IA</StateAbbreviationCd>
            <ZIPCd>52442</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION IOWA (SIM-IA)</GrantOrContributionPurposeTxt>
          <Amt>714411</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF KANSAS CENTER FOR RESEARCH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2385 IRVING HILL ROAD</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>KS</StateAbbreviationCd>
            <ZIPCd>66045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL DEVELOPMENT TO ADVANCE A TYPE 1 DIABETES ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D</GrantOrContributionPurposeTxt>
          <Amt>579370</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF KANSAS CENTER FOR RESEARCH INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>2385 IRVING HILL ROAD</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>KS</StateAbbreviationCd>
            <ZIPCd>66045</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PRECLINICAL DEVELOPMENT TO ADVANCE A TYPE 1 DIABETES ANTIGEN-SPECIFIC IMMUNOTHERAPY CALLED SAGA-T1D</GrantOrContributionPurposeTxt>
          <Amt>706324</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 LAKE AVENUE NORTH</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01655</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DIETA ANTI-INFLAMATORIA: A CROHNS DISEASE MANAGEMENT STRATEGY TAILORED FOR PUERTO RICANS</GrantOrContributionPurposeTxt>
          <Amt>473409</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MELBOURNE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 4 ALAN GILBERT BUILDING</AddressLine1Txt>
            <CityNm>VICTORIA</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>405066</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MELBOURNE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>LEVEL 4 ALAN GILBERT BUILDING</AddressLine1Txt>
            <CityNm>VICTORIA</CityNm>
            <CountryCd>AS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>USE OF WHEY PROTEIN TO REDUCE RISK OF HYPOGLYCEMIA DURING EXERCISE FOR PEOPLE WITH T1D</GrantOrContributionPurposeTxt>
          <Amt>490922</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>326055</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>THE GEORGE S. EISENBARTH NPOD AWARD FOR TEAM SCIENCE</GrantOrContributionPurposeTxt>
          <Amt>328238</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES</GrantOrContributionPurposeTxt>
          <Amt>286197</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MIAMI</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1320 SOUTH DIXIE HIGHWAY SUITE 650</AddressLine1Txt>
            <CityNm>CORAL GABLES</CityNm>
            <StateAbbreviationCd>FL</StateAbbreviationCd>
            <ZIPCd>33146</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOP A NEW METHOD OF STUDYING ALPHA CELL FUNCTION IN PANCREATIC SLICES</GrantOrContributionPurposeTxt>
          <Amt>242826</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR</GrantOrContributionPurposeTxt>
          <Amt>1027184</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS</GrantOrContributionPurposeTxt>
          <Amt>1038654</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A CONTINUOUS INSULIN SENSOR</GrantOrContributionPurposeTxt>
          <Amt>1116830</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CD OF THE POUCH</GrantOrContributionPurposeTxt>
          <Amt>336550</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>PILOTING INTEGRATION OF PORTABLE ULTRASOUNDS</GrantOrContributionPurposeTxt>
          <Amt>1058738</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GENOMIC AND MICROBIAL SIGNATURES PREDICT POST-OPERATIVE CROHNS DISEASE OUTCOMES</GrantOrContributionPurposeTxt>
          <Amt>149796</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>104 AIRPORT DRIVE SUITE 2200 CB</AddressLine1Txt>
            <AddressLine2Txt>1350</AddressLine2Txt>
            <CityNm>CHAPEL HILL</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>275991350</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FREQUENCY AND TITER OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AUTO-ANTIBODIES IN PATIENTS WITH CD OF THE POUCH</GrantOrContributionPurposeTxt>
          <Amt>71233</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH DAKOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SCHOOL OF MEDICINE HEALTH SCIENCES</AddressLine1Txt>
            <CityNm>GRAND FORKS</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION (SIM) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>74153</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NORTH DAKOTA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SCHOOL OF MEDICINE HEALTH SCIENCES</AddressLine1Txt>
            <CityNm>GRAND FORKS</CityNm>
            <StateAbbreviationCd>ND</StateAbbreviationCd>
            <ZIPCd>58202</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SIMULATION IN MOTION (SIM) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>27496</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>GLUCOSE-BINDING MOTIFS FROM DYNAMIC COMBINATORIAL LANDSCAPES</GrantOrContributionPurposeTxt>
          <Amt>671881</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF NOTRE DAME DU LAC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>940 GRACE HALL</AddressLine1Txt>
            <CityNm>NOTRE DAME</CityNm>
            <StateAbbreviationCd>ID</StateAbbreviationCd>
            <ZIPCd>465565708</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEVELOPMENT OF A NOVEL GLUCOSE-RESPONSIVE GLUCAGON DELIVERY SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>705510</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF OULU</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO BOX 8000</AddressLine1Txt>
            <CityNm>OULU</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING</GrantOrContributionPurposeTxt>
          <Amt>135549</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF OULU</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>PO BOX 8000</AddressLine1Txt>
            <CityNm>OULU</CityNm>
            <CountryCd>FI</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MATERNAL AND PATERNAL TYPE 1 DIABETES MECHANISMS FOR THE DISTINCT RECURRENCE RISK IN THE OFFSPRING</GrantOrContributionPurposeTxt>
          <Amt>274391</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PITTSBURGH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3420 FORBES AVENUE</AddressLine1Txt>
            <CityNm>PITTSBURGH</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>152603203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SINGLE CELL MULTIMODAL OMICS ANALYSIS OF COLONOSCOPIC BIOPSY-DERIVED IMMUNE CELLS IN CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>237102</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3925 WEST BRAKER LANE</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>787595316</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN</GrantOrContributionPurposeTxt>
          <Amt>198646</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3925 WEST BRAKER LANE</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>787595316</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN</GrantOrContributionPurposeTxt>
          <Amt>200927</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TEXAS SYSTEM FOR THE UNIVERSITY OF TEXAS AT AUSTIN</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3925 WEST BRAKER LANE</AddressLine1Txt>
            <CityNm>AUSTIN</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>787595316</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INCREASING ACCESS TO CROHNS DISEASE CLINICAL CARE FOR THE IBD CENTER AT UT HEALTH AUSTIN</GrantOrContributionPurposeTxt>
          <Amt>200927</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF UTAH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>201 S PRESIDENTS CIRCLE</AddressLine1Txt>
            <CityNm>SALT LAKE CITY</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84112</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INDUCTION OF PERIPHERAL TOLERANCE TO BETA CELL ANTIGENS BY SPECIFIC TARGETING OF LANGERIN+ DENDRITIC CELLS</GrantOrContributionPurposeTxt>
          <Amt>290806</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WASHINGTON</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>SEATTLE</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>981959472</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DESIGN OF ISLET TARGETED AGONISTS OF PD1 AND CTLA4</GrantOrContributionPurposeTxt>
          <Amt>387576</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WESTERN ONTARIO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>339 WINDERMERE RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>756873</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WESTERN ONTARIO</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>339 WINDERMERE RD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>CA</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ENDPOINT DEVELOPMENT FOR OSTOMY CLINICAL TRIALS (ENDO-TRIAL) CONSORTIUM</GrantOrContributionPurposeTxt>
          <Amt>606448</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WYOMING FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>222 S 22ND ST</AddressLine1Txt>
            <CityNm>LARAMIE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND TRAINING INITIATIVE IN WYOMING</GrantOrContributionPurposeTxt>
          <Amt>458857</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF WYOMING FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>222 S 22ND ST</AddressLine1Txt>
            <CityNm>LARAMIE</CityNm>
            <StateAbbreviationCd>WY</StateAbbreviationCd>
            <ZIPCd>82070</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ULTRASOUND TRAINING INITIATIVE IN WYOMING</GrantOrContributionPurposeTxt>
          <Amt>458857</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UPPSALA UNIVERSITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BOX 256</AddressLine1Txt>
            <CityNm>UPPSALA</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION</GrantOrContributionPurposeTxt>
          <Amt>1139284</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UPPSALA UNIVERSITY HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BOX 256</AddressLine1Txt>
            <CityNm>UPPSALA</CityNm>
            <CountryCd>SW</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>IMMUNE-EVASIVE ISLETS FOR TRANSPLANTATION</GrantOrContributionPurposeTxt>
          <Amt>360374</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION OF PANCREATLAS CONNECTIVITY PLATFORM AND PHENOTYPING OF HANDEL SAMPLES BY CUTTING-EDGE SINGLE CELL MULTIOME TECHNOLOGY</GrantOrContributionPurposeTxt>
          <Amt>513936</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>121999</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ISOLATING ISLETS TO UNDERSTAND HYPOGLYCEMIA IN TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>163405</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEWAPPROACHES TO PREVENT HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>232525</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DEFINING MOLECULAR MECHANISMS OF CELL DYSFUNCTION IN TYPE 1 DIABETES TO DEVELOP NEWAPPROACHES TO PREVENT HYPOGLYCEMIA</GrantOrContributionPurposeTxt>
          <Amt>104599</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROGRAMS</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>37203</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>ADAPTING FAMS TO OPTIMIZE CGM USE AMONG EMERGING ADULTS WITH TYPE 1 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>182168</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VANDERBILT UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>SPONSORED PROGRAMS ADMINISTRATION</AddressLine1Txt>
            <CityNm>NASHVILLE</CityNm>
            <StateAbbreviationCd>TN</StateAbbreviationCd>
            <ZIPCd>372032417</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>NORMALIZING HYPOGLYCEMIA-INDUCED GLUCAGON SECRETION IN T1D THROUGH PHARMACOLOGICAL RESTORATION OF ALPHA-CELL CALCIUM HANDLING</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>2978657</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FEASIBILITY PILOT TO DESIGN A VALUE BASED PAYMENT ECOSYSTEM TO IMPROVE HEALTH AND EQUITY FOR MEDICAID BENEFICIARIES LIVING WITH T1D AND T2D.</GrantOrContributionPurposeTxt>
          <Amt>318000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>3039905</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>4336124</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VAYU HEALTH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>19 ALISO WAY</AddressLine1Txt>
            <CityNm>PORTOLA VALLEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94028</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>VAYU HEALTH PHASE 2 - SCALE AND SPREAD OF VALUE BASED PAYMENT ECOSYSTEM FOR MEDICAID BENEFICIARIES LIVING WITH TYPE 1 AND TYPE 2 DIABETES</GrantOrContributionPurposeTxt>
          <Amt>2203040</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>VIVLI INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>101 MIDDLESEX TURNPIKE SUITE 6</AddressLine1Txt>
            <CityNm>BURLINGTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>018034914</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DATA SHARING PLATFORM FOR T1-DEXI DATASETS</GrantOrContributionPurposeTxt>
          <Amt>74348</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WARREN MEMORIAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>905 2ND ST</AddressLine1Txt>
            <CityNm>FRIEND</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68359</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TELE-EMERGENCY SERVICES AT FRIEND COMMUNITY HEALTHCARE SYSTEM</GrantOrContributionPurposeTxt>
          <Amt>11027</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>CAMPUS BOX 1054</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>631304862</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CELLULAR BIOMARKERS FOR PEDIATRIC CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>488300</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>CAMPUS BOX 1054</AddressLine1Txt>
            <CityNm>SAINT LOUIS</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>631304862</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>RESTORATION OF NORMAL GLUCAGON SECRETORY DYNAMICS BY DIRECT MANIPULATION OF ALPHA CELL SIGNALING</GrantOrContributionPurposeTxt>
          <Amt>330000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 YORK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100654805</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>863618</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 YORK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>100654805</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING THE MYCOBIOME IN PATIENTS WITH CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>202620</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WEIZMANN INSTITUTE OF SCIENCE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>POB 26</AddressLine1Txt>
            <CityNm>REHOVOT</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>QUANTUM COMPUTING AND SENSING WITH ATOMS, ELECTRONS, AND PHOTONS</GrantOrContributionPurposeTxt>
          <Amt>2700000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORLD HEALTH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE APPIA 20</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS</GrantOrContributionPurposeTxt>
          <Amt>3477889</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORLD HEALTH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE APPIA 20</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT</GrantOrContributionPurposeTxt>
          <Amt>3521461</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORLD HEALTH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE APPIA 20</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING INTEGRATED PREVENTION AND CONTROL OF CHRONIC AND SEVERE NCDS IN THE WHO AFRICAN REGION, USING T1D, SCD, ARF, AND RHD AS ENTRY POINTS</GrantOrContributionPurposeTxt>
          <Amt>2658639</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORLD HEALTH ORGANIZATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>AVENUE APPIA 20</AddressLine1Txt>
            <CityNm>GENEVA</CityNm>
            <CountryCd>SZ</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>STRENGTHENING THE CAPACITY OF THE GLOBAL DIABETES COMPACT</GrantOrContributionPurposeTxt>
          <Amt>2738915</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>599035</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208327</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TARGETING NEWLY DISCOVERED HOST-MICROBIOTA INTERACTION NODES TO TREAT OR PREVENT CROHNS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>605522</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YEHUDA ABARBANEL GOVERNMENT HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>15 KEREN KAYEMET ST</AddressLine1Txt>
            <CityNm>BAT YAM</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MODERNIZATION OF ABARBANELS INFORMATION TECHNOLOGY AND SECURITY SYSTEMS</GrantOrContributionPurposeTxt>
          <Amt>454960</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YITZHAK SHAMIR MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>BEER YAAKOV</AddressLine1Txt>
            <CityNm>TZRIFIN</CityNm>
            <CountryCd>IS</CountryCd>
          </RecipientForeignAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>EXPANSION AND RENOVATION OF THE CANCER INSTITUTE AT SHAMIR MEDICAL CENTER</GrantOrContributionPurposeTxt>
          <Amt>1978286</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUTH DEVELOPMENT ORGANIZATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15 UNION STREET 563</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING PROJECT SUPPORT 2024-2026</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YOUTH DEVELOPMENT ORGANIZATION INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>15 UNION STREET 563</AddressLine1Txt>
            <CityNm>LAWRENCE</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01840</ZIPCd>
          </RecipientUSAddress>
          <RecipientRelationshipTxt>N/A</RecipientRelationshipTxt>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CAPACITY BUILDING PROJECT SUPPORT 2024-2026</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <TotalGrantOrContriApprvFutAmt>586831945</TotalGrantOrContriApprvFutAmt>
      </SupplementaryInformationGrp>
      <AnalysisIncomeProducingActyGrp>
        <IntOnSavAndTempCashInvstGrp>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>4018817</ExclusionAmt>
        </IntOnSavAndTempCashInvstGrp>
        <DividendsAndInterestFromSecDtl>
          <BusinessCd>901101</BusinessCd>
          <UnrelatedBusinessTaxblIncmAmt>5123477</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>61972395</ExclusionAmt>
        </DividendsAndInterestFromSecDtl>
        <OtherInvestmentIncomeGrp>
          <BusinessCd>901101</BusinessCd>
          <UnrelatedBusinessTaxblIncmAmt>23232266</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>28425875</ExclusionAmt>
        </OtherInvestmentIncomeGrp>
        <GainSalesAstOthThanInvntryGrp>
          <BusinessCd>901101</BusinessCd>
          <UnrelatedBusinessTaxblIncmAmt>5858689</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionCd>18</ExclusionCd>
          <ExclusionAmt>228845211</ExclusionAmt>
        </GainSalesAstOthThanInvntryGrp>
        <OtherRevenueDescribedGrp>
          <Desc>GRANT RECOVERIES</Desc>
          <ExclusionCd>01</ExclusionCd>
          <ExclusionAmt>7742742</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <OtherRevenueDescribedGrp>
          <Desc>OTHER NON-TAXABLE INCOME</Desc>
          <ExclusionCd>01</ExclusionCd>
          <ExclusionAmt>9058</ExclusionAmt>
        </OtherRevenueDescribedGrp>
        <SubtotalsIncmProducingActyGrp>
          <UnrelatedBusinessTaxblIncmAmt>34214432</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionAmt>331014098</ExclusionAmt>
          <RelatedOrExemptFunctionIncmAmt>0</RelatedOrExemptFunctionIncmAmt>
        </SubtotalsIncmProducingActyGrp>
        <TotalIncomeProducingActyAmt>365228530</TotalIncomeProducingActyAmt>
      </AnalysisIncomeProducingActyGrp>
      <TrnsfrTransRlnNonchrtblEOGrp>
        <TrnsfrOfCashToNonchrtblEOInd>1</TrnsfrOfCashToNonchrtblEOInd>
        <TrnsfrOtherAssetNonchrtblEOInd>0</TrnsfrOtherAssetNonchrtblEOInd>
        <SalesOrExchangesOfAssetsInd>0</SalesOrExchangesOfAssetsInd>
        <PurchaseOfAssetsNonchrtblEOInd>0</PurchaseOfAssetsNonchrtblEOInd>
        <RentalOfFacilitiesOthAssetsInd>0</RentalOfFacilitiesOthAssetsInd>
        <ReimbursementArrangementsInd>0</ReimbursementArrangementsInd>
        <LoansOrLoanGuaranteesInd>0</LoansOrLoanGuaranteesInd>
        <PerformanceOfServicesEtcInd>0</PerformanceOfServicesEtcInd>
        <SharingOfFacilitiesEtcInd>0</SharingOfFacilitiesEtcInd>
        <TransferScheduleDetail>
          <LineNumberTxt>1a(1)</LineNumberTxt>
          <InvolvedAmt>831327</InvolvedAmt>
          <NoncharitableExemptOrgName>
            <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
          </NoncharitableExemptOrgName>
          <TransfersTransAndShrArrngmDesc>GRANT IN SUPPORT OF EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE</TransfersTransAndShrArrngmDesc>
        </TransferScheduleDetail>
        <RelationshipsNonchrtblEOInd>0</RelationshipsNonchrtblEOInd>
      </TrnsfrTransRlnNonchrtblEOGrp>
    </IRS990PF>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <GeneralRuleInd>X</GeneralRuleInd>
      <ContributorInformationGrp>
        <ContributorNum>1</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1Txt>ESTATE OF LEONA M HELMSLEY</BusinessNameLine1Txt>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1Txt>230 PARK AVENUE SUITE 659</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10169</ZIPCd>
        </ContributorUSAddress>
        <TotalContributionsAmt>20000000</TotalContributionsAmt>
        <PersonContributionInd>X</PersonContributionInd>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <AccountingFeesSchedule documentId="RetDoc2002200001">
      <AccountingFeesDetail>
        <CategoryTxt>AUDIT AND TAX PREPARATION</CategoryTxt>
        <Amt>250826</Amt>
        <NetInvestmentIncomeAmt>112329</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>160305</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
      <AccountingFeesDetail>
        <CategoryTxt>BOOKKEEPING</CategoryTxt>
        <Amt>66736</Amt>
        <NetInvestmentIncomeAmt>3901</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>69049</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
      <AccountingFeesDetail>
        <CategoryTxt>OTHER ACCOUNTING SERVICES</CategoryTxt>
        <Amt>109527</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>116371</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
    </AccountingFeesSchedule>
    <AllOthProgRltdInvestmentsSch documentId="RetDoc2063500001">
      <AllOtherProgramRelatedInvstGrp>
        <Desc>BIORASIS, INC. - EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD IN CARE FOR T1D</Desc>
        <Amt>687500</Amt>
      </AllOtherProgramRelatedInvstGrp>
      <AllOtherProgramRelatedInvstGrp>
        <Desc>PERCUSENSE, INC. - DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER TO IMPROVE CARE OF T1D</Desc>
        <Amt>500000</Amt>
      </AllOtherProgramRelatedInvstGrp>
    </AllOthProgRltdInvestmentsSch>
    <ExpenditureResponsibilityStmt documentId="RetDoc2118100001">
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>3103 BEE CAVES ROAD SUITE 201</AddressLine1Txt>
          <CityNm>AUSTIN</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>78746</ZIPCd>
        </USAddress>
        <GrantDt>2018-02-20</GrantDt>
        <GrantAmt>5000000</GrantAmt>
        <PurposeOfGrantTxt>INTEGRATED COMMUNITY DEVELOPMENT IN AMHARA, ETHIOPIA</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>5000000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2019, 1/2020, 2/2021, 1/2022, 1/2023, 1/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>3103 BEE CAVES ROAD SUITE 201</AddressLine1Txt>
          <CityNm>AUSTIN</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>78746</ZIPCd>
        </USAddress>
        <GrantDt>2019-09-09</GrantDt>
        <GrantAmt>7923870</GrantAmt>
        <PurposeOfGrantTxt>INTEGRATED COMMUNITY DEVELOPMENT IN ODA BULTUM, ETHIOPIA</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>7923870</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+7/2021, 1/2022, 7/2022, 1/2023, 1/2024, 4/2024, 5/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>A GLIMMER OF HOPE FOUNDATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>3103 BEE CAVES ROAD SUITE 201</AddressLine1Txt>
          <CityNm>AUSTIN</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>78746</ZIPCd>
        </USAddress>
        <GrantDt>2022-12-20</GrantDt>
        <GrantAmt>4800000</GrantAmt>
        <PurposeOfGrantTxt>EMPOWERING FAMILIES TO BUILD RESILIENCE AND REDUCE POVERTY</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>968479</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ABVANCE THERAPEUTICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>38 BENNINGTON COURT</AddressLine1Txt>
          <CityNm>RENO</CityNm>
          <StateAbbreviationCd>NV</StateAbbreviationCd>
          <ZIPCd>89511</ZIPCd>
        </USAddress>
        <GrantDt>2024-06-18</GrantDt>
        <GrantAmt>3920820</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF ABV100, A FIXED-RATIO COFORMULATION OF INSULIN AND GLUCAGON TO IMPROVE THE LIVES OF THOSE LIVING WITH T1D.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PENDING</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>AKSTON BIOSCIENCES CORPORATION</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>100 CUMMINGS CENTER SUITE 454C</AddressLine1Txt>
          <CityNm>BEVERLY</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01915</ZIPCd>
        </USAddress>
        <GrantDt>2017-03-01</GrantDt>
        <GrantAmt>6194000</GrantAmt>
        <PurposeOfGrantTxt>PRECLINICAL TRIAL OF INSULIN-FUSION TO END AUTOIMMUNITY &amp; IMPROVE QUALITY OF LIFE FOR PEOPLE LIVING WITH T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>5843336</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+2/2021, 6/2022, 3/2023, 6/2023, 12/2023, 3/2024, 6/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALIMENTIV INC (FKA ROBARTS)</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <ProvinceOrStateNm>ONTARIO</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
        </ForeignAddress>
        <GrantDt>2018-11-20</GrantDt>
        <GrantAmt>3390428</GrantAmt>
        <PurposeOfGrantTxt>STENOSIS THERAPY AND ANTI-FIBROTIC RESEARCH (STAR) CONSORTIUM TO IMPROVE CARE OF CD PATIENTS</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2751742</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+6/2021, 12/2021, 6/2022, 2/2023, 7/2023, 11/2023, 3/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALIMENTIV INC (FKA ROBARTS)</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>100 DUNDAS STREET</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <ProvinceOrStateNm>ONTARIO</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
        </ForeignAddress>
        <GrantDt>2022-02-10</GrantDt>
        <GrantAmt>894043</GrantAmt>
        <PurposeOfGrantTxt>DEVELOP AN INTESTINAL MUCOSAL AND IMAGING BIOMARKER FOR STRICTURING CD AND IMPROVE HEALTH OUTCOMES FOR PATIENTS</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>287504</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>2/2023, 6/2023, 3/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ASSOCIATION OF DIABETES CARE &amp; EDUCATION SPECIALISTS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>125 S WACKER DRIVE SUITE 600</AddressLine1Txt>
          <CityNm>CHICAGO</CityNm>
          <StateAbbreviationCd>IL</StateAbbreviationCd>
          <ZIPCd>60606</ZIPCd>
        </USAddress>
        <GrantDt>2021-11-20</GrantDt>
        <GrantAmt>2500000</GrantAmt>
        <PurposeOfGrantTxt>EXPANSION OF THE DANATECH PLATFORM TO IMPROVE T1D CARE</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1270333</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2022, 5/2022, 12/2022, 1/2023, 12/2023, 1/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>AUSTRALASIAN GASTRO INTESTINAL RESEARCH FOUNDATION LTD</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>55 VICTORIA PARADE LEVEL 2</AddressLine1Txt>
          <CityNm>FITZROY</CityNm>
          <CountryCd>AS</CountryCd>
        </ForeignAddress>
        <GrantDt>2020-07-23</GrantDt>
        <GrantAmt>3560371</GrantAmt>
        <PurposeOfGrantTxt>FECAL MICROBIOTA TRANSPLANTATION IN CROHN'S DISEASE: THE MIRO STUDY TO IMPROVE HEALTH OUTCOMES</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2296388</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR +2/2022, 7/2022, 8/2022, 2/2023, 8/2023, 3/2024, 8/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BIORASIS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1392 STORRS RD U4213 ATL ROOM 106</AddressLine1Txt>
          <CityNm>STORRS</CityNm>
          <StateAbbreviationCd>CT</StateAbbreviationCd>
          <ZIPCd>06269</ZIPCd>
        </USAddress>
        <GrantDt>2018-02-06</GrantDt>
        <GrantAmt>3016000</GrantAmt>
        <PurposeOfGrantTxt>EARLY FEASIBILITY STUDIES OF THE GLUCOWIZZARD IN CARE FOR T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1988500</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 2/2021, 7/2021, 5/2022, 11/2022, 5/2023, 6/2024, 7/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BREAKTHROUGH T1D (FKA JDRF INTERNATIONAL)</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>200 VESEY STREET 28TH FLOOR</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10281</ZIPCd>
        </USAddress>
        <GrantDt>2012-05-21</GrantDt>
        <GrantAmt>8200000</GrantAmt>
        <PurposeOfGrantTxt>ORTHOGONALLY REDUNDANT GLUCOSE SENSOR TO IMPROVE CARE OF T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>8200000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR + 7/2016, 6/2017, 6/2019, 11/2019, 5/2020, 8/2020</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>CAPILLARY BIOMEDICAL INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2 WRIGLEY</AddressLine1Txt>
          <CityNm>IRVINE</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92617</ZIPCd>
        </USAddress>
        <GrantDt>2020-09-02</GrantDt>
        <GrantAmt>1500000</GrantAmt>
        <PurposeOfGrantTxt>ADVANCED EXTENDED INFUSION SET TO IMPROVE CARE OF T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1428325</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR + 1/2022, 5/2022, 6/2022, 3/2023, 8/2023, 8/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>DIABETOMICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2345 NE OVERLOOK DRIVE SUITE 140</AddressLine1Txt>
          <CityNm>HILLSBORO</CityNm>
          <StateAbbreviationCd>OR</StateAbbreviationCd>
          <ZIPCd>97006</ZIPCd>
        </USAddress>
        <GrantDt>2018-01-11</GrantDt>
        <GrantAmt>4031900</GrantAmt>
        <PurposeOfGrantTxt>POINT-OF-CARE RAPID TESTS FOR TID SCREENING AND INTERVENTION</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>4031900</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+ 4/2022, 9/2022, 10/2022, 7/2023, 10/2023, 7/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>DREAMED DIABETES LTD</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>14 KAPLAN ST</AddressLine1Txt>
          <CityNm>PETAH TIKVA</CityNm>
          <ProvinceOrStateNm>TEL AVIV</ProvinceOrStateNm>
          <CountryCd>IS</CountryCd>
        </ForeignAddress>
        <GrantDt>2023-02-23</GrantDt>
        <GrantAmt>2850000</GrantAmt>
        <PurposeOfGrantTxt>INCREASING ACCESS TO DECISION SUPPORT TOOLS FOR IMPROVED INSULIN DOSING FOR PEOPLE WITH DIABETES</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>5/2023</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>FEROX THERAPEUTICS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>111 TOWN SQUARE PLACE SUITE 1203</AddressLine1Txt>
          <AddressLine2Txt>PMB 1034</AddressLine2Txt>
          <CityNm>JERSEY CITY</CityNm>
          <StateAbbreviationCd>NJ</StateAbbreviationCd>
          <ZIPCd>07310</ZIPCd>
        </USAddress>
        <GrantDt>2018-11-20</GrantDt>
        <GrantAmt>872300</GrantAmt>
        <PurposeOfGrantTxt>INSULIN INDUCED HYPOGLYCEMIA PREVENTION PROGRAM TO IMPROVE CARE OF T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>872300</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR + 4/2020, 7/2020, 12/2020, 1/2021, 4/2021, 7/2021</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>GRAND CANYON UNIVERSITY</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>3300 WEST CAMELBACK ROAD</AddressLine1Txt>
          <CityNm>PHOENIX</CityNm>
          <StateAbbreviationCd>AZ</StateAbbreviationCd>
          <ZIPCd>85017</ZIPCd>
        </USAddress>
        <GrantDt>2019-06-26</GrantDt>
        <GrantAmt>2274027</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF A CONTINUOUS INSULIN-GLUCOSE SENSOR TO IMPROVE T1D CARE</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2274027</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>6/2020, 7/2020, 7/2021, 4/2022, 1/2023</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
          <CityNm>MUNSTER</CityNm>
          <CountryCd>GM</CountryCd>
        </ForeignAddress>
        <GrantDt>2023-11-08</GrantDt>
        <GrantAmt>1614000</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF ELEARNING PLATFORM FOR STANDARDIZATION AND DISSEMINATION OF INTESTINAL ULTRASOUND EDUCATION.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>0</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PENDING</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
          <CityNm>MUNSTER</CityNm>
          <CountryCd>GM</CountryCd>
        </ForeignAddress>
        <GrantDt>2020-10-22</GrantDt>
        <GrantAmt>4752086</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF AN INTESTINAL ULTRASOUND SCORE TO EVALUATE INFLAMMATION AND TREATMENT RESPONSE IN CROHNS DISEASE.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2141708</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>6/2021, 12/2021, 8/2022, 11/2022, 12/2022, 8/2023, 2/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
          <CityNm>MUNSTER</CityNm>
          <CountryCd>GM</CountryCd>
        </ForeignAddress>
        <GrantDt>2022-03-23</GrantDt>
        <GrantAmt>342387</GrantAmt>
        <PurposeOfGrantTxt>POINT-OF-CARE INTESTINAL ULTRASOUND TRAINING IN THE UNITED STATES: INTRODUCTION TO INTESTINAL ULTRASONOGRAPHY FOR CD PATIENTS</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>172967</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>3/2023</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INTERNATIONAL BOWEL ULTRASOUND GROUP EV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>HARKORTSTR 1</AddressLine1Txt>
          <CityNm>MUNSTER</CityNm>
          <CountryCd>GM</CountryCd>
        </ForeignAddress>
        <GrantDt>2023-06-22</GrantDt>
        <GrantAmt>1556119</GrantAmt>
        <PurposeOfGrantTxt>THE EXTENT STUDY TO IMPROVE THE CARE OF CROHN'S DISEASE.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>338377</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>5/2024, 8/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PERCUSENSE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>25134 RYE CANYON LOOP</AddressLine1Txt>
          <CityNm>VALENCIA</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>91355</ZIPCd>
        </USAddress>
        <GrantDt>2020-09-02</GrantDt>
        <GrantAmt>2500000</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF CONTINUOUS GLUCOSE AND KETONE METER TO IMPROVE CARE OF T1D</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1850000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR + 4/2023, 5/2023, 7/2023, 8/2023, 10/2023, 6/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>STARTUP HEALTH T1D PRI LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2000 BROADWAY 18TH FLOOR</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10023</ZIPCd>
        </USAddress>
        <GrantDt>2023-01-30</GrantDt>
        <GrantAmt>5000000</GrantAmt>
        <PurposeOfGrantTxt>CATALYZING SEED AND EARLY-STAGE COMPANIES DEVELOPING INNOVATIVE T1D CARE SOLUTIONS</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>2573260</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>3/2023, 11/2023, 6/2024, 9/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>CUMBRAE STEWART BUILDING 72 THE</AddressLine1Txt>
          <AddressLine2Txt>UNIVERSITY OF QUEENSLAND</AddressLine2Txt>
          <CityNm>BRISBANE</CityNm>
          <ProvinceOrStateNm>QUEENSLAND</ProvinceOrStateNm>
          <CountryCd>AS</CountryCd>
        </ForeignAddress>
        <GrantDt>2021-09-08</GrantDt>
        <GrantAmt>2493864</GrantAmt>
        <PurposeOfGrantTxt>LIPOSOMAL ANTIGEN-SPECIFIC IMMUNOTHERAPY OF RECENT-ONSET TYPE 1 DIABETES</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>865466</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>1/2023, 3/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THE UNIVERSITY OF QUEENSLAND</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>CUMBRAE STEWART BUILDING 72 THE</AddressLine1Txt>
          <AddressLine2Txt>UNIVERSITY OF QUEENSLAND</AddressLine2Txt>
          <CityNm>BRISBANE</CityNm>
          <ProvinceOrStateNm>QUEENSLAND</ProvinceOrStateNm>
          <CountryCd>AS</CountryCd>
        </ForeignAddress>
        <GrantDt>2023-05-22</GrantDt>
        <GrantAmt>226017</GrantAmt>
        <PurposeOfGrantTxt>GUT MICROBIAL METABOLITES DURING EARLY-LIFE DEVELOPMENT AS PREDICTORS OF ISLET AUTOIMMUNITY</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>45564</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>3/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THETIS PHARMACEUTICALS LLC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>54 DANBURY ROAD SUITE 285</AddressLine1Txt>
          <CityNm>RIDGEFIELD</CityNm>
          <StateAbbreviationCd>NJ</StateAbbreviationCd>
          <ZIPCd>06877</ZIPCd>
        </USAddress>
        <GrantDt>2022-02-24</GrantDt>
        <GrantAmt>5069660</GrantAmt>
        <PurposeOfGrantTxt>DEVELOPMENT OF A NOVEL RESOLVIN E1 THERAPY FOR TREATMENT OF CROHNS DISEASE</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>3934500</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRIOR+5/2023,9/2023, 12/2023, 2/2024, 4/2024, 6/2024, 7/2024</DatesOfReportsByGranteeTxt>
      </ExpenditureResponsibilityGrp>
    </ExpenditureResponsibilityStmt>
    <GeneralExplanationAttachment documentId="RetDoc2258700001">
      <GeneralExplanationGrp>
        <IdentifierTxt>CONTROLLED ENTITIES</IdentifierTxt>
        <FormAndLineReferenceDesc>FORM 990-PF, PART VI-A, LINE 11:</FormAndLineReferenceDesc>
        <MediumExplanationTxt>THE FOLLOWING CONTROLLED ENTITIES ARE NOT EXCESS BUSINESS HOLDINGS:CHATHAM CO-INVEST26 MAIN STREET, SUITE 204CHATHAM, NJ 07928EIN# 85-0651355ESTATE OF LEONA M. HELMSLEY230 PARK AVENUE, SUITE 659NEW YORK, NY 10169EIN# 20-7535047HELMSLEY ENTERPRISES, INC.230 PARK AVENUE, SUITE 659NEW YORK, NY 10169EIN# 13-2665914LACM WORLD SMALL CAP EQUITY FUND, L.P.11150 SANTA MONICA BLVD., STE. 200LOS ANGELES, CA 90025EIN# 83-2888004MARATHON-LONDON GLOBAL SELECTORION HOUSE, 5 UPPER ST. MARTIN'S LANELONDON, UK WC2H 9EAEIN# 61-1915057MHR LONGEVITY PARTNERS1345 AVENUE OF THE AMERICAS 42ND FLOORNEW YORK, NY 10105EIN# 98-1471155NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER, L.P.2929 ARCH STREET 17TH FLOORPHILADELPHIA, PA 19104EIN# 98-1142649PITANGO SPVBEIT ACKERSHTEIN - BLDG. B, 11 HAMENOFIM ST. 11TH FL.HERZLIYA, ISRAELEIN# 98-1492234STARTUP HEALTH T1D PRI LP2000 BROADWAY, 18TH FLOORNEW YORK, NY 10023EIN# 93-2618051</MediumExplanationTxt>
      </GeneralExplanationGrp>
      <GeneralExplanationGrp>
        <FormAndLineReferenceDesc>FORM 990-PF, PART VII, LINE 1 AND 2, COLUMN (C), COMPENSATION:</FormAndLineReferenceDesc>
        <MediumExplanationTxt>ALL REPORTED COMPENSATION AMOUNTS INCLUDE "SALARY, FEES, BONUSES AND SEVERANCE PAYMENTS RECEIVED BY EACH PERSON LISTED," AS WELL AS CURRENT YEAR PAYMENTS OF AMOUNTS REPORTED OR REPORTABLE AS DEFERRED COMPENSATION IN CURRENT OR PRIOR YEARS.</MediumExplanationTxt>
      </GeneralExplanationGrp>
    </GeneralExplanationAttachment>
    <InvestmentsCorpStockSchedule documentId="RetDoc2018900001">
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 45,079 SHRS</StockNm>
        <EOYBookValueAmt>6863729</EOYBookValueAmt>
        <EOYFMVAmt>6863729</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AMAZON.COM INC, 62,440 SHRS</StockNm>
        <EOYBookValueAmt>11262927</EOYBookValueAmt>
        <EOYFMVAmt>11262927</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ANSYS INC, 16,010 SHRS</StockNm>
        <EOYBookValueAmt>5558032</EOYBookValueAmt>
        <EOYFMVAmt>5558032</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ATLASSIAN CORP, 7,353 SHRS</StockNm>
        <EOYBookValueAmt>1434644</EOYBookValueAmt>
        <EOYFMVAmt>1434644</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BIO-TECHNE CORP, 70,579 SHRS</StockNm>
        <EOYBookValueAmt>4968056</EOYBookValueAmt>
        <EOYFMVAmt>4968056</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CBRE GROUP INC, 65,438 SHRS</StockNm>
        <EOYBookValueAmt>6363191</EOYBookValueAmt>
        <EOYFMVAmt>6363191</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARMAX INC, 22,974 SHRS</StockNm>
        <EOYBookValueAmt>2001265</EOYBookValueAmt>
        <EOYFMVAmt>2001265</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>COSTAR GROUP INC, 37,037 SHRS</StockNm>
        <EOYBookValueAmt>3577774</EOYBookValueAmt>
        <EOYFMVAmt>3577774</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CROWDSTRIKE HOLDINGS INC, 4,441 SHRS</StockNm>
        <EOYBookValueAmt>1423740</EOYBookValueAmt>
        <EOYFMVAmt>1423740</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DANAHER CORP, 25,903 SHRS</StockNm>
        <EOYBookValueAmt>6468497</EOYBookValueAmt>
        <EOYFMVAmt>6468497</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ECOLAB INC, 20,961 SHRS</StockNm>
        <EOYBookValueAmt>4839895</EOYBookValueAmt>
        <EOYFMVAmt>4839895</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FASTENAL CO, 32,549 SHRS</StockNm>
        <EOYBookValueAmt>2510830</EOYBookValueAmt>
        <EOYFMVAmt>2510830</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GUIDEWIRE SOFTWARE INC, 45,210 SHRS</StockNm>
        <EOYBookValueAmt>5276459</EOYBookValueAmt>
        <EOYFMVAmt>5276459</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>HEICO CORP, 40,957 SHRS</StockNm>
        <EOYBookValueAmt>6304921</EOYBookValueAmt>
        <EOYFMVAmt>6304921</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INTUIT INC, 5,110 SHRS</StockNm>
        <EOYBookValueAmt>3321500</EOYBookValueAmt>
        <EOYFMVAmt>3321500</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INTUITIVE SURGICAL INC, 12,879 SHRS</StockNm>
        <EOYBookValueAmt>5139880</EOYBookValueAmt>
        <EOYFMVAmt>5139880</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KINSALE CAPITAL GROUP INC, 6,921 SHRS</StockNm>
        <EOYBookValueAmt>3631726</EOYBookValueAmt>
        <EOYFMVAmt>3631726</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MARKEL GROUP INC, 2,553 SHRS</StockNm>
        <EOYBookValueAmt>3884338</EOYBookValueAmt>
        <EOYFMVAmt>3884338</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MASTERCARD INC, 17,212 SHRS</StockNm>
        <EOYBookValueAmt>8288783</EOYBookValueAmt>
        <EOYFMVAmt>8288783</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MICROSOFT CORP, 16,736 SHRS</StockNm>
        <EOYBookValueAmt>7041170</EOYBookValueAmt>
        <EOYFMVAmt>7041170</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MONOLITHIC POWER SYSTEMS INC, 5,448 SHRS</StockNm>
        <EOYBookValueAmt>3690584</EOYBookValueAmt>
        <EOYFMVAmt>3690584</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MOODY'S CORP, 11,080 SHRS</StockNm>
        <EOYBookValueAmt>4354772</EOYBookValueAmt>
        <EOYFMVAmt>4354772</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>OLD DOMINION FREIGHT LINE INC, 24,254 SHRS</StockNm>
        <EOYBookValueAmt>5319145</EOYBookValueAmt>
        <EOYFMVAmt>5319145</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>S&amp;P GLOBAL INC, 16,804 SHRS</StockNm>
        <EOYBookValueAmt>7149262</EOYBookValueAmt>
        <EOYFMVAmt>7149262</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SHERWIN-WILLIAMS CO/THE, 11,066 SHRS</StockNm>
        <EOYBookValueAmt>3843554</EOYBookValueAmt>
        <EOYFMVAmt>3843554</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SITEONE LANDSCAPE SUPPLY INC, 21,900 SHRS</StockNm>
        <EOYBookValueAmt>3822645</EOYBookValueAmt>
        <EOYFMVAmt>3822645</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SPROUT SOCIAL INC, 41,508 SHRS</StockNm>
        <EOYBookValueAmt>2478443</EOYBookValueAmt>
        <EOYFMVAmt>2478443</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>THERMO FISHER SCIENTIFIC INC, 9,077 SHRS</StockNm>
        <EOYBookValueAmt>5275643</EOYBookValueAmt>
        <EOYFMVAmt>5275643</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TRANSDIGM GROUP INC, 7,112 SHRS</StockNm>
        <EOYBookValueAmt>8759139</EOYBookValueAmt>
        <EOYFMVAmt>8759139</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VEEVA SYSTEMS INC, 24,036 SHRS</StockNm>
        <EOYBookValueAmt>5568901</EOYBookValueAmt>
        <EOYFMVAmt>5568901</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VERALTO CORP, 59,355 SHRS</StockNm>
        <EOYBookValueAmt>5262414</EOYBookValueAmt>
        <EOYFMVAmt>5262414</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VISA INC, 29,616 SHRS</StockNm>
        <EOYBookValueAmt>8265233</EOYBookValueAmt>
        <EOYFMVAmt>8265233</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>VULCAN MATERIALS CO, 25,753 SHRS</StockNm>
        <EOYBookValueAmt>7028509</EOYBookValueAmt>
        <EOYFMVAmt>7028509</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WASTE CONNECTIONS INC, 28,597 SHRS</StockNm>
        <EOYBookValueAmt>4918970</EOYBookValueAmt>
        <EOYFMVAmt>4918970</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WEST PHARMACEUTICAL SERVICES I, 10,068 SHRS</StockNm>
        <EOYBookValueAmt>3984008</EOYBookValueAmt>
        <EOYFMVAmt>3984008</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WILLSCOT MOBILE MINI HOLDINGS, 63,928 SHRS</StockNm>
        <EOYBookValueAmt>2972652</EOYBookValueAmt>
        <EOYFMVAmt>2972652</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>WORKIVA INC, 21,421 SHRS</StockNm>
        <EOYBookValueAmt>1816501</EOYBookValueAmt>
        <EOYFMVAmt>1816501</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZOETIS INC, 14,278 SHRS</StockNm>
        <EOYBookValueAmt>2415980</EOYBookValueAmt>
        <EOYFMVAmt>2415980</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ASML HOLDING NV, 2,389 SHRS</StockNm>
        <EOYBookValueAmt>2318453</EOYBookValueAmt>
        <EOYFMVAmt>2318453</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ARCH CAPITAL GROUP LTD, 31,860 SHRS</StockNm>
        <EOYBookValueAmt>2945138</EOYBookValueAmt>
        <EOYFMVAmt>2945138</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SCHLUMBERGER LTD, 38,086 SHRS</StockNm>
        <EOYBookValueAmt>2087494</EOYBookValueAmt>
        <EOYFMVAmt>2087494</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FRESENIUS MEDICAL CARE AG, 105,911 SHRS</StockNm>
        <EOYBookValueAmt>2041964</EOYBookValueAmt>
        <EOYFMVAmt>2041964</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EATON CORP PLC, 7,035 SHRS</StockNm>
        <EOYBookValueAmt>2199704</EOYBookValueAmt>
        <EOYFMVAmt>2199704</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SONY GROUP CORP, 56,877 SHRS</StockNm>
        <EOYBookValueAmt>4876634</EOYBookValueAmt>
        <EOYFMVAmt>4876634</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FERGUSON PLC, 33,211 SHRS</StockNm>
        <EOYBookValueAmt>7254279</EOYBookValueAmt>
        <EOYFMVAmt>7254279</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>KONINKLIJKE PHILIPS NV, 130,914 SHRS</StockNm>
        <EOYBookValueAmt>2618280</EOYBookValueAmt>
        <EOYFMVAmt>2618280</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SMITH &amp; NEPHEW PLC, 89,859 SHRS</StockNm>
        <EOYBookValueAmt>2278824</EOYBookValueAmt>
        <EOYFMVAmt>2278824</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNILEVER PLC, 81,279 SHRS</StockNm>
        <EOYBookValueAmt>4079393</EOYBookValueAmt>
        <EOYFMVAmt>4079393</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ALPHABET INC, 43,685 SHRS</StockNm>
        <EOYBookValueAmt>6593377</EOYBookValueAmt>
        <EOYFMVAmt>6593377</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AVERY DENNISON CORP, 25,477 SHRS</StockNm>
        <EOYBookValueAmt>5687740</EOYBookValueAmt>
        <EOYFMVAmt>5687740</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BERKSHIRE HATHAWAY INC, 15,142 SHRS</StockNm>
        <EOYBookValueAmt>6367514</EOYBookValueAmt>
        <EOYFMVAmt>6367514</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BLACKROCK INC, 3,156 SHRS</StockNm>
        <EOYBookValueAmt>2631157</EOYBookValueAmt>
        <EOYFMVAmt>2631157</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BOOKING HOLDINGS INC, 1,484 SHRS</StockNm>
        <EOYBookValueAmt>5383774</EOYBookValueAmt>
        <EOYFMVAmt>5383774</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CDW CORP/DE, 12,394 SHRS</StockNm>
        <EOYBookValueAmt>3170137</EOYBookValueAmt>
        <EOYFMVAmt>3170137</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARLISLE COS INC, 13,377 SHRS</StockNm>
        <EOYBookValueAmt>5241777</EOYBookValueAmt>
        <EOYFMVAmt>5241777</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARMAX INC, 62,091 SHRS</StockNm>
        <EOYBookValueAmt>5408747</EOYBookValueAmt>
        <EOYFMVAmt>5408747</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CARRIER GLOBAL CORP, 71,175 SHRS</StockNm>
        <EOYBookValueAmt>4137403</EOYBookValueAmt>
        <EOYFMVAmt>4137403</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOLLAR GENERAL CORP, 25,941 SHRS</StockNm>
        <EOYBookValueAmt>4048352</EOYBookValueAmt>
        <EOYFMVAmt>4048352</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOLLAR TREE INC, 23,960 SHRS</StockNm>
        <EOYBookValueAmt>3190274</EOYBookValueAmt>
        <EOYFMVAmt>3190274</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MASCO CORP, 72,819 SHRS</StockNm>
        <EOYBookValueAmt>5743963</EOYBookValueAmt>
        <EOYFMVAmt>5743963</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MICRON TECHNOLOGY INC, 43,584 SHRS</StockNm>
        <EOYBookValueAmt>5138118</EOYBookValueAmt>
        <EOYFMVAmt>5138118</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NORTHERN TRUST CORP, 39,309 SHRS</StockNm>
        <EOYBookValueAmt>3495356</EOYBookValueAmt>
        <EOYFMVAmt>3495356</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>OMNICOM GROUP INC, 37,610 SHRS</StockNm>
        <EOYBookValueAmt>3639144</EOYBookValueAmt>
        <EOYFMVAmt>3639144</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PROGRESSIVE CORP/THE, 19,411 SHRS</StockNm>
        <EOYBookValueAmt>4014583</EOYBookValueAmt>
        <EOYFMVAmt>4014583</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>QUEST DIAGNOSTICS INC, 29,141 SHRS</StockNm>
        <EOYBookValueAmt>3878959</EOYBookValueAmt>
        <EOYFMVAmt>3878959</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CHARLES SCHWAB CORP/THE, 92,922 SHRS</StockNm>
        <EOYBookValueAmt>6721977</EOYBookValueAmt>
        <EOYFMVAmt>6721977</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SYSCO CORP, 48,254 SHRS</StockNm>
        <EOYBookValueAmt>3917260</EOYBookValueAmt>
        <EOYFMVAmt>3917260</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TJX COS INC/THE, 15,463 SHRS</StockNm>
        <EOYBookValueAmt>1568257</EOYBookValueAmt>
        <EOYFMVAmt>1568257</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNITEDHEALTH GROUP INC, 8,091 SHRS</StockNm>
        <EOYBookValueAmt>4002618</EOYBookValueAmt>
        <EOYFMVAmt>4002618</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RB GLOBAL INC, 197,129 SHRS</StockNm>
        <EOYBookValueAmt>15015316</EOYBookValueAmt>
        <EOYFMVAmt>15015316</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AON PLC, 34,711 SHRS</StockNm>
        <EOYBookValueAmt>11583755</EOYBookValueAmt>
        <EOYFMVAmt>11583755</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NINTENDO CO LTD, 165,000 SHRS</StockNm>
        <EOYBookValueAmt>8935478</EOYBookValueAmt>
        <EOYFMVAmt>8935478</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NOVARTIS AG, 92,230 SHRS</StockNm>
        <EOYBookValueAmt>8946525</EOYBookValueAmt>
        <EOYFMVAmt>8946525</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NESTLE SA, 52,246 SHRS</StockNm>
        <EOYBookValueAmt>5554074</EOYBookValueAmt>
        <EOYFMVAmt>5554074</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CIE FINANCIERE RICHEMONT SA, 46,562 SHRS</StockNm>
        <EOYBookValueAmt>7108110</EOYBookValueAmt>
        <EOYFMVAmt>7108110</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UNILEVER PLC, 149,110 SHRS</StockNm>
        <EOYBookValueAmt>7491525</EOYBookValueAmt>
        <EOYFMVAmt>7491525</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>RECKITT BENCKISER GROUP PLC, 185,024 SHRS</StockNm>
        <EOYBookValueAmt>10545968</EOYBookValueAmt>
        <EOYFMVAmt>10545968</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INFORMA PLC, 903,750 SHRS</StockNm>
        <EOYBookValueAmt>9489496</EOYBookValueAmt>
        <EOYFMVAmt>9489496</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GSK PLC, 446,812 SHRS</StockNm>
        <EOYBookValueAmt>9643941</EOYBookValueAmt>
        <EOYFMVAmt>9643941</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BOOKING HOLDINGS INC, 2,779 SHRS</StockNm>
        <EOYBookValueAmt>10081879</EOYBookValueAmt>
        <EOYFMVAmt>10081879</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BRISTOL-MYERS SQUIBB CO, 208,007 SHRS</StockNm>
        <EOYBookValueAmt>11280220</EOYBookValueAmt>
        <EOYFMVAmt>11280220</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CORTEVA INC, 213,075 SHRS</StockNm>
        <EOYBookValueAmt>12288035</EOYBookValueAmt>
        <EOYFMVAmt>12288035</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>EBAY INC, 151,642 SHRS</StockNm>
        <EOYBookValueAmt>8003665</EOYBookValueAmt>
        <EOYFMVAmt>8003665</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ELECTRONIC ARTS INC, 64,871 SHRS</StockNm>
        <EOYBookValueAmt>8606436</EOYBookValueAmt>
        <EOYFMVAmt>8606436</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FOX CORP, 243,057 SHRS</StockNm>
        <EOYBookValueAmt>7600392</EOYBookValueAmt>
        <EOYFMVAmt>7600392</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FOX CORP, 92,047 SHRS</StockNm>
        <EOYBookValueAmt>2634385</EOYBookValueAmt>
        <EOYFMVAmt>2634385</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>INTERCONTINENTAL EXCHANGE INC, 87,691 SHRS</StockNm>
        <EOYBookValueAmt>12051374</EOYBookValueAmt>
        <EOYFMVAmt>12051374</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>JOHNSON &amp; JOHNSON, 60,279 SHRS</StockNm>
        <EOYBookValueAmt>9535535</EOYBookValueAmt>
        <EOYFMVAmt>9535535</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ESTEE LAUDER COS INC/THE, 35,524 SHRS</StockNm>
        <EOYBookValueAmt>5476025</EOYBookValueAmt>
        <EOYFMVAmt>5476025</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NEWS CORP, 422,306 SHRS</StockNm>
        <EOYBookValueAmt>11055971</EOYBookValueAmt>
        <EOYFMVAmt>11055971</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NEWS CORP, 151,503 SHRS</StockNm>
        <EOYBookValueAmt>4099671</EOYBookValueAmt>
        <EOYFMVAmt>4099671</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ORACLE CORP, 81,611 SHRS</StockNm>
        <EOYBookValueAmt>10251158</EOYBookValueAmt>
        <EOYFMVAmt>10251158</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>REVVITY INC, 27,855 SHRS</StockNm>
        <EOYBookValueAmt>2924775</EOYBookValueAmt>
        <EOYFMVAmt>2924775</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TKO GROUP HOLDINGS INC, 39,152 SHRS</StockNm>
        <EOYBookValueAmt>3383124</EOYBookValueAmt>
        <EOYFMVAmt>3383124</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TRANSUNION, 114,304 SHRS</StockNm>
        <EOYBookValueAmt>9121459</EOYBookValueAmt>
        <EOYFMVAmt>9121459</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZILLOW GROUP INC, 32,498 SHRS</StockNm>
        <EOYBookValueAmt>1555354</EOYBookValueAmt>
        <EOYFMVAmt>1555354</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ZILLOW GROUP INC, 180,747 SHRS</StockNm>
        <EOYBookValueAmt>8816839</EOYBookValueAmt>
        <EOYFMVAmt>8816839</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>PDD HOLDINGS INC, 216,396 SHRS</StockNm>
        <EOYBookValueAmt>25156035</EOYBookValueAmt>
        <EOYFMVAmt>25156035</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>STRUCTURE THERAPEUTICS INC, 1,336 SHRS</StockNm>
        <EOYBookValueAmt>57261</EOYBookValueAmt>
        <EOYFMVAmt>57261</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>NU HOLDINGS LTD/CAYMAN ISLANDS, 708,356 SHRS</StockNm>
        <EOYBookValueAmt>8450687</EOYBookValueAmt>
        <EOYFMVAmt>8450687</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CHINA RENAISSANCE HOLDINGS LTD, 127,556 SHRS</StockNm>
        <EOYBookValueAmt>118487</EOYBookValueAmt>
        <EOYFMVAmt>118487</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>YUBICO AB, 73,585 SHRS</StockNm>
        <EOYBookValueAmt>1311683</EOYBookValueAmt>
        <EOYFMVAmt>1311683</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AFFIRM HOLDINGS INC, 21,250 SHRS</StockNm>
        <EOYBookValueAmt>791775</EOYBookValueAmt>
        <EOYFMVAmt>791775</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>AIRBNB INC, 89,793 SHRS</StockNm>
        <EOYBookValueAmt>14812253</EOYBookValueAmt>
        <EOYFMVAmt>14812253</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>BILL HOLDINGS INC, 6,110 SHRS</StockNm>
        <EOYBookValueAmt>419879</EOYBookValueAmt>
        <EOYFMVAmt>419879</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>COINBASE GLOBAL INC, 62,036 SHRS</StockNm>
        <EOYBookValueAmt>16446984</EOYBookValueAmt>
        <EOYFMVAmt>16446984</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CONFLUENT INC, 27,537 SHRS</StockNm>
        <EOYBookValueAmt>840429</EOYBookValueAmt>
        <EOYFMVAmt>840429</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>CROWDSTRIKE HOLDINGS INC, 14,711 SHRS</StockNm>
        <EOYBookValueAmt>4716199</EOYBookValueAmt>
        <EOYFMVAmt>4716199</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>DOORDASH INC, 22,663 SHRS</StockNm>
        <EOYBookValueAmt>3121148</EOYBookValueAmt>
        <EOYFMVAmt>3121148</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>META PLATFORMS INC, 9,000 SHRS</StockNm>
        <EOYBookValueAmt>4370220</EOYBookValueAmt>
        <EOYFMVAmt>4370220</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FRESHWORKS INC, 2,700 SHRS</StockNm>
        <EOYBookValueAmt>49167</EOYBookValueAmt>
        <EOYFMVAmt>49167</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>GUARDANT HEALTH INC, 4,000 SHRS</StockNm>
        <EOYBookValueAmt>82520</EOYBookValueAmt>
        <EOYFMVAmt>82520</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>MAPLEBEAR INC, 13,360 SHRS</StockNm>
        <EOYBookValueAmt>498194</EOYBookValueAmt>
        <EOYFMVAmt>498194</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>ROBLOX CORP, 72,000 SHRS</StockNm>
        <EOYBookValueAmt>2748960</EOYBookValueAmt>
        <EOYFMVAmt>2748960</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>SNOWFLAKE INC, 57,211 SHRS</StockNm>
        <EOYBookValueAmt>9245298</EOYBookValueAmt>
        <EOYFMVAmt>9245298</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>TOAST INC, 7,000 SHRS</StockNm>
        <EOYBookValueAmt>174440</EOYBookValueAmt>
        <EOYFMVAmt>174440</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UBER TECHNOLOGIES INC, 5,921 SHRS</StockNm>
        <EOYBookValueAmt>455858</EOYBookValueAmt>
        <EOYFMVAmt>455858</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>UIPATH INC, 128,002 SHRS</StockNm>
        <EOYBookValueAmt>2901805</EOYBookValueAmt>
        <EOYFMVAmt>2901805</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
    </InvestmentsCorpStockSchedule>
    <InvestmentsOtherSchedule2 documentId="RetDoc2018100001">
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM US LARGE CAP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>177279037</BookValueAmt>
        <EOYFMVAmt>177279037</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SPDR TRUST SERIES I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>115257951</BookValueAmt>
        <EOYFMVAmt>115257951</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM CORE BOND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1228783297</BookValueAmt>
        <EOYFMVAmt>1228783297</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM SHORT DURATION BOND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>311100609</BookValueAmt>
        <EOYFMVAmt>311100609</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CHATHAM</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>119844821</BookValueAmt>
        <EOYFMVAmt>119844821</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CHATHAM OFFSHORE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>118008474</BookValueAmt>
        <EOYFMVAmt>118008474</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CAMBER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>136629017</BookValueAmt>
        <EOYFMVAmt>136629017</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED GENESIS FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>49036762</BookValueAmt>
        <EOYFMVAmt>49036762</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA CAP GLOBAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>189217984</BookValueAmt>
        <EOYFMVAmt>189217984</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACADIAN FRONTIER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>176593</BookValueAmt>
        <EOYFMVAmt>176593</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIGHCLERE INTL SC</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>134358764</BookValueAmt>
        <EOYFMVAmt>134358764</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIGHCLERE INTL SMID</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>66330787</BookValueAmt>
        <EOYFMVAmt>66330787</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>LA CAPITAL GLOBAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>95462096</BookValueAmt>
        <EOYFMVAmt>95462096</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>LACM WORLD SMALL CAP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>97962582</BookValueAmt>
        <EOYFMVAmt>97962582</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>MARATHON GLOBAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>181832660</BookValueAmt>
        <EOYFMVAmt>181832660</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SILCHESTER INTL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>151839703</BookValueAmt>
        <EOYFMVAmt>151839703</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>BLACKROCK US DEBT</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>141112373</BookValueAmt>
        <EOYFMVAmt>141112373</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>BAYVIEW</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>856754</BookValueAmt>
        <EOYFMVAmt>856754</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EIG ENERGY FUND XVI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>36496509</BookValueAmt>
        <EOYFMVAmt>36496509</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EIG ENERGY XV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3317372</BookValueAmt>
        <EOYFMVAmt>3317372</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FDAF DISLOCATED II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>25362236</BookValueAmt>
        <EOYFMVAmt>25362236</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FDAF DISLOCATED III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>35430388</BookValueAmt>
        <EOYFMVAmt>35430388</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FDAF DISLOCATED IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30533776</BookValueAmt>
        <EOYFMVAmt>30533776</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GSO CAPITAL SOLS II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2361684</BookValueAmt>
        <EOYFMVAmt>2361684</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BAYSIDE III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3377026</BookValueAmt>
        <EOYFMVAmt>3377026</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>MHR AXIOM</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>243605491</BookValueAmt>
        <EOYFMVAmt>243605491</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>MHR INST PARTNERS IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>63010246</BookValueAmt>
        <EOYFMVAmt>63010246</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>NEWMARKET IIFC</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19137487</BookValueAmt>
        <EOYFMVAmt>19137487</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ROYALTY II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1544922</BookValueAmt>
        <EOYFMVAmt>1544922</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH FUND IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17738020</BookValueAmt>
        <EOYFMVAmt>17738020</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13189479</BookValueAmt>
        <EOYFMVAmt>13189479</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11522052</BookValueAmt>
        <EOYFMVAmt>11522052</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28308899</BookValueAmt>
        <EOYFMVAmt>28308899</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL GROWTH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13248632</BookValueAmt>
        <EOYFMVAmt>13248632</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12618661</BookValueAmt>
        <EOYFMVAmt>12618661</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7927095</BookValueAmt>
        <EOYFMVAmt>7927095</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL INDIA VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2587355</BookValueAmt>
        <EOYFMVAmt>2587355</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS 4</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7723401</BookValueAmt>
        <EOYFMVAmt>7723401</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13610357</BookValueAmt>
        <EOYFMVAmt>13610357</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7980029</BookValueAmt>
        <EOYFMVAmt>7980029</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL LEADERS III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>25691472</BookValueAmt>
        <EOYFMVAmt>25691472</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5501339</BookValueAmt>
        <EOYFMVAmt>5501339</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>24441487</BookValueAmt>
        <EOYFMVAmt>24441487</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12686251</BookValueAmt>
        <EOYFMVAmt>12686251</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XIV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8403040</BookValueAmt>
        <EOYFMVAmt>8403040</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ACCEL XV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4891255</BookValueAmt>
        <EOYFMVAmt>4891255</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO FUND I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6215300</BookValueAmt>
        <EOYFMVAmt>6215300</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO FUND II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16332915</BookValueAmt>
        <EOYFMVAmt>16332915</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17539078</BookValueAmt>
        <EOYFMVAmt>17539078</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH BIO IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5164862</BookValueAmt>
        <EOYFMVAmt>5164862</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH CNK IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9973313</BookValueAmt>
        <EOYFMVAmt>9973313</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH CNK SEED I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1812964</BookValueAmt>
        <EOYFMVAmt>1812964</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH FUND VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10637499</BookValueAmt>
        <EOYFMVAmt>10637499</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH FUND VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4792855</BookValueAmt>
        <EOYFMVAmt>4792855</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>37063336</BookValueAmt>
        <EOYFMVAmt>37063336</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH III PARALLEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8022513</BookValueAmt>
        <EOYFMVAmt>8022513</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>42823557</BookValueAmt>
        <EOYFMVAmt>42823557</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH IV PARALLEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16791658</BookValueAmt>
        <EOYFMVAmt>16791658</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH LSV FUND II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17482444</BookValueAmt>
        <EOYFMVAmt>17482444</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH LSV FUND III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11279330</BookValueAmt>
        <EOYFMVAmt>11279330</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH LSV I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>18669497</BookValueAmt>
        <EOYFMVAmt>18669497</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>41678594</BookValueAmt>
        <EOYFMVAmt>41678594</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH V PARALLEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>27081839</BookValueAmt>
        <EOYFMVAmt>27081839</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>AH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>25593295</BookValueAmt>
        <EOYFMVAmt>25593295</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ANGELENO INV III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17678812</BookValueAmt>
        <EOYFMVAmt>17678812</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2731511</BookValueAmt>
        <EOYFMVAmt>2731511</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9848177</BookValueAmt>
        <EOYFMVAmt>9848177</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16692098</BookValueAmt>
        <EOYFMVAmt>16692098</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ARBORETUM VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3110754</BookValueAmt>
        <EOYFMVAmt>3110754</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>COLLER VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3508788</BookValueAmt>
        <EOYFMVAmt>3508788</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>COLLER VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>25558568</BookValueAmt>
        <EOYFMVAmt>25558568</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>COLLER VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30577456</BookValueAmt>
        <EOYFMVAmt>30577456</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CONGRUENT CONTINUITY</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5628815</BookValueAmt>
        <EOYFMVAmt>5628815</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CRESTVIEW ELO</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7079890</BookValueAmt>
        <EOYFMVAmt>7079890</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CRESTVIEW III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>38332056</BookValueAmt>
        <EOYFMVAmt>38332056</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>CRESTVIEW IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28522754</BookValueAmt>
        <EOYFMVAmt>28522754</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EIG ENERGY XVII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11459284</BookValueAmt>
        <EOYFMVAmt>11459284</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>49402869</BookValueAmt>
        <EOYFMVAmt>49402869</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22667037</BookValueAmt>
        <EOYFMVAmt>22667037</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE OPP I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6474026</BookValueAmt>
        <EOYFMVAmt>6474026</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22820659</BookValueAmt>
        <EOYFMVAmt>22820659</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EMERGENCE VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9697673</BookValueAmt>
        <EOYFMVAmt>9697673</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EPIRIS ELEC CO INV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12983712</BookValueAmt>
        <EOYFMVAmt>12983712</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EPIRIS II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>24549597</BookValueAmt>
        <EOYFMVAmt>24549597</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>EPIRIS III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9507394</BookValueAmt>
        <EOYFMVAmt>9507394</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FORTISSIMO IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22466775</BookValueAmt>
        <EOYFMVAmt>22466775</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FORTISSIMO V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>24897842</BookValueAmt>
        <EOYFMVAmt>24897842</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FORTISSIMO VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2052354</BookValueAmt>
        <EOYFMVAmt>2052354</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER GTH BUYOUT X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14157034</BookValueAmt>
        <EOYFMVAmt>14157034</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8527401</BookValueAmt>
        <EOYFMVAmt>8527401</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER OVERAGE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17432536</BookValueAmt>
        <EOYFMVAmt>17432536</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER PUBLIC FUND</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>23859182</BookValueAmt>
        <EOYFMVAmt>23859182</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER SUNMD CO INV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19746931</BookValueAmt>
        <EOYFMVAmt>19746931</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14892171</BookValueAmt>
        <EOYFMVAmt>14892171</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>FRAZIER XI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7591048</BookValueAmt>
        <EOYFMVAmt>7591048</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GAVEA IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1493387</BookValueAmt>
        <EOYFMVAmt>1493387</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GAVEA V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3630248</BookValueAmt>
        <EOYFMVAmt>3630248</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GAVEA V PLUS</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>423181</BookValueAmt>
        <EOYFMVAmt>423181</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GENERL ATLANTIC 2013</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>61406512</BookValueAmt>
        <EOYFMVAmt>61406512</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>GENERL ATLANTIC 2018</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>80379997</BookValueAmt>
        <EOYFMVAmt>80379997</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BIOVENTURE II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12556914</BookValueAmt>
        <EOYFMVAmt>12556914</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BRAZIL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4342221</BookValueAmt>
        <EOYFMVAmt>4342221</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BRAZIL LATAM B</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>18846817</BookValueAmt>
        <EOYFMVAmt>18846817</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG BRAZIL LATAM C</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>18846817</BookValueAmt>
        <EOYFMVAmt>18846817</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG CAPITAL V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9219459</BookValueAmt>
        <EOYFMVAmt>9219459</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG GROWTH B&amp;E F II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16876670</BookValueAmt>
        <EOYFMVAmt>16876670</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG GROWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5450751</BookValueAmt>
        <EOYFMVAmt>5450751</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG MID MARKET II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13318133</BookValueAmt>
        <EOYFMVAmt>13318133</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HIG MID MARKET III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>18405040</BookValueAmt>
        <EOYFMVAmt>18405040</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>86634726</BookValueAmt>
        <EOYFMVAmt>86634726</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>26626078</BookValueAmt>
        <EOYFMVAmt>26626078</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>30316741</BookValueAmt>
        <EOYFMVAmt>30316741</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19761283</BookValueAmt>
        <EOYFMVAmt>19761283</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN GROWTH VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1825297</BookValueAmt>
        <EOYFMVAmt>1825297</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10645322</BookValueAmt>
        <EOYFMVAmt>10645322</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>695717</BookValueAmt>
        <EOYFMVAmt>695717</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8875329</BookValueAmt>
        <EOYFMVAmt>8875329</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>8235075</BookValueAmt>
        <EOYFMVAmt>8235075</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5713480</BookValueAmt>
        <EOYFMVAmt>5713480</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>HONGSHAN VTR VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4486252</BookValueAmt>
        <EOYFMVAmt>4486252</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG BREYER</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6442626</BookValueAmt>
        <EOYFMVAmt>6442626</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG CHINA CAP III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28060681</BookValueAmt>
        <EOYFMVAmt>28060681</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG CHINA VTR IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>24022389</BookValueAmt>
        <EOYFMVAmt>24022389</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG CHINA VTR V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>37326845</BookValueAmt>
        <EOYFMVAmt>37326845</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG-ACCEL CHINA CAP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>13923874</BookValueAmt>
        <EOYFMVAmt>13923874</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IDG-ACCEL CHINA GWTH</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12018748</BookValueAmt>
        <EOYFMVAmt>12018748</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>IRON POINT IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>17995936</BookValueAmt>
        <EOYFMVAmt>17995936</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>JPM PEG SECONDRY III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5480557</BookValueAmt>
        <EOYFMVAmt>5480557</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ASIA III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>51045883</BookValueAmt>
        <EOYFMVAmt>51045883</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ASIA IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>20890121</BookValueAmt>
        <EOYFMVAmt>20890121</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ISRAEL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3103591</BookValueAmt>
        <EOYFMVAmt>3103591</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED ISRAEL II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22413588</BookValueAmt>
        <EOYFMVAmt>22413588</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6998250</BookValueAmt>
        <EOYFMVAmt>6998250</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11171826</BookValueAmt>
        <EOYFMVAmt>11171826</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22808946</BookValueAmt>
        <EOYFMVAmt>22808946</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBIMED PI VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>21470500</BookValueAmt>
        <EOYFMVAmt>21470500</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ORBMIED ASIA V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4180666</BookValueAmt>
        <EOYFMVAmt>4180666</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV GWTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>10938427</BookValueAmt>
        <EOYFMVAmt>10938427</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV GWTH IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>955224</BookValueAmt>
        <EOYFMVAmt>955224</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV SEA I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1381998</BookValueAmt>
        <EOYFMVAmt>1381998</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12918796</BookValueAmt>
        <EOYFMVAmt>12918796</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12207222</BookValueAmt>
        <EOYFMVAmt>12207222</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>758109</BookValueAmt>
        <EOYFMVAmt>758109</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEAK XV VTR VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3097553</BookValueAmt>
        <EOYFMVAmt>3097553</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP IV CORE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19860</BookValueAmt>
        <EOYFMVAmt>19860</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP IV SUPPL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4324</BookValueAmt>
        <EOYFMVAmt>4324</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PEP VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>19858804</BookValueAmt>
        <EOYFMVAmt>19858804</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PIATNGO VTR IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>447234</BookValueAmt>
        <EOYFMVAmt>447234</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO GROWTH</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>58225338</BookValueAmt>
        <EOYFMVAmt>58225338</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO GROWTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>21071726</BookValueAmt>
        <EOYFMVAmt>21071726</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO HEALTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2472759</BookValueAmt>
        <EOYFMVAmt>2472759</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO HEALTHTECH I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12704126</BookValueAmt>
        <EOYFMVAmt>12704126</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO SPV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>22027563</BookValueAmt>
        <EOYFMVAmt>22027563</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO VI, LP</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28484864</BookValueAmt>
        <EOYFMVAmt>28484864</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO VTR VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>29265006</BookValueAmt>
        <EOYFMVAmt>29265006</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>PITANGO VTR VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>15198039</BookValueAmt>
        <EOYFMVAmt>15198039</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>RIDGEWOOD III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>39922324</BookValueAmt>
        <EOYFMVAmt>39922324</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>RIDGEWOOD IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>28352131</BookValueAmt>
        <EOYFMVAmt>28352131</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>S CAPITAL</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>23742984</BookValueAmt>
        <EOYFMVAmt>23742984</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>S CAPITAL II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12692175</BookValueAmt>
        <EOYFMVAmt>12692175</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>S CAPITAL III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2427909</BookValueAmt>
        <EOYFMVAmt>2427909</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SCF LIQUID PORTFOLIO</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>55363184</BookValueAmt>
        <EOYFMVAmt>55363184</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GBL GRTH III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>96303980</BookValueAmt>
        <EOYFMVAmt>96303980</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GG 3 CH ANX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14267485</BookValueAmt>
        <EOYFMVAmt>14267485</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GLB GROWTH</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>26574063</BookValueAmt>
        <EOYFMVAmt>26574063</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA GLB GRWTH II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>39413558</BookValueAmt>
        <EOYFMVAmt>39413558</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA ISRAEL V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7408714</BookValueAmt>
        <EOYFMVAmt>7408714</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA SCOUT III</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2374137</BookValueAmt>
        <EOYFMVAmt>2374137</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA SCOUT IV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1103113</BookValueAmt>
        <EOYFMVAmt>1103113</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US ECO I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>502600</BookValueAmt>
        <EOYFMVAmt>502600</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US EXP I</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>5623411</BookValueAmt>
        <EOYFMVAmt>5623411</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GROWTH V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1208181</BookValueAmt>
        <EOYFMVAmt>1208181</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GRTH VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>9628750</BookValueAmt>
        <EOYFMVAmt>9628750</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GRWTH VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>3868124</BookValueAmt>
        <EOYFMVAmt>3868124</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GWTH IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7461815</BookValueAmt>
        <EOYFMVAmt>7461815</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GWTH VI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2618668</BookValueAmt>
        <EOYFMVAmt>2618668</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US GWTH X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1377016</BookValueAmt>
        <EOYFMVAmt>1377016</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US SEED V</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>283543</BookValueAmt>
        <EOYFMVAmt>283543</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VENT XVI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7864806</BookValueAmt>
        <EOYFMVAmt>7864806</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XIV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7614201</BookValueAmt>
        <EOYFMVAmt>7614201</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XV</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4735787</BookValueAmt>
        <EOYFMVAmt>4735787</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XVII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>4034175</BookValueAmt>
        <EOYFMVAmt>4034175</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SEQUOIA US VTR XVIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>408452</BookValueAmt>
        <EOYFMVAmt>408452</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>SQUOIA GG 3 US IN AX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>14028615</BookValueAmt>
        <EOYFMVAmt>14028615</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>STARWOOD X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>16895377</BookValueAmt>
        <EOYFMVAmt>16895377</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>STARWOOD XI</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>43811791</BookValueAmt>
        <EOYFMVAmt>43811791</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>STARWOOD XII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>27488966</BookValueAmt>
        <EOYFMVAmt>27488966</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>TAURUS RESOURCES II</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>36588660</BookValueAmt>
        <EOYFMVAmt>36588660</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL IX</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12826350</BookValueAmt>
        <EOYFMVAmt>12826350</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL VII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>7696800</BookValueAmt>
        <EOYFMVAmt>7696800</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL VIII</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>11849425</BookValueAmt>
        <EOYFMVAmt>11849425</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>WTI VLL X</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>6300263</BookValueAmt>
        <EOYFMVAmt>6300263</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>YORK CO INVEST 1</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>1002040</BookValueAmt>
        <EOYFMVAmt>1002040</EOYFMVAmt>
      </InvestmentsOtherGrp>
    </InvestmentsOtherSchedule2>
    <LandEtcSchedule2 documentId="RetDoc2059000001">
      <LandEtcGrp>
        <CategoryOrItemTxt>FURNITURE, FIXTURES AND EQUIPMENT</CategoryOrItemTxt>
        <CostOrOtherBasisAmt>3070395</CostOrOtherBasisAmt>
        <AccumulatedDepreciationAmt>1934123</AccumulatedDepreciationAmt>
        <BookValueAmt>1136272</BookValueAmt>
        <EOYFMVAmt>1136272</EOYFMVAmt>
      </LandEtcGrp>
      <LandEtcGrp>
        <CategoryOrItemTxt>LEASEHOLD IMPROVEMENTS</CategoryOrItemTxt>
        <CostOrOtherBasisAmt>7420501</CostOrOtherBasisAmt>
        <AccumulatedDepreciationAmt>1927641</AccumulatedDepreciationAmt>
        <BookValueAmt>5492860</BookValueAmt>
        <EOYFMVAmt>5492860</EOYFMVAmt>
      </LandEtcGrp>
      <LandEtcGrp>
        <CategoryOrItemTxt>WORK IN PROGRESS</CategoryOrItemTxt>
        <CostOrOtherBasisAmt>41130</CostOrOtherBasisAmt>
        <AccumulatedDepreciationAmt>0</AccumulatedDepreciationAmt>
        <BookValueAmt>41130</BookValueAmt>
        <EOYFMVAmt>41130</EOYFMVAmt>
      </LandEtcGrp>
    </LandEtcSchedule2>
    <LegalFeesSchedule documentId="RetDoc2002100001">
      <LegalFeesGrp>
        <CategoryTxt>LEGAL FEES - INVESTMENTS</CategoryTxt>
        <LegalFeesAmt>113927</LegalFeesAmt>
        <NetInvestmentIncomeAmt>113927</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
      <LegalFeesGrp>
        <CategoryTxt>LEGAL FEES - PROGRAMS</CategoryTxt>
        <LegalFeesAmt>131480</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>154619</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
      <LegalFeesGrp>
        <CategoryTxt>LEGAL FEES - GENERAL ADMINISTRATIVE</CategoryTxt>
        <LegalFeesAmt>177853</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>173296</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
    </LegalFeesSchedule>
    <OtherAssetsSchedule documentId="RetDoc2046600001">
      <OtherAssetsScheduleGrp>
        <Desc>ACCRUED INCOME RECEIVABLE</Desc>
        <BOYBookValueAmt>1995290</BOYBookValueAmt>
        <EOYBookValueAmt>1416200</EOYBookValueAmt>
        <EOYFMVAmt>1416200</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>DUE FROM BROKER</Desc>
        <BOYBookValueAmt>12161295</BOYBookValueAmt>
        <EOYBookValueAmt>25945689</EOYBookValueAmt>
        <EOYFMVAmt>25945689</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>RETIREMENT PLAN ASSET</Desc>
        <BOYBookValueAmt>1969036</BOYBookValueAmt>
        <EOYBookValueAmt>2162642</EOYBookValueAmt>
        <EOYFMVAmt>2162642</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>ADVANCES AND OTHER RECEIVABLES</Desc>
        <BOYBookValueAmt>64252</BOYBookValueAmt>
        <EOYBookValueAmt>6037</EOYBookValueAmt>
        <EOYFMVAmt>6037</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>PREPAID FEDERAL EXCISE TAX</Desc>
        <BOYBookValueAmt>5573002</BOYBookValueAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>PROGRAM RELATED INVESTMENTS</Desc>
        <BOYBookValueAmt>25653304</BOYBookValueAmt>
        <EOYBookValueAmt>18971538</EOYBookValueAmt>
        <EOYFMVAmt>18971538</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
      <OtherAssetsScheduleGrp>
        <Desc>OPERATING LEASE RIGHT OF USE ASSET</Desc>
        <BOYBookValueAmt>8596861</BOYBookValueAmt>
        <EOYBookValueAmt>7359283</EOYBookValueAmt>
        <EOYFMVAmt>7359283</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
    </OtherAssetsSchedule>
    <OtherDecreasesSchedule documentId="RetDoc2049800001">
      <OtherDecreasesDetail>
        <Desc>UNREALIZED LOSS ON PRI</Desc>
        <Amt>2973465</Amt>
      </OtherDecreasesDetail>
      <OtherDecreasesDetail>
        <Desc>PROVISION FOR DEFERRED FEDERAL EXCISE TAX</Desc>
        <Amt>2587525</Amt>
      </OtherDecreasesDetail>
      <OtherDecreasesDetail>
        <Desc>PROVISION FOR CREDIT LOSSES - RELATED TO PROGRAM RELATED INVESTMENTS</Desc>
        <Amt>8923492</Amt>
      </OtherDecreasesDetail>
    </OtherDecreasesSchedule>
    <OtherExpensesSchedule documentId="RetDoc2003200001">
      <OtherExpensesScheduleGrp>
        <Desc>AMERICAN DEPOSITARY RECEIPT FEE</Desc>
        <RevenueAndExpensesPerBooksAmt>16670</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>16670</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>CONSULTING REIMBURSEMENTS</Desc>
        <RevenueAndExpensesPerBooksAmt>83574</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>91313</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>CUSTODY, BANK, &amp; PERFORMANCE REPORTING FEES</Desc>
        <RevenueAndExpensesPerBooksAmt>577640</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>577640</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>STATE FILING FEES AND PENALTIES</Desc>
        <RevenueAndExpensesPerBooksAmt>1550</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>1500</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>INFORMATION TECHNOLOGY/COMPUTERS</Desc>
        <RevenueAndExpensesPerBooksAmt>1574939</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>242796</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>1096012</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>INSURANCE</Desc>
        <RevenueAndExpensesPerBooksAmt>432434</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>39929</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>397200</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>OFFICE EXPENSES</Desc>
        <RevenueAndExpensesPerBooksAmt>1330082</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>400414</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>841353</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>PORTFOLIO DEDUCTIONS</Desc>
        <RevenueAndExpensesPerBooksAmt>14699662</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>55993792</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
    </OtherExpensesSchedule>
    <OtherIncomeSchedule2 documentId="RetDoc2001500001">
      <OtherIncomeDetail>
        <Desc>FX TRANSACTION NET GAIN</Desc>
        <RevenueAndExpensesPerBooksAmt>75679</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>107230</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>75679</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>CLASS ACTION PROCEEDS, NET</Desc>
        <RevenueAndExpensesPerBooksAmt>27425</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>27425</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>27425</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER PARTNERSHIP INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>51555006</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>18797169</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>51555006</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>SECTION 951(A) INCOME INCLUSION</Desc>
        <NetInvestmentIncomeAmt>12869467</NetInvestmentIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER INVESTMENT INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>31</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>31</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>31</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>GRANT RECOVERIES</Desc>
        <RevenueAndExpensesPerBooksAmt>7742742</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>7742742</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER NON-TAXABLE INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>9058</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>9058</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
    </OtherIncomeSchedule2>
    <OtherIncreasesSchedule documentId="RetDoc2049700001">
      <OtherIncreasesDetail>
        <Desc>UNREALIZED GAIN ON INVESTMENTS</Desc>
        <Amt>186800511</Amt>
      </OtherIncreasesDetail>
    </OtherIncreasesSchedule>
    <OtherLiabilitiesSchedule documentId="RetDoc2065700001">
      <OtherLiabilitiesDetail>
        <Desc>DEFERRED FEDERAL EXCISE TAX</Desc>
        <BOYBookValueAmt>22248640</BOYBookValueAmt>
        <EOYBookValueAmt>24836165</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>RETIREMENT PLAN LIABILITY</Desc>
        <BOYBookValueAmt>2748166</BOYBookValueAmt>
        <EOYBookValueAmt>2432030</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>ACCRUED VACATION</Desc>
        <BOYBookValueAmt>890327</BOYBookValueAmt>
        <EOYBookValueAmt>1168550</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>GRANT REFUNDS PENDING MODIFICATION</Desc>
        <BOYBookValueAmt>6355762</BOYBookValueAmt>
        <EOYBookValueAmt>3852387</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>OPERATING LEASE LIABILITIES</Desc>
        <BOYBookValueAmt>9441992</BOYBookValueAmt>
        <EOYBookValueAmt>8365590</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>FEDERAL EXCISE TAX PAYABLE</Desc>
        <BOYBookValueAmt>0</BOYBookValueAmt>
        <EOYBookValueAmt>4555771</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
      <OtherLiabilitiesDetail>
        <Desc>ALLOWANCE FOR CREDIT LOSSES</Desc>
        <BOYBookValueAmt>0</BOYBookValueAmt>
        <EOYBookValueAmt>646935</EOYBookValueAmt>
      </OtherLiabilitiesDetail>
    </OtherLiabilitiesSchedule>
    <OtherProfessionalFeesSchedule documentId="RetDoc2002300001">
      <OtherProfessionalFeesDetail>
        <CategoryTxt>GRANTS MANAGEMENT CONSULTING</CategoryTxt>
        <Amt>187909</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>169633</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>HUMAN RESOURCE CONSULTING</CategoryTxt>
        <Amt>59283</Amt>
        <NetInvestmentIncomeAmt>6250</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>66833</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INFORMATION TECHNOLOGY CONSULTING</CategoryTxt>
        <Amt>431360</Amt>
        <NetInvestmentIncomeAmt>42495</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>390141</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INVESTMENT ADVISORY</CategoryTxt>
        <Amt>495009</Amt>
        <NetInvestmentIncomeAmt>495009</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INVESTMENT MANAGEMENT</CategoryTxt>
        <Amt>3744150</Amt>
        <NetInvestmentIncomeAmt>3744150</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>MANAGEMENT CONSULTING</CategoryTxt>
        <Amt>53667</Amt>
        <NetInvestmentIncomeAmt>385</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>23291</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>PROGRAM CONSULTING</CategoryTxt>
        <Amt>1401182</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>1313020</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>PUBLIC RELATIONS</CategoryTxt>
        <Amt>537596</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>502546</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>RECRUITMENT</CategoryTxt>
        <Amt>236412</Amt>
        <NetInvestmentIncomeAmt>75000</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>166096</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
    </OtherProfessionalFeesSchedule>
    <TaxesSchedule documentId="RetDoc2002500001">
      <TaxesDetail>
        <CategoryTxt>STATE UBI AND OTHER TAXES</CategoryTxt>
        <Amt>2344680</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>FOREIGN TAXES WITHHELD</CategoryTxt>
        <Amt>513757</Amt>
        <NetInvestmentIncomeAmt>2384774</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>FEDERAL EXCISE TAX</CategoryTxt>
        <Amt>5128773</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>FEDERAL UNRELATED BUSINESS INCOME TAX</CategoryTxt>
        <Amt>1600000</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
    </TaxesSchedule>
    <TransfersFrmControlledEntities documentId="RetDoc2204900001">
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>CHATHAM CO-INVEST</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>26 MAIN STREET SUITE 204</AddressLine1Txt>
          <CityNm>CHATHAM</CityNm>
          <StateAbbreviationCd>NJ</StateAbbreviationCd>
          <ZIPCd>07928</ZIPCd>
        </USAddress>
        <EIN>850651355</EIN>
        <Desc>DISTRIBUTION FROM PARTNERSHIP</Desc>
        <Amt>0</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ESTATE OF LEONA M HELMSLEY</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>230 PARK AVENUE SUITE 659</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10169</ZIPCd>
        </USAddress>
        <EIN>207535047</EIN>
        <Desc>CONTRIBUTION</Desc>
        <Amt>0</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MHR LONGEVITY PARTNERS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1345 AVENUE OF THE AMERICAS 42ND</AddressLine1Txt>
          <AddressLine2Txt>FLOOR</AddressLine2Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10105</ZIPCd>
        </USAddress>
        <EIN>981471155</EIN>
        <Desc>DISTRIBUTION FROM PARTNERSHIP</Desc>
        <Amt>60730000</Amt>
      </TransfersFromControlledEntGrp>
      <TransfersFromControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2929 ARCH STREET 17TH FLOOR</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19104</ZIPCd>
        </USAddress>
        <EIN>981142649</EIN>
        <Desc>DISTRIBUTION</Desc>
        <Amt>720114</Amt>
      </TransfersFromControlledEntGrp>
      <TotalAmt>69727290</TotalAmt>
    </TransfersFrmControlledEntities>
    <TransfersToControlledEntities documentId="RetDoc2205000001">
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MARATHON-LONDON GLOBAL SELECT INVESTMENT TRUST</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>ORION HOUSE 5 UPPER ST MARTINS LANE</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <CountryCd>UK</CountryCd>
          <ForeignPostalCd>WC2H 9EA</ForeignPostalCd>
        </ForeignAddress>
        <EIN>611915057</EIN>
        <Desc>CONTRIBUTION OF CAPITAL</Desc>
        <Amt>50000000</Amt>
      </TransfersToControlledEntGrp>
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MHR LONGEVITY PARTNERS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1345 AVENUE OF THE AMERICAS 42ND</AddressLine1Txt>
          <AddressLine2Txt>FLOOR</AddressLine2Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10105</ZIPCd>
        </USAddress>
        <EIN>981471155</EIN>
        <Desc>CONTRIBUTION OF CAPITAL</Desc>
        <Amt>60730000</Amt>
      </TransfersToControlledEntGrp>
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NEWMARKET INTERNATIONAL INFRASTRUCTURE FINANCE COMPANY FEEDER LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2929 ARCH STREET 17TH FLOOR</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19104</ZIPCd>
        </USAddress>
        <EIN>981142649</EIN>
        <Desc>MANAGEMENT FEE</Desc>
        <Amt>720114</Amt>
      </TransfersToControlledEntGrp>
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PITANGO SPV</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>BEIT ACKERSHTEIN - BLDG B 11</AddressLine1Txt>
          <AddressLine2Txt>HAMENOFIM ST 11TH FL</AddressLine2Txt>
          <CityNm>HERZLIYA</CityNm>
          <CountryCd>IS</CountryCd>
        </ForeignAddress>
        <EIN>981492234</EIN>
        <Desc>CONTRIBUTION OF CAPITAL</Desc>
        <Amt>377510</Amt>
      </TransfersToControlledEntGrp>
      <TransfersToControlledEntGrp>
        <BusinessName>
          <BusinessNameLine1Txt>STARTUP HEALTH T1D PRI LP</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2000 BROADWAY 18TH FLOOR</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10023</ZIPCd>
        </USAddress>
        <EIN>932618051</EIN>
        <Desc>CONTRIBUTION OF CAPITAL</Desc>
        <Amt>5000000</Amt>
      </TransfersToControlledEntGrp>
      <TotalAmt>116827624</TotalAmt>
    </TransfersToControlledEntities>
  </ReturnData>
</Return>